Physicochemical characterization and anticancer activity evaluation of βcyclodextrin-gemini based nano-delivery systems by Poorghorban, Masoomeh
 
 
 
 
 
Physicochemical characterization and anticancer activity evaluation of 
βcyclodextrin-gemini based nano-delivery systems 
 
 
A Thesis Submitted to the College of  
Graduate Studies and Research 
in Partial Fulfillment of the Requirements  
for the Degree of Doctor of Philosophy  
in the College of Pharmacy & Nutrition  
University of Saskatchewan  
Saskatoon 
 
 
By 
Masoomeh Poorghorban 
 
 
© Copyright Masoomeh Poorghorban, June 2015. All rights reserved 
 
 
i 
 
 
PERMISSION TO USE 
In presenting this thesis/dissertation in partial fulfillment of the requirements for a Postgraduate 
degree from the University of Saskatchewan, I agree that the Libraries of this University may 
make it freely available for inspection. I further agree that permission for copying of this 
thesis/dissertation in any manner, in whole or in part, for scholarly purposes may be granted by 
the professors (Dr. Ildiko Badea and Dr. Pawel Grochulski) who supervised my 
thesis/dissertation work or, in their absence, by the Head of the Department or the Dean of the 
College in which my thesis work was done. It is understood that any copying or publication or 
use of this thesis/dissertation or parts thereof for financial gain shall not be allowed without my 
written permission. It is also understood that due recognition shall be given to me and to the 
University of Saskatchewan in any scholarly use which may be made of any material in my 
thesis/dissertation.  
 
Requests for permission to copy or to make other uses of materials in this thesis/dissertation in 
whole or part should be addressed to: 
  
Dean of the College of Pharmacy & Nutrition  
University of Saskatchewan  
Saskatoon, Saskatchewan S7N 2Z4  
Canada 
 
 
 
 
 
 
 
 
ii 
 
Abstract 
Lipophilic anticancer agents such as curcumin analogs have low water solubility and low in vivo 
bioavailability. βCyclodextrin-gemini surfactant is a novel drug delivery agent synthesized by 
attachment of βcyclodextrin to cationic gemini surfactants. βCyclodextrin can accommodate 
lipophilic guest molecules in its cavity and form host/guest inclusion complexes. The 
amphiphilic nature of the gemini surfactants enable them to self-assemble into nano-structures. 
Herein, physicochemical properties of the delivery agent, free βcyclodextrin-gemini surfactant 
and the complexes composed of a curcumin analog (NC 2067) and βcyclodextrin or 
βcyclodextrin-gemini surfactant were evaluated to comprehend the geometry of the host/guest 
interactions and the nano-structural arrangements of the βcyclodextrin-gemini surfactant-based 
formulations. Anticancer activity and cell death mechanisms associated with NC 2067 in the 
presence of the delivery agent were evaluated.  
The physicochemical characterization of the host/guest complexes was performed using various 
synchrotron and non-synchrotron based techniques such as powder X-ray diffraction, Fourier 
transform infrared spectroscopy and thermogravimetric analysis. 1D and 2D NMR techniques, 
namely rotating frame Overhauser effect spectroscopy, were employed to characterize the 
structural properties of the free βcyclodextrin gemini surfactant and NC 2067 complexes with 
βcyclodextrin or βcyclodextrin-gemini surfactant comprehensively. Size measurements and 
small and wide-angle X-ray scattering studies employed to study the nanoparticulate 
characteristics of the βcyclodextrin-gemini surfactant-based formulations. Cell viability analysis 
and flow cytometry assays were employed to appraise the cell death induction in A375 
melanoma cells. 
It was found that NC 2067 is able to form complexes with βcyclodextrin at 1:2 mole ratio 
through the interactions of the aromatic moieties with the βcyclodextrin cavity. Moreover, in 
βcyclodextrin-gemini surfactant, the hydrocarbon tail of the gemini moiety was inserted into 
βcyclodextrin through intra-molecular interactions. NC 2067 formed complexes with 
βcyclodextrin-gemini surfactant and retained its ability to kill selected cancer cells and showed 
proapoptotic activity. However, it was not able to alter the self-inclusion of the βcyclodextrin-
gemini surfactant significantly. 
The  physicochemical assessment of the interaction of a novel gemini surfactant-based 
βcyclodextrin delivery agent with a model cytotoxic agent for the first time and evaluation of the 
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βcyclodextrin-gemini surfactant-based formulations will aid to design and develop more efficient 
anticancer drug delivery systems. 
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1. INTRODUCTION 
1.1. Problem at hand, proposed solution and methodology 
Many anticancer agents synthesized recently have poor water solubility, insufficient absorption 
through biomembranes and, subsequently, low bioavailability. Application of organic solvents 
such as dimethylsulfoxide (DMSO) and surfactants
1
 for solubilization and delivery of these 
anticancer agents is limited due to the high risk of toxicity to biological systems. Various 
nanotechnology-based drug delivery systems have been developed to increase the solubility of 
hydrophobic anticancer compounds and enhance their efficacy. Hence, the design and 
development of a delivery agent which is capable of combining the advantageous properties such 
as solubilization enhancement, nano-assembly and low toxicity, are highly valued. 
A curcumin analog, named NC 2067, was selected for this study as it showed strong in vitro 
cytotoxic activity towards a variety of cancer cell lines. Despite the fact that NC 2067 exerted 
toxicity towards a cancer cell line at a concentration in the order of μM, due to its high 
lipophilicity (logP value of 4.6)
2
 the in vivo effect is limited. To overcome this deficiency, a 
novel cyclodextrin-substituted gemini surfactant-based drug delivery agent was designed
3
, 
named βcyclodextrin-gemini surfactant (βCDgemini surfactant), to increase the solubility of a 
cytotoxic agent (curcumin analog) and enhance the delivery to cancer cells (A375 melanoma cell 
line). This novel carrier is composed of βcyclodextrin (βCD) attached by a linker to a cationic 
gemini surfactant, thus combining the properties of the two components into a single molecule. 
A ring-shaped molecule, βCD, is a solubilizing agent which has the capability to encapsulate 
insoluble drugs in its hydrophobic internal cavity and increase their aqueous solubility. The 
resulting host-guest complexes of βCD and hydrophobic compounds are well-defined in 
pharmaceutical research. Moreover, the amphiphilic nature of the gemini surfactants induce self-
assembly which enhances the biomembrane diffusion and cellular penetration of the drug 
delivery system. 
The physicochemical characterization of the possible inclusion of NC 2067 molecule into the 
ring-shaped inner cavity of the βCD is critical to understanding the interaction of the anticancer 
agent with the delivery agent in their complex form. Different methods such as powder X-ray 
diffraction, Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA) 
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and 1D/2D 
1
H NMR were utilized to confirm the incorporation of NC 2067 into the βCD cavity. 
Specifically, the rotating frame Overhauser enhancement spectroscopy (ROESY) and docking 
played an important role in the simulation of the three dimensional structure of the inclusion 
complexes. Furthermore, to assess the nano-structured arrangements formed by NC 2067 
complexed with the βCDgemini surfactant, synchrotron-based small- and wide angle X-ray 
scattering (SAXS/WAXS) was employed. By combining the results from these methods, we 
believed we would be able to resolve the molecular structure and physicochemical properties of 
the CD-based delivery systems to advance the development and optimization of the 
formulations. 
In the second part of this work, the molecular mechanism associated with the anticancer activity 
of NC 2067 complexes with βCDgemini surfactants toward A375 melanoma was evaluated by 
flow cytometry-based assays. Different approaches, such as calculating the IC50 value, evaluation 
of the mechanisms of cell death, cell cycle arrest, mitochondrial related assays, reactive oxygen 
species (ROS) measurements and caspase inhibitor assays were used to explore the cell death 
pathways related to the toxicity of the curcumin analog delivery system. 
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2. BACKGROUND: NANOPARTICLES, CANCER AND 
CURCUMIN ANALOGS 
2.1. Advancements of nanotechnology related to the delivery of anticancer 
drugs 
Nanomedicine employs nanotechnology to design particles within a range of 5-200 nm as drug 
delivery agents.  Different types of nanoparticles are utilized to enhance drug delivery into the 
site of therapy.
4
 Novel nano-particulate delivery systems are promising carriers, especially for 
anticancer agents which encounter significant deficiency in terms of delivery and efficacy. 
Conventional chemotherapy agents comprised mostly of small molecules generally have poor 
solubility, leading to low efficacy and non-specific tissue distribution causing serious side 
effects. Nanomedicine approaches to cancer therapy have introduced an innovative tool to 
overcome these limitations.  
Key physicochemical properties of nanoparticles such as size (average and distribution), surface 
charge, particle morphology and chemistry, drug loading and release capacity and the ability to 
enhance the solubility of poorly soluble anticancer agents render them as suitable options for 
anticancer drug delivery. 
Permeation through biomembranes and internalization by the target cells of small molecule 
chemotherapeutics is highly dependent on their solubility in water. The “rule of 5” proposed by 
Lipinski et al explains four situations in which poor molecular solubility and permeation is 
expected, namely the molecular weight is greater than 500 Da and the calculated log P value of 
more than 5 are the major obstacles for penetration. Moreover, the number of hydrogen-bond 
donors (NHD, calculated as the sum of the OHs and NHs) of more than 5 and hydrogen-bond 
acceptors (NHA, associated with the sum of the Os and Ns) of greater than 10, limit the 
molecular permeation into biomembranes.
5
 Even though, Lipinski’s experimental rule primarily 
applied to the oral delivery, it can be applicable to other routes of administration. For absorption 
through skin, an investigation on 17 FDA-approved transdermal drugs suggested a more 
restrictive version of Lipinski’s rule in which the thresholds of NHD, NHA and molecular 
weight are assigned to be less than 2, 5 and 335 Da, respectively.
6
 
Incorporation of anticancer agents in nanoparticles can increase the solubility of hydrophobic 
compounds, protect them from unfavorable interactions with biological elements and improve 
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their pharmacokinetic properties to enhance the delivery into the target organ without significant 
exposure to non-target tissues. 
Many new hydrophobic cytotoxic agents are synthesized every year in an effort to combat 
different cancers. The major challenge is typically their low water solubility which results in 
poor absorption through biomembranes and low bioavailability. Organic solvents such as 
dimethylsulfoxide (DMSO) and non-ionic surfactants such as Cremophor EL® 
(polyoxyethyleneglycerol triricinoleate 35)
7
 and Tween 80® (polyoxyethylene (20) sorbitan 
monooleate) are used to enhance solubilization of these molecules. However, DMSO is not an 
appropriate solvent for in vivo application because of its own influence on the cells. Surfactants 
such as Cremophor EL® and Tween 80® used in conventional chemotherapy formulations are 
associated with fatal hypersensitivity reactions.
1,8
 Nanoparticles having hydrophobic 
compartments are capable of the encapsulation of hydrophobic agents and increasing their 
solubility. For instance, it has been reported that a lipid-polymer based nanoparticle increased the 
solubility and stability of wortmannin along with its efficacy in vivo.
9
 
Optimal nanoparticle size for cancer therapy is assumed to be in the range of 10-100 nm.
10
 Even 
though the upper limit is still not well defined, the lower limit of 10 nm is related to the 
glomerular capillary wall measurement of the kidney glomeruli responsible for blood filtering 
and first-pass elimination.
11
  On the upper end, particles larger than 200 nm in size can be 
removed from blood by the reticuloendothelial system (RES, previously known as the 
mononuclear phagocyte system) of the liver and spleen which is responsible for clearance of 
macromolecules from circulation.
12
 There are strategies to create nanoparticles that evade the 
RES, thus improving their biodistribution and deposition in tumors.
13
 
Nanoparticles benefit from enhanced permeability and retention (EPR) effect which leads to their 
accumulation in the tumor. Based on the permeable nature of tumor vasculature with a pore size 
range of 380-780 nm, nanoparticles can easily extravasate into the tumor, whereas in normal 
tissue, the pore size of the capillaries is small (1-2 nm) which only small molecules can 
traverse.
14
 Furthermore, the lymphatic system with capability of macromolecular removal is 
damaged in tumors, further aiding the retention of nanoparticles within the tumors.
15 
Another 
characteristic of nanoparticles affecting their uptake through RES is their surface chemistry. 
Surface modification of nanoparticles with polyethylene glycol (PEG) will prevent nanoparticle 
recognition by opsonin and subsequent phagocytosis.
16
 Moreover, the presence of the 
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hydrophobic moieties on the nanoparticle surface will enhance the penetration into cell 
membranes.17 
Generally, due to the negatively charged biomembranes, nanoparticles with a positive surface 
charge can enter cells more efficiently.
18
 However, some studies confirmed that negatively 
charged nanoparticles are able to enter cells successfully as well.  
In addition to the ability to overcome tumor environmental barriers such as microvasculature 
permeability and RES, the physicochemical properties of nanoparticles influence cellular 
internalization pathways and subcellular targeting in cancer. Cellular internalization known as 
endocytosis occurs in mammalian cells by different mechanisms such as macropinocytosis, 
caveolae-mediated endocytosis and clathrin-mediated endocytosis. Nanoparticles follow 
endocytotic internalization instead of diffusion or protein-channel mediated pathways, due to 
their larger size in comparison to small molecules. Even though intracellular trafficking of 
nanoparticles is a cell-type dependent phenomenon, the size and shape of nanoparticles can 
influence internalization rate and pathway in different cells. For example, it has been shown that 
increasing the size of the nanoparticles formed by latex beads from 200 nm to 500 nm changes 
their internalization mechanism from clathrin-mediated to caveolae-mediated pathway in 
melanoma B16 cells.
19
 Another study showed that the rate of the internalization of PLGA 
nanoparticles with size of 100 nm is significantly higher than larger particles (more than 500 nm) 
in Caco-2 cells.
20
 The shape or supramolecular arrangement is another property that can alter the 
internalization of the nanoparticles, though the findings in this area are diverse in various studies. 
Investigation of gold nanoparticles showed that spherical nanoparticles can be internalized more 
quickly and to a higher extent than rod-like structures
21
, whereas other studies showed 
cylindrical shapes are able to be internalized more efficiently.
18
 As well, engineering various 
nanoparticles decorated with surface functional groups plays an important role in the 
internalization (endocytosis) pathway.
22
 For example, functionalization of dendrimers with 
cationic, anionic and neutral functional groups showed that dendrimers with cationic or neutral 
moieties were internalized by lung epithelial cells via non-clathrin and non-caveolae mediated 
mechanisms while anionic dendrimers entered cells through caveolae mediated pathway.
23
 
Another area where nanoparticles might benefit cancer treatment is by interference with tumor 
resistance to chemotherapy. Tumor cells are able to develop drug resistance by various 
mechanisms. Overexpression of the efflux pumps such as P-glycoprotein is one of the most 
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common mechanisms in which the intracellular accumulation of the anticancer agents is 
decreased. Different strategies employed by nanoparticles to prevent multidrug resistance 
(MDR) such as combination delivery of pro-apoptotic agents, pump inhibitors or MDR-targeted 
siRNA with chemotherapeutics.
24
 Moreover, some groups used pharmacologically active carriers 
such as polaxamers directly to inhibit drug efflux pumps.
25
 
An issue requiring special attention in the study of nanoparticles encapsulating anticancer drugs 
is their intracellular fate. Following the internalization of nanoparticles, endosomes are formed 
and encapsulate the nanoparticles. The early endosomes transform into late endosomes and 
subsequently lysosomes, in which the internal pH decreases continously.
26
 This 
endosomal/lysosomal degradation is an obstacle in the endocytotic internalization pathway. 
Modified nanoparticles such as pH-sensitive nanoparticles have been developed to bypass this 
barrier. A pH-induced fusion of particles with lysosomal membrane will result in drug release 
into cytoplasm; thus efflux pumps which are located in the cell membrane cannot excrete the 
drug out of the cell.
27
 
The design and development of nanoparticles for subcellular targeting is a novel area of research 
dealing with the delivery of the drugs not only to target cells but also to subcellular organelles 
such as mitochondria
28
, nucleus
29
 and cytosol
30
. For example, in the case of targeting 
mitochondria, based on the negative mitochondrial membrane potential cationic liposomes such 
as ceramide
31
 and sclareol
32
 have been utilized to deliver anticancer agents.
 
In conclusion, there is a need for the design of delivery agents that can efficiently encapsulate 
chemotherapeutic agents to create pharmaceutically acceptable nanoparticulate delivery systems. 
Our research focuses on a new family of cyclodextrin-gemini surfactant delivery agents that can 
form nanostructures and incorporate poorly soluble anticancer drugs. 
2.1.1 Lipid-based nanoparticles: focus on lyotropic liquid crystals 
The introduction of liposomes, lipid-based vesicles as drug delivery agents, was a milestone in 
the design and development of an innovative class of drug carriers: lipid-based nanoparticles.
33
 
In general, the most important advantages associated with lipid-based formulations are 
biocompatibility and stability.
34
 Amphiphilic lipids such as surfactants containing hydrophilic 
and hydrophobic moieties can self-assemble in aqueous media at certain concentrations (critical 
micelle concentration, CMC) and temperature, forming particles called micelles. In a micellar 
structure, the hydrophobic parts of the surfactant form a particle core while polar head groups 
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locate between the core and aqueous media. The hydrophilic part is made of cationic, anionic or 
nonionic head groups whereas the hydrophobic component is commonly formed by hydrocarbon 
aliphatic chains. Micelles subsequently can aggregate further and build ordered nanoparticulate 
structures known as lyotropic liquid crystals (LLC) based on the physicochemical properties of 
the amphiphilic lipid constituent. Liquid crystal mesophases illustrate characteristics between 
crystalline solid, and liquid.
35
 Nanostructured LLCs can be distinguished from micelles or 
vesicular lipid aggregations by the presence of the internal molecular organization in the 
structure. Different types of lyotropic liquid crystals have been introduced as lamellar, 
hexagonal, cubic, nematic, gel and intermediate.
36
 Examples of the LLC nanoparticles for drug 
delivery that have been reported to date are cubosomes, micellar cubosomes and hexosomes  
(Figure 2.1) which are formed by the dispersion of the bulk cubic and hexagonal LLC 
mesophases in excess water.
37
 These nanoparticles have internal water channels with or without 
connections to the external aqueous environment.
38
 Polar drugs can be loaded in water channels 
while lipophilic drugs can accommodate in the lipophilic part of the nanoparticles.
39
 
Nanoparticles built of LLC mesophases are able to incorporate small molecule anticancer agents 
to enhance their bioavailability via various routes of administration. Irinotecan, a hydrophilic 
anticancer drug, entrapped in glycerate-based amphiphiles in the form of hexosomes retained the 
active form of the drug at neutral pH which can be a substitute to the current low-pH 
formulation.
40
 Paclitaxel, a hydrophobic drug loaded in LLC-based nanoparticles having reverse 
cubic and hexagonal phases, showed enhanced oral bioavailability.
41
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Figure 2.1-  Schematic of different lyotropic liquid crystalline nanoparticles for drug delivery.
42
 
 [Open Access] 
 
As described in this chapter, the assembly of nanoparticles is one of the key properties that 
influence the fate of the drug. Thus, in our studies we focus on understanding the interaction 
between a model cytotoxic agent and a delivery agent in addition to the structural elements 
contributing to the ability to form LLCs. 
 
2.2. Melanoma: model cancer 
Melanoma is the most fatal type of skin cancer and originates from gene mutations in 
melanocytes which are located deeply in the epidermis. Based on data from the World Health 
Organization, the incidence of malignant melanoma is increasing worldwide, converting this 
high-mortality cancer into a major public health issue. Malignant melanoma is one of the top 7 
fastest growing cancers in Canada and it was estimated that 6800 new cases will be diagnosed in 
2015( Canadian Cancer Society, www.cancer.ca). 
Although the pathogenesis of melanoma is not fully understood, the role of oncogenes and 
impaired DNA is evident.
43
 Various gene mutations and signaling molecules are responsible for 
proliferation of cutaneous melanoma such as cell survival pathways of mitogen activated protein 
kinase (MAPK) and AKt (protein kinase B). Moreover, oncogene BRAF mutations have been 
reported in 50% of cutaneous melanomas.
44
 Nuclear factor-κB, which regulates DNA 
transcription, is another factor influencing metastasis and angiogenesis in melanoma.
45
 A 
comprehensive review on the molecular pathology of melanoma was published recently.
46
 
Various melanoma cell lines derived from malignant melanoma express mitochondria-focused 
genes such as antioxidant, proapoptotic and antiapoptotic genes at different levels.
47
 
2.2.1. Melanoma treatment 
Despite significant efforts to treat melanoma, challenges such as chemoresistance
48,49
 and fatal 
metastasis
50
, problems addressing cancer management and survival, still remain. Treatment 
options vary depending on the severity and progress of the disease. According to the American 
Joint Committee on Cancer (AJCC), there are five stages of melanoma.
51
  
Lentigo maligna (stage 0) arises on chronically sun-exposed skin and has a protracted in situ 
 9 
 
phase. It is generally seen as pigmented asymmetric lesions on the head and neck in the elderly 
but other sun-exposed sites may be affected.
52
 The surgical excision of such lesions is often 
difficult and may result in disfiguring scarring. The incidence of this melanoma subtype has 
increased in the past twenty years
53
 and it has the potential to transform into invasive melanoma 
in 2-50% of the cases.
54,55
 Non-surgical options for lentigo maligna are radiotherapy and topical 
therapies such as imiquimod. The effectiveness of imiquimod in the treatment of lentigo maligna 
is controversial. It has been reported that the use of topical imiquimod resulted in a low rate of 
cure in lentigo maligna.
56
 On the other hand new findings showed that imiquimod cream was 
efficient as primary or adjuvant therapy in elderly patients with lentigo maligna.
57
 Furthermore, 
the recurrence rate of lentigo maligna is the highest among other types of cutaneous melanoma 
because of the difficulty in the estimation of the lesion margins.
58
 Therefore, the challenge for 
dermatologists is to balance the side effects of surgery and the low risk of possible progression to 
malignant melanoma. 
The major management strategy for stage I and II which corresponds to localized melanoma is 
surgery. Isolated limb perfusion (ILP) with melphalan has been established for in-transit 
melanoma (stage III or regional metastatic melanoma) in patients whose lesions are not 
surgically excisable. The use of surgery and ILP is confined as they are invasive techniques and 
can be performed only by specialists. 
Systemic chemotherapy and immunotherapy are the mainstay treatments for distant metastatic 
melanoma (stage IV). Conventional chemotherapeutics such as dacarbazine showed low 
response in metastatic melanoma.
59
 Fotemustine, a nitrosurea, showed only 2% complete 
response and 24% overall response in a multicenter phase II study.
60
 Carboplatin demonstrated 
7% complete response in malignant melanoma in a phase II clinical trial.
61
 Low response, 
chemoresistance and serious side effects restrict the use of chemotherapy agents. A meta-
analysis demonstrated that immunotherapy agents such as interferon-α and interleukin-2 yielded 
the same results, but were associated with higher toxicity.
62
 
Moreover, radiotherapy is not a suitable strategy for melanoma treatment as melanoma is more 
radioresistant in comparison to other cancers. In melanoma a fraction size of 4 Gy is needed for 
complete response while for the other types of cancer 1.8-2 Gy of fraction size is commonly 
used.
63 
Clinical data showed that the average response rate for fractions less than 4 Gy is only 
36%. Radiotherapy can be employed in selected patients with lentigo maligna as well.
64
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Recently a number of studies investigated the efficacy of a new family of antimelanoma agents, 
such as vemurafenib and imatinib that target the signaling molecules, BRAF and tyrosine kinase, 
respectively. BRAF belongs to the Raf kinase family that regulates the MAP kinase/ERKs 
signaling pathway and is mutated in approximately 50% of melanomas.
65
 The selective BRAF 
inhibitor, vemurafenib, showed 80% response rate at the maximum daily dose in a phase I trial 
on 32 selected patients.
66
 Early phase II clinical studies on tyrosine kinase inhibitors such as 
imatinib demonstrated a 16% overall response rate in metastatic melanoma.
67
 Another anti-
melanoma agent, ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 antibody, increased the 
survival rate in patients suffering from metastatic melanoma at phase III clinical trials.
68
 
Moreover, recently two other therapies dabrafenib (BRAF inhibitor) and trametinib (MEK 
inhibitor) have been approved by the Food and Drug Administration. Although these novel anti-
melanoma agents are promising, they still show high risks of relapse, low efficacy and severe 
side effects.
69
 The use of these agents for malignant melanoma treatment needs further 
research.
70
 
Since the systemic treatment and surgery for melanoma encounters some challenges, an urgent 
need exists to seek novel strategies. Nano-based drug delivery systems made of anti-melanoma 
agents are promising, particularly for the in situ or minimally invasive melanomas. 
2.2.2. Nanoformulations for melanoma treatment 
Nanotechnology-based pharmaceutical formulations have been widely studied in melanoma 
treatment. Liposomes
71
, niosomes
72
, carbon-based nanoparticles
73
, dendrimers
74
, and 
polymerosomes
75
 are some examples that have been employed recently to increase the efficacy 
of anti-melanoma agents. For example 5-fluorouracil formulated in a bola-niosome showed 100 
times lower IC50 in vitro and 8 times more percutaneous permeation compared to the free drug.
72
  
Furthermore, lipid-based nanoparticles have been investigated as promising nano-carriers for 
dermal delivery to overcome the stratum corneum barrier without irritating or sensitizing 
effects.
76,77 
A number of studies evaluated the effects of liposomes as delivery agents for 
chemotherapeutics
78-81
, immunotherapeutic agents
82
 and nucleic acids
83,84
 in melanoma in vitro 
and in vivo. A liposome composed of phosphatidylethanolamine was able to increase the tumor 
accumulation of cisplatin 3.6 times higher than the free drug.
78
 Moreover, CD-based nano-
vectors have been developed to increase the delivery of anti-melanoma agents.
85-87
 Apart from 
ordinary chemotherapeutics on the market, novel chemical entities such as curcumin are also 
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incorporated into lipid- or cyclodextrin-based nano-carriers as well to enhance melanoma 
treatment. 
2.3. Curcumin in cancer therapy 
Curcumin, a non-steroidal diphenolic compound, is the major active ingredient of turmeric 
extracted from Curcuma longa rhizome (Figure 2.2).
88
 The antiproliferative activity of curcumin 
and its analogs toward a variety of cancer cells lines such as breast 
89
, colon
90
, pancreatic
91
 
cancers and leukemia
92 
have been demonstrated.  
 
 
Figure 2.2- Chemical structure of curcumin 
 
Current limitations in curcumin therapy are its high lipophilicity and low aqueous solubility and 
bioavailability.
93
 For instance, it was reported that the oral bioavailability of curcumin in rat is 
only 1%.
94
 Different nano-based drug delivery systems such as liposomes
95,96
 , solid lipid 
nanoparticles
97,98
, polymer-based nanoparticles
99
 and CD complexes
100-104
 have been developed 
to enhance curcumin delivery in various cancers. Curcumin encapsulated in liposome-PEG 
(polyethyleneglycol)–PEI (polyetherimide) showed 5 times lower IC50 towards different cancer 
cell lines in vitro and 60-90% decrease in tumor size induced by melanoma in mice in 
comparison to free curcumin.
95 
In another nano-based formulation, curcumin integrated into 
bilayers of dodecanoic acid bound to magnetite nanoparticles, showed enhanced water solubility 
and toxicity towards melanoma in vitro.
105
 Moreover, the solubility and stability of curcumin 
increased by its incorporation into poly(ethylene oxide)-b-poly(εcaprolactone) micelles while 
toxicity towards B16F10 mouse melanoma cell line was retained.
99
  
Yallapu et al incorporated hydrophobic curcumin into a βCD cavity to increase its solubility 
towards prostate cancer cells.
103
 Furthermore, they synthesized poly(βCD) which was capable of 
loading curcumin while forming self-assembling nanoparticles with a size of 250 nm.
104
  
The relatively high IC50 and poor aqueous solubility of curcumin limited its application as an 
O
CH3
OH
O O H
O
CH3
O H
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anticancer drug in vivo. To further improve the performance of curcumin, derivatives and 
analogs were developed by medicinal chemists. 
2.3.1. Curcumin analogs in melanoma treatment 
Recently, several research groups dedicated their attention to synthesize new curcumin related 
compounds/analogs to improve its biological and anticancer activities. 
Arezki et al grafted an organometallic moiety to curcumin and curcuminoids and synthesized 
new ferrocenyl derivatives which showed higher toxicity (lower IC50 values) in murine B16 
melanoma cell line compared to curcumin.
106
 
Based on computational modeling a novel curcumin analog (FLLL32) derived from curcumin 
and a diketone tautomer was synthesized to interact with transcription factor (STAT3) in 
melanoma cells. The results showed 10 times lower IC50 values towards A375, HT144 and 
Hs294T human melanoma cell lines via caspase-dependent apoptosis and STAT3 
phosphorylation inhibition.
107 
The in vitro analysis of a series of 1,5-diaryl-3-oxo-1,4-
pentadienes (curcumin analogs) on various cancer cell lines such as G361 melanoma showed that 
some of the compounds had higher toxicity (at least 10 times) compared to curcumin.
108 
Another 
biphenyl curcumin-related compound containing α,β-unsaturated ketone, named D6, showed 
higher efficacy with 5-10 times lower IC50 value to a melanoma cell line and sub-cutaneous 
melanoma xenograft mouse model in comparison to curcumin.
109 
Sodium 4-[5-(4-hydroxy-3-
methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate, another curcumin analog, was 
able to increase the survival by Mcl-1 and Bcl-xL downregulation and decrease tumor load in 
melanoma-bearing mice.
110
 
A novel family of curcumin analogs/related compounds has been designed and synthesized by 
Dr. Dimmock and his colleagues (College of Pharmacy and Nutrition, University of 
Saskatchewan) and evaluated in several cancer cell lines.
111
 The 1,5-diaryl-3-oxo-1,4-
pentadienyl pharmacophore (Figure 2.3), a conjugated α,β-unsaturated ketone, has been attached 
to different moieties and formed large series of curcumin analogs.
112
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Figure 2.3- 3,5-bis-(Arylidene)-4-piperidone containing postulated pharmacophore binding sites.  
The conjugated unsaturated styryl ketones in the pharmacophore have shown a high affinity 
toward thiol groups instead of amino or hydroxyl groups on the structure of nucleic acids.
113,114
 
Some of the existing anticancer therapeutic agents that target amino and hydroxyl groups on 
nucleic acids result in genotoxic outcomes.
115
 In contrast, the curcumin analogs may avoid 
genotoxicity based on their thiol selectivity. Furthermore, the diaryldienone moiety of the 
pharmacophore has two thiol-alkylating groups which are able to target cellular thiol groups 
serially which can lead to higher toxicity toward tumor cells in comparison to the corresponding 
normal cells.
106
 This phenomenon can be explained by the fact that when a primary alkylator 
attacks the cancer cells, chemosensitization may occur, resulting in greater vulnerability toward a 
subsequent alkylator in comparison to normal cells. Hence, curcumin analogs showed selective 
toxicity toward malignant cells through “sequential cytotoxicity”.116
 
Integrating a piperidine ring 
into 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore formed the 3,5-bis-(arylidene)-4-
piperidone compounds. The 4-piperidone group can act as a cyclic Mannich base which affects 
mitochondrial respiration.
117
 
Moreover, inserting the N-acyl group to the latter compounds has yielded 48% higher potency in 
many cases attributed to the further attachment to a secondary binding site, strengthening the 
binding of the pharmacophore to the primary site. Due to their high cytotoxicity and specificity, 
curcumin analogs are ideal candidates for drug development for melanoma. 
NC 2067, a 3,5-bis-(benzylidene)-4-piperidone compound (Figure 2.4) attached to the N-[4-(2-
alkylaminoethoxy)phenylcarbonyl] group, was used as a model drug in our studies. Addition of 
the latter group resulted in three times higher cytotoxicity of NC 2067 toward human T-
 14 
 
lymphocytes (Molt4/C8 bioassay) compared to compounds lacking N-acyl group.
112
 Moreover, 
NC 2067 induced mitochondrial respiration in rat liver at concentration of 10 μM and did not kill 
the mice at concentrations up to 300 mg/kg.
118
 
In addition, different 3,5-bis-(benzylidene)-4-piperidone derivatives demonstrated high in vitro 
selective toxicity toward human leukemic cells and human squamous cell carcinomas
119
, though 
they suffer from unfavorable pharmacokinetic properties and in vivo inefficacy.
120
 
 
Figure 2.4- Chemical structure of NC 2067 
 
Recent evaluation of NC 2067, dissolved in DMSO, has indicated the high in vitro toxicity 
towards the A375 human melanoma cell line with an IC50 value of 0.47±0.03 μM.
3
 The highly 
lipophilic nature of curcumin analogs such as NC 2067 defined as high octanol-water partition 
coefficient value (log P of 4.6)
2
, represents the major challenge for the utilization of these 
compounds as suitable drug candidates in cancer therapy. Although NC 2067 can penetrate 
easily into the stratum corneum via passive diffusion, it lacks the potential to enter viable cells 
such as melanocytes. The design and development of new drug delivery systems to counteract 
the unfavorable physicochemical characteristics of NC 2067 might improve the delivery into 
melanoma cells. In our research group, a novel nanocarrier consisting of CD attached to a gemini 
surfactant, was designed to improve NC 2067 solubility and deliver it into melanoma cells by 
crossing biomembranes. In a previous study, the IC50 of NC 2067  in complexed with 
βCDgemini surfactant towards A375 melanoma cells was calculated as 2 μM.3 Moreover, NC 
2067 /βCDgemini surfactant increased apoptotic markers, caspase-3 and -7, significantly in 
comparison to control cells whereas free βCDgemini surfactant did not induce apoptosis.3 This 
study is a proof-of concept evidence for the suitability of the derivatized CDs for delivery of 
curcumin analogs. 
N
O
O
O
NH
+
CH3
CH3
Cl
-
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2.4. Drug delivery agent: βCDgemini surfactant 
This chapter depicts some of the pharmaceutical applications of the components of the 
βCDgemini surfactant, βCD and gemini surfactant. 
2.4.1. Cyclodextrins 
Cyclodextrins (CDs), discovered a century ago, are widely used in different fields such as food 
and cosmetic industries to stabilize flavoring agents and minimize unpleasant odors.
121
 
Nowadays, CDs are available as common pharmaceutical excipients, and accordingly, their 
novel and unique applications in pharmaceutical sciences have been studied comprehensively 
and continuously.
122
 
CDs are macrocyclic oligosaccharides formed of six, seven or eight α-D-glucopyranose units 
called α, β and γ CD, respectively. 
2.4.1.1. βcyclodextrin (βCD) 
 As mentioned above, βCD is composed  of  seven  (α-1,4)-linked α-D-glucopyranose units 
(Figure 2.5.a) and based on the rigid construction of glucopyranose units, it forms a truncated 
cone shape with primary hydroxyl groups (OH-6 on the glucopyranose unit) extending from the 
narrow interface and secondary hydroxyl groups (OH-2 and OH-3 on the glucopyranose unit) 
from the wide interface (Figure 2.5.b)
123
.  Moreover, the C-H bonds and nonbonding electrons of 
the etheric oxygen point toward the interior of the cavity. This configuration results in a 
hydrophilic outer surface and lipophilic inner cavity with high electron density which is the key 
property of βCD related to its ability to carry lipophilic agents.124  
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Figure 2.5- a) Chemical structure of βCD, b) hydroxyl groups of βCD. 
 
The lipophilicity of the cavity has been approximated to be comparable to an aqueous ethanolic 
solution.
125
 Moreover, secondary hydroxyl groups can interact with each other to form 
intermolecular hydrogen bonds which restricts the water solubility of βCD (18.5 mg/ml at room 
temperature).
125 To overcome the limitations associated with βCD, various βCD derivatives have 
been synthesized by substitution of methyl, hydroxypropyl, and sulfobutyl ether moieties on the 
secondary hydroxyl groups.
122
 
Chemical characteristics of βCDs are listed in Table 2.1.126,127 
Table 2.1- Characteristics of βCD and its derivatives. 
 
Molecular 
weight 
Solubility* 
[g/100ml] 
Cavity 
diameter 
[Å] 
Cavity 
height 
[Å] 
Cavity 
volume 
[Å
3
] 
Outer 
periphery 
diameter 
[Å] 
LogP 
value 
Crystal 
water 
content 
[wt%] 
βCD 1135 1.85 6.0-6.5 7.9 262 15.4 -14 
13.2-
14.5 
2-
Hydroxylprpoyl-
βCD (HP- βCD) 
1400 >600 -- -- -- -- -11 -- 
Sulfobutylether- 
βCD (SB- βCD) 
2163 >500 -- -- -- -- <-10 -- 
Randomly 
methylated- βCD 
(RM- βCD) 
1312 >600 -- -- -- -- -6 -- 
*solubility in water at room temperature 
 
 
The natural origin of βCD dictates its bioadaptability, low toxicity and biodegradability. 
However, the safety of βCDs in dermal administration is related to the possible interaction of 
βCD with lipid components of cell membranes. βCDs could cause hemolysis, related to their 
interaction with phospholipids of the erythrocyte cell membrane altering the morphology of the 
erythrocytes.
128
 It has been reported that more hydrophobic βCDs such as methylated βCDs can 
extract cholesterol as well.
129
 The ability of βCDs to solubilize and extract cholesterol from cell 
membranes can be used as a predictive criterion for cell toxicity.
130
 
The traditional role of βCDs is to substitute organic solvents such as ethanol in drug delivery 
systems. For example, tretinoin complexes with βCD showed 3.4x105 times higher solubility in 
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comparison to free tretinoin.
131
 
2.4.1.2. Inclusion complexes of curcumin and its analogs with βCD  
Application of βCD as a carrier for curcumin has drawn the attention of researchers lately. It was 
found that the inclusion of curcumin in βCD improved its cellular uptake and enhanced in vitro 
toxicity towards various prostate cancer cell lines.
103
 In addition, the anti-proliferative and anti-
inflammatory effects of curcumin and its half-life in cells increased via complexation with βCD 
in comparison to free curcumin.
101
 Curcumin encapsulated in HP-βCD showed 3 times higher 
oral bioavailability in comparison to free curcumin at the same dose in vivo.
132
 Moreover, a 
difluorinated curcumin complex with βCD showed a half IC50 value compared to the drug alone 
in different cancer cell lines.
133
 
2.4.1.3. Cyclodextrin-based nanoparticles 
As stated earlier, hydrophobic drugs can be encapsulated in the internal cavity of CDs by 
forming non-covalent bonds. The ability of CDs to encapsulate and solubilize hydrophobic drugs 
renders them suitable carriers in cancer therapy. For instance, βCD and its derivatives are used to 
increase the solubility of a number of anticancer drugs such as doxorubicin
134
, paclitaxel
135
 and 
cisplatin
136. 
In addition to the traditional pharmaceutical role of CDs as solubilizer and stabilizer, CD-based 
nanoformulations have been used as drug delivery agents.  Drug-in-CD-in-liposomes are 
nanoformulations in which the drug/CD complex is placed in the central aqueous core of the 
liposomes. In other words, the hydrophobic drugs will be carried by CDs instead of incorporation 
into the lipid bilayers. In this case, the drug does not change the structure of bilayers and the 
drug/CD complex is protected by liposome.
137
 Furthermore, elastic liposomes can be utilized to 
encapsulate the drug/CD complex to enhance the penetration through skin similar to a system 
comprised of meloxicam-in-βCD-in-elastic liposome as a transdermal delivery system.138
 
However, in this system there is a possibility that lipid components of liposome compete with the 
drug for the hydrophobic cavity and consequently obliterate the structure of the liposome. 
However, when the drug shows high affinity to CD, the liposome structure remains intact. For 
example, upon the inclusion of betamethasone in βCD derivatives in liposome made of 
cholesterol and other lipids, no liposomal deformation was observed.
139
 
CD-grafted polymers are synthesized to provide multiple CD moieties to enhance drug inclusion 
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either by cross-linking of CDs or combining polymers with CDs.
140
 Different compounds have 
been employed to cross-link CDs. To create a linear βCD-based polymer, the backbone was 
formed by cross-linking βCDs with polyethylene glycol (PEG).141 Another study showed that 
βCDs can be covalently conjugated on the PEG backbone to build CD-flanking polymers, thus 
fabricating various types of self-assembling structures upon the inclusion of suitable guest 
molecules.
142
 
Amphiphilic CDs are noteworthy CD derivatives synthesized by conjugation of various 
functional groups to enhance self-assembly and interaction of CDs with biomembranes.
143
 They 
can be divided into three subcategories based on the nature of the conjugating components: 
neutral, cationic and anionic CDs. Neutral amphiphilic βCDs are synthesized by attaching 
aliphatic chains (five-carbon) with amide or ester linkers to the primary and secondary faces. 
These non-surfactant amphiphiles form nanospheres with a size of less than 300 nm. The CD 
moieties formed 1:1 mole ratio inclusion complexes with aromatic-bearing guest molecules.
144
 
Another group synthesized amphiphilic CDs by transesterification of CDs on the primary face 
with vinyl-acyl esters.
145
 CD-grafted decanoic alkyl chain formed nanoparticles in the shape of 
nanospheres or nanoreservoirs with particles of sizes in a range of 70-220 nm which was used to 
load lipophilic artemisinin.
146
 Cationic amphiphilic βCDs synthesized by substitution of alkyl 
groups on a primary face and ω-amino-oligo-(ethylene glycol) on a secondary face were able to 
form different nanoparticles and bilayer vesicles based on the chemical nature of the alkyl 
group.
147
 
Cationic amphiphilic βCDs148 and cationic polymer containing βCDs149 have been used as 
promising nonviral gene delivery agents. Moreover, co-delivery of genes and drugs  increased 
transfection efficiency
150,151
, provided synergistic effects and decreased multidrug resistance
150
 
associated with P-glycoprotein efflux pumps. Sophisticated core-shell nanosystems were 
designed by grafting βCD on a cationic polymer with a hydrophobic polymer included in βCD as 
guest. This multifunctional nano-assembly system contains a hydrophobic core to load the 
hydrophobic drug and cationic surface to interact with DNA simultaneously.
152
 
 
2.4.2. Cationic gemini surfactant as a delivery agent 
Gemini surfactants, coded as m-s-m, are a family of surfactants composed of two tails of 
aliphatic chains (length of m) and two polar head groups attached to each other via a spacer 
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(length of s).
153
 Quaternary ammonium ions can be used as the head groups in cationic gemini 
surfactants (Figure 2.6).  
 
Figure 2.6- m-s-m structure of gemini surfactants. 
 
Favorable characteristics of the gemini surfactants in comparison to mono cationic surfactants 
are their lower critical micelle concentrations (CMC)
153,154
 and lower toxicity
155
. Cationic gemini 
surfactants are appropriate candidates for non-viral gene delivery, competing with the viral 
vectors. Their self-aggregation behavior is based on three types of interactions: intramolecular, 
intermolecular and interaction with solvent molecules.
156 
The self-aggregation behavior of 
gemini surfactants results in the formation of various morphological structures which can be 
defined by the surfactant packing parameter, S, 
𝑆 =
𝜈
𝑙𝑎0
              Equation (2.1) 
where ν and l are the volume and the length of hydrocarbon tail, respectively and a0 is the 
surface area of the head group. Surfactant packing parameter is an indicator of the curvature of 
the structures. For example, spherical micelles with high curvatures have the packing parameter 
of 0.3. 
Gemini surfactants have the potential to build LLC mesophases in excess of water similar to 
amphiphilic molecules. For example, the quaternary diammonium gemini surfactant (12-3(OH)-
12) showed micellar aggregations altering to lamellar, hexagonal and monoclinic liquid 
crystalline mesophases at different concentrations and temperatures.
157
 In another study, it was 
reported that ammonium and phosphonium based gemini surfactants demonstrate a bicontinous 
cubic phase. Quaternary ammonium gemini surfactants with higher lengths of tails displayed 
cubic, lamellar and hexagonal arrangements in their phase diagrams.
158
 
The length, flexibility and nature (hydrophobic or hydrophilic) of the spacer are important 
parameters that affect the self-assembling behavior. Cationic gemini surfactants bearing 
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alkanediyl spacers, consisting of 5-6 carbon atoms
153
 and bulky head groups
159
 have the highest 
CMC values. Arginine-based gemini surfactants having a spacer length of 3 or 6 carbons showed 
lamellar and hexagonal phases whereas with the spacer of 9 carbon atoms only the lamellar 
phase was observed.
160
 Comparison between 12-s-12 and 12-EOx-12 gemini surfactants showed 
that increased hydrophilicity of the spacer in 12-EOx-12 gemini surfactants will lead to the 
development of various LLC phases.
161
 As well, the nature and length of the hydrocarbon tail 
and the type of the counter ion impact the phase behavior of gemini surfactants. Variable LLC 
phases such as a bicontinous cubic phase and intermediates were observed with a 16-s-16
162 
gemini surfactant in comparison to 12-s-12 gemini surfactant
163
. The ion binding capability of 
aromatic counterions is higher than halide counterions (Cl
-
 and Br
-
) leading to the formation of 
worm-like micelles instead of spherical micelles in monomeric cationic surfactants.
164
 
Various generations of cationic gemini surfactants have been synthesized by different research 
groups to date and their efficacy in gene delivery
165-168
 has been investigated extensively. 
Cationic nanoparticles of a 16-3-16 gemini surfactant have been used to enhance the skin 
penetration of interferon-γ-genes in mice models.169,170 The gemini surfactants in our study are 
imino substituted gemini surfactants with different length of hydrocarbon tails as follows: 12-
7NH-12 (Figure 2.7), 16-7NH-16 and 18-7NH-18:1. 
 
Figure 2.7- Molecular structure of 12-7NH-12 Gemini surfactant 
 
Gene delivery efficacy of the 12-7NH-12 gemini surfactant was evaluated in COS7 cells using 
luciferase and the results showed higher protein expression even without helper lipids in 
comparison to other non-substituted or aza-substituted gemini surfactants. The spacing between 
each ammonium head group and the NH calculated as 5.1 Å which is the optimum distance to 
interact with DNA phosphate groups.
166
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2.4.3. βCDgemini surfactants 
βCDgemini surfactants were synthesized3 by mono-substitution of the gemini surfactants (12-
7NH-12, 16-7NH-16 and 18-7NH-18:1) on O6 of the βCD via an ester or amide linkage (Figure 
2.8) and are promising delivery agents in vitro. Theoretically, the lipophilic inner cavity of βCD 
in a βCDgemini surfactant can accommodate NC 2067 similar to the host-guest inclusion 
systems of βCD, while the hydrophilic outer membrane can increase the solubility of the poorly 
soluble drug. The tails of the gemini surfactant have the potential to self-assemble and form 
nanoparticles. Moreover, the cationic ammonium head groups will facilitate the attachment of 
the delivery system to a negatively charged cell surface. However, based on the average 
dimension of a linear hydrocarbon chain (4.85 Å), it is possible that the βCD cavity will 
accommodate hydrophobic tails. Studies showed that the hydrocarbon tails of gemini surfactants 
and other types of surfactants are able to be placed inside the cavity of various CDs.
171-180
 Mutual 
interactions between a gemini surfactant and βCD can alter both the aggregation behavior of the 
gemini surfactant and the ability of βCD to accommodate another guest molecule. A major 
consequence of the inclusion of a gemini surfactant in βCD is that it can avoid or delay the self-
assembly of the gemini surfactant. Accommodation of the hydrophobic tails of a gemini 
surfactant, bis (dodecyl dimethylammonium) diethyl ether dibromide (12-EO1-12), in βCD 
altered the micellization behavior of the gemini surfactant.
173
 In another study on the complex 
system made of a cysteine-based anionic gemini surfactant inclusion in βCD, increasing the 
concentration of βCD resulted in an increase in the critical micelle concentration (CMC) as the 
gemini surfactant monomers became unavailable to self-assemble in the presence of the βCD 
cavity.
178
 In the case of the βCDgemini surfactant, where the gemini surfactant is attached to the 
βCD, the possibility of the interaction of gemini surfactant tail(s) with βCD cavity (self-inclusion 
phenomenon) can play an important role in the physicochemical behavior of the inclusion 
complexes and supramolecular arrangements of the delivery system in solution. It was 
previously reported that in a modified βCD, the alkenyl part of the attached amphiphilic moiety 
can be encapsulated by the cavity.
181
  
To comprehend the exact mechanism of the interaction between the guest molecule, NC 2067, 
and βCDgemini surfactant and also the self-inclusion behavior of βCDgemini surfactant, 
advanced techniques are required. 
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Figure 2.8- Molecular structures of βCDgemini surfactants made of different gemini surfactant moieties: 
A) 12-7N-12, B)16-7N-16 and C)18-7N-18 attached to βCD. 
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3. MOLECULAR MECHANISMS OF ANTICANCER AGENTS: 
FOCUS ON APOPTOSIS 
In addition to the physicochemical characterization of the drug/delivery agent complexes, the 
evaluation of their biological activity is important in the process of drug discovery and 
development. Several cellular signaling pathways are involved in the procedures resulting in the 
development of cancer. Monitoring apoptosis, one of the desired pathways for cell death in 
cancer therapy, is frequently used for the assessment of drug efficacy. 
3.1. Apoptosis 
Apoptosis is a programmed cell death which is naturally occurring in a variety of cells to 
maintain homeostasis. The apoptotic stimulation initiates a volunteer suicidal process, resulting 
in the removal of the unhealthy cells. It is distinct from necrosis, an accidental cell death which 
develops based on the homicidal factors such as heat, toxic compounds and physical damages. 
During apoptosis, the cells experience different morphological and biochemical properties 
distinctive from the necrotic characteristics. Apoptotic morphological changes involve nuclear 
cell shrinkage
182
, cytoskeleton disintegration
183
, chromatin condensation
184
, DNA 
fragmentation
185
, membrane budding and formation of apoptotic bodies. Phagocytes recognize 
and engulf the apoptotic cells through the phosphatidylserine (PS) exposure signaling.
186,187
 
Studies showed that the presence of PS on lymphocytes and thymocytes experiencing apoptosis, 
will result in identification by phagocytes.
186
 PS is an aminophospholipid located on the inner-
leaflet of the cell membrane in normal cells. During apoptosis, PS will be externalized and 
localized on the surface of the cell membrane. This phenomenon, featuring the redistribution of 
the plasma membrane phospholipids, occurs before other hallmarks of apoptosis such as release 
of cytochrome c and decrease of the mitochondrial membrane potential happen.
188
 The 
asymmetric presence of PS on the surface of the cell membrane, known as apoptotic flag, is used 
as a probe in flow cytometry assays to confirm apoptosis. In such assays, the fluorescent-labelled 
Annexin-V is used to bind to PS in the presence of calcium ions.
189
 Conversely, cell death 
through necrosis pathway is initiated by cellular/organelle swelling and bursting, leading to 
inflammation and immunological responses.
190
 
Apoptosis is a process of three steps: initiation, decision and degradation. At the initiation step, 
external or internal stimuli participate in the initiation of the signal transduction specific to the 
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type of the apoptotic pathway. In the external pathway, death receptors commence the apoptotic 
signals, whereas the internal pathway is initiated by the alterations in cell organelles such as 
mitochondria, endoplasmic reticulum, nucleus or lysosome. The decision phase involves the 
activation of caspases and mitochondrial effectors leading to the irreversible point of cell suicide. 
During the degradation phase, the cell death is completed by drastic alterations in the cell 
morphology and ultimately the clearance of the cell remnants. 
3.1.1. Apoptotic signaling pathways: role of caspases 
A hallmark biochemical change in apoptosis is the cleavage of a family of proteolytic enzymes 
known as caspases. Caspases are a group of cysteine aspartate-specific proteases
191
 which are 
categorized by the size of their prodomain to two groups: initiators and executioners. Initiator 
caspases such as caspase-2, 8, 9 and 10 have a larger prodomain and are responsible for the 
caspase cascade initiation. Caspase-3 and 7 are executioners with a smaller prodomain. Caspases 
are able to be activated by two different pathways in apoptosis: extrinsic and intrinsic routes. The 
extrinsic pathway is triggered by cell death receptors and has a less significant role in 
chemotherapy-induced apoptosis.
192
 Extracellular ligands, such as tumor necrosis factor (TNF) 
and Fas can form complexes with cell surface receptors to develop a death-inducing signal 
complex (DISC) which can activate the initiator caspases-8 and 10 (Figure 3.1).
193
 Different 
internal stimuli such as cytotoxic agents, hypoxia and DNA damage activate the apoptosis via 
the intrinsic pathway. Chemotherapeutic agent-induced apoptosis is predominantly through the 
intrinsic pathway. Mitochondria, as the foremost players in this pathway, receive the signals 
from Bcl-2 protein family members which regulate the mitochondrial signal transduction.
194
 Bcl-
2 family comprises proapoptotic (Bid, Bad and Bim) and antiapoptotic (Bcl-2 and Bcl-xL) 
proteins.
195
 Mitochondria  release different proapoptotic proteins such as cytochrome c into the 
cytoplasm which can trigger caspase-9 via formation of apoptosome complex (cytochrome 
c/Apaf-1/caspase-9) and subsequently activate caspases-3 and -7 (Figure 3.1).
196
 Caspases are 
synthesized in an inactive form and can be stimulated through proteolytic cleavage by upstream 
proteases in a cellular cascade. 
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Figure 3.1- Simplified schematic of the intrinsic and extrinsic apoptotic pathways. Apoptosis pathway can be 
initiated through different sites, for instance, at the plasma membrane by ligation to cell death receptors such as Fas 
in extrinsic pathway or at mitochondria by activation of proapoptotic proteins such as Bax. In extrinsic pathway 
death receptor activation, activates caspase-8 and -3 and in the intrinsic pathway, cytochrome c release from 
mitochondria will form apoptosomes and consequently activates caspase-3.  
3.1.2. Apoptosis in cancer cells: role of mitochondria 
Oncogenic alterations in cancer influence the routine behavior of the cells. The most important 
changes occur in mitochondria and include the energy metabolism remodeling
197
, increase in 
reactive oxygen species (ROS)
198
 and resistance to apoptosis.
199
 Chemotherapy, as one of the 
principal strategies to contend with cancer, performs its role by inducing apoptosis in cancerous 
cells. In addition, anticancer treatments seek strategies to target the cancer cells without affecting 
the normal cells. 
Mitochondria (cell furnace) are key player organelles associated with different physiological 
activities in mammalian cells from energy production through metabolism to apoptotic cell 
death. Mitochondria are dynamic organelles made of two membranes (outer and inner) and the 
space between these two layers and within the inner membrane named as intermembrane space 
(IMS) and matrix, respectively. 
Energy production in cancer shifts from the common metabolic oxidative phosphorylation to 
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lactic acid fermentation (Warburg theory).
200
 Moreover, ROS, such as H2O2 produced by 
mitochondria, play an important role in regulating cell death.
201
 Increased amount of ROS in 
cancer results in oxidative stress and finally death.
202
 Cancer cells are able to evade apoptosis 
through various molecular mechanisms such as inactivation of transcription factor p53
203
, 
downregulation of caspases
204
, upregulation of antiapoptotic proteins such as inhibitors of 
apoptosis protein family (IAPs)
205
 and even the death receptor (e.g. Fas) inhibition. 
As it was mentioned earlier, mitochondria release proapoptotic proteins to activate caspases. The 
mitochondrial permeabilization can be triggered by two proposed mechanisms including 
mitochondrial membrane permeabilization (MMP) and mitochondrial permeability transition 
(MPT). MMP, known as a point of no return in cell death, is regulated by proapoptotic members 
of Bcl-2 family specifically Bcl-2-associated X protein (Bax) and Bcl-2-associated killer (Bak) 
proteins. The reconformation and oligomerization of these proteins build channel-like pores in 
the mitochondrial outer membrane which results in the release of cytochrome c from IMS into 
cytoplasm.
206
 Release of cytochrome c from mitochondria triggers the activation of caspase -3 
and -9.
207
 Furthermore, MMP makes the transmembrane potential (∆Ψm) to decrease which can 
damage mitochondrial normal functions and increase ROS generation.
208
 
Furthermore, oxidative stress can increase the Ca
2+
 release from endoplasmic reticulum (ER)
209
 
and subsequently enhance the Ca
2+
 uptake by mitochondria. This charge imbalance triggers the 
opening of the protein pores and induces MPT leading to mitochondrial swelling, membrane 
disruption and release of the proapoptotic agents.
210
 
 
3.2. Molecular mechanism of apoptosis induced by curcumin and its analogs 
in cancer cells  
Signal transduction pathways and morphological alterations, associated with curcumin-induced 
apoptosis, have been studied in different cancerous cell lines, revealing the cell-type dependent 
response to curcumin. Curcumin can induce apoptosis via both intrinsic and extrinsic pathways 
and apoptotic morphological hallmarks such as cell shrinkage and chromatin condensation are 
associated with the process.
211
 Based on a microarray study, curcumin treatment can alter the 
expression of 104 apoptosis-associated genes out of the total 214 genes.
89
 This study suggested 
that apoptosis induced by curcumin was controlled by various signal transduction pathways such 
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as mitochondrial pathway, caspase-mediated pathways, cell proliferation pathway (c-myc), cell 
survival pathway (Bcl-2 family and XIAP), tumor suppressor pathway (P53), cell death receptor 
pathway and protein kinase pathways (Table 3.1). 
Curcumin demonstrated its proapoptotic activity in cervical cancer cells through the 
mitochondrial pathway by decreasing the expression of the antiapoptotic proteins such as Bcl-2 
and Bcl-xL, increasing the expression of the proapoptotic proteins (e.g. Bax and AIF), releasing 
cytochrome c and activating of caspase-9 and 3.
212
 In colorectal cancer cells, curcumin induced 
apoptosis by upregulating Bax and p53, downregulating Bcl-2 and survivin, decreasing 
mitochondrial membrane potential, releasing cytochrome c and activating caspase-3 and 9. 
213 
Curcumin was able to induce apoptosis in colon cancer by caspase-3 activation, mitochondrial 
membrane potential collapse, cytochrome c release, ROS generation, inhibition of Bcl-2 and 
increase of Bax, p53 and p21 and Ca
2+
 levels.
214
 
Another study on gastrointestinal carcinoma cell lines confirmed that curcumin induced 
mitochondrial-dependent apoptosis via ER stress leading to alterations of Ca
2+
 levels in 
mitochondria, ER and cytoplasm. In addition, curcumin activated different caspases (3, 7, 8 and 
9) associated with both intrinsic and extrinsic apoptotic pathways.
215
 The impact of Ca
2+
 
accumulation on mitochondrial apoptosis induced by curcumin at 25 μM concentration in 
hepatocellular carcinoma was described using a calcium chelating agent. The reduction in the 
intracellular Ca
2+
 resulted in decrease in ROS generation, caspase-3 and ΔΨm and increase in 
cell viability.
216
 
In a lung cancer model, curcumin stimulated the ER stress, mitochondrial-mediated apoptosis 
and caspase-3 activation at 30 μM concentration.217 
Another investigation demonstrated that curcumin promoted apoptosis via increasing the ROS 
and Ca
2+
 levels, decreasing the MMP, caspase-3 activation, antiapoptotic protein Bcl-2 
inhibition and proapoptotic Bax protein increase.
218 
In a human cutaneous squamous cell 
carcinoma cell line, curcumin acted as a pro-oxidant and increased ROS generation.
219 
It was 
reported that curcumin inhibited the antiapoptotic protein expression (Bcl-2, Bcl-xL, survivin, 
XIAP) and enhanced the proapoptotic protein expression (Bax, Bak, PUMA, Bim, Noxa and cell 
death receptors) in prostate cancer cells.
220
 
Furthermore, the molecular mechanisms of a number of curcumin analogs/derivatives were 
investigated. Bis-dehydroxy-curcumin induces ER stress, caspase activation and mitochondrial-
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mediated apoptosis in colon cancer.
221
 The anticancer activity of bis-demethoxy-curcumin 
towards breast cancer was associated with elevated ROS production, reduced mitochondrial 
membrane potential and p53 activation.
222 
A tropinone-curcumin analog, named P1, inhibited the 
NF-κB pathway (DNA transcription factor known as for cell survival) and increased 
mitochondrial ROS generation at a lower concentration compared to curcumin in different cancer 
cell lines.
223
 It was shown previously that two other mono ketone curcumin analogs, EF24
224
 and 
GO-Y030
225
, structurally similar to P1, induced apoptosis via NF-κB inhibition as well. The anti-
proliferative effect of NC 2067 toward HCT-116 human colon cancer cell line has been 
evaluated recently.
226
 The NC 2067 IC50 value towards HCT-116 cells was 0.65 μM while it was 
significantly less toxic toward normal colon cells, with a selectivity index of more than 39. 
Moreover, NC 2067 was able to decrease the mitochondrial membrane potential, increase ROS 
generation and produce mitochondrial swelling in isolated rat liver mitochondria. NC 2067 
interacted with glutathione as a thiol alkylator which may circumvent genotoxicity that is a major 
deficiency of many anticancer drugs.
226
 
Several studies showed that curcumin encapsulated by delivery agents enhanced its solubility 
and bioavailability and retained the ability of the drug to induce mitochondrial-dependent 
apoptosis. An inclusion complex of curcumin in hydroxylpropyl cyclodextrin (HP-CD) can 
stimulate apoptosis via ROS generation, mitochondrial membrane potential decrease and Ca
2+
 
accumulation in lung cancer line.
227 
Incorporated in solid lipid nanoparticles, curcumin retained 
its proapoptotic activity by releasing cytochrome c, reducing the mitochondrial membrane 
potential and causing caspase activation in various cancer cell lines.
228
 
Similarly, curcumin and its analogs induced apoptosis through various alterations in signaling 
molecules and pathways in melanoma cells. It has been reported that curcumin was able to 
increase caspase-3 expression along with the decrease in c-myc oncogene expression in a 
concentration-dependent manner in A375 melanoma cell line at 30 μM concentration.229 Another 
study on the same cell line showed that curcumin at concentrations more than 10 μM induced 
apoptosis by a decrease in cell proliferation proteins such as activators of transcription 3 
(STAT3) and Bcl-2.
230
 Curcumin caused apoptosis through the death receptor pathway by 
accumulation of Fas and activation of caspase 8 and 3 in various melanoma cell lines without 
any effect on p53.
231
 Moreover, it was reported that curcumin at a low concentration of 5 μM did 
 29 
 
not alter the mitochondrial membrane potential.
232
 One of the mechanisms that cancer cells 
develop to evade apoptosis, is the activation of NF-κB.233 Curcumin blocked NF-κB activity and 
induced apoptosis by caspase-3 activation in mouse melanoma cells.
234
 Moreover, the inhibitory 
effect of curcumin on NF-κB was investigated in other melanoma cell lines revealing 
independence from BRAF/MEK/ERK and Akt pathways.
235
 Another investigation demonstrated 
that in the A375 melanoma cell line, curcumin performed its anti-proliferative activity via 
downregulation of NF-κB and upregulation of p53 in a dose- and time-dependent manner.236 As 
well, curcumin triggered apoptosis through ER stress enhancement, Ca
2+
-ATPase pump 
inhibition and antiapoptotic protein inhibition in murine melanoma cells in a dose-dependent 
manner.
237
 
Different curcumin analogs showed proapoptotic effects mostly through the mitochondrial 
mediated pathway showing caspase-3, 7, 9 activation and mitochondrial membrane potential 
decrease in melanoma cells. For example, a synthetic diphenyl curcumin-related compound was 
able to activate caspase-3 and 7, decrease mitochondrial membrane potential and increase 
cytochrome c release in a melanoma cell line and inhibit tumor growth in a melanoma mouse 
model.
109
 Another curcumin analog, DM1 induced apoptosis in the A375 melanoma cell line 
through downregulation of the antiapoptotic Bcl-2 proteins (e.g. Mcl-1 and Bcl-xL) and the 
inactive form of caspase-3 and upregulation of the active form of caspase-9.
238
 FLLL32, a 
curcumin analog, synthesized based on the diketone tautomeric form of curcumin, blocked 
STAT3 phosphorylation, induced apoptosis in a caspase-dependent manner and lowered the 
mitochondrial membrane potential in the A375 melanoma cell line.
107
 Diphenyl difluoroketone 
curcumin analog (EF24) inhibits NF-κB pathway and cyclin D1 (cell cycle regulator) in the B16 
murine melanoma cell line.
239
   
It was reported that curcumin induced the formation of the mitochondrial permeability transition 
pores (PTP) by oxidation of the thiol functional groups located on the membrane of the isolated 
mitochondria which resulted in mitochondrial swelling, mitochondrial membrane potential drop 
and finally apoptosis.
240
 Curcumin analogs synthesized by the substitution of different functional 
groups on the aromatic rings or cyclohexanone with di-ketone moiety also had an effect on the 
PTP. It was shown that the presence of the hydroxyl groups on the aromatic ring and di-ketone 
moiety are crucial to trigger mitochondrial swelling.
241
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Overall, curcumin and its analogs have the potential to induce apoptosis in various melanoma 
cell lines via regulation of multiple molecules such as the death receptor mediated pathway, 
caspase-3 activation, decrease in antiapoptotic proteins, oncogenes and cell survival factors. We 
concluded that the proapoptotic performance of curcumin is related to cell type and experimental 
protocols. 
3.3. Molecular mechanisms of cell cycle arrest induced by curcumin and its 
analogs in cancer cells 
Curcumin can affect cell cycle phases. Morphologically, in G1 phase, the cell increases in size 
and chromosomes arrange for replication, in the S phase, DNA replication occurs, in the G2 
phase the cell grows once again and in the M phase mitosis arises.  
Most of the studies on the effect of curcumin treatment on cell cycle phases showed G2/M cell 
cycle arrest. It has been shown that curcumin at low concentrations (5-10 μM) was able to arrest 
the cell cycle at the G2/M phase in lung carcinoma.
217
 Moreover, curcumin encapsulated in HP-
CD retained its effect on G2/M cell cycle arrest in lung cancer cells.
227
 A similar behavior was 
reported in several studies on various cancer cell lines such as leukemia
218
, cutaneous squamous 
cell carcinoma
219
 and bladder cancer where curcumin induced a mitotic spindle defect
242
. The 
main metabolite of curcumin, tetrahydrocurcumin, inhibited cell growth in breast cancer cells by 
G2/M arrest as well.
243
 Conversely, curcumin arrested cells at the S phase and G0/G1 in colorectal 
cancer
213
 and leukemia
244
, respectively.  
In addition, the influence of curcumin on the cell cycle was evaluated in melanoma cells. In 
A375 melanoma cells, curcumin arrested the cells at G2/M.
236
 Similar results were obtained by a 
curcumin analog, DM6, that inhibited cell growth by blocking the cell cycle at G2/M.
245
 G0/G1 
cell cycle arrest was also reported by 5 μM concentration of curcumin in the SK-MEL-37 human 
melanoma cell line.
109
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Table 3.1- Molecular mechanism of curcumin and its analogs in various cancer cells. 
Cytotoxic 
agent 
Cancer cell 
line 
Apoptosis 
Caspase 
activation 
↑Proapoptotic 
proteins 
↓Antiapoptotic 
proteins 
↓MMP 
Cytochrome              
c release 
↑ROS 
generation 
↑p53 
↑ER 
stress 
Curcumin 
Cervical212  Caspases 
9 and 3 
Bax, AIF Bcl-2, 
Bcl-xL 
- √ - - - 
Colorectal213 Caspases 
3 and 9 
Bax 
Bcl-2, 
Survivin 
√ √ - √ - 
Colon214 Caspase 3 Bax Bcl-2 √ √ √ √ - 
Gastrointestinal215 
Caspases 
3,7,8 and 
9 
- - - - - - √ 
Lung217 Caspase 3 - - - - - - √ 
Leukemia218 Caspase 3 Bax Bcl-2 √ - √ - √ 
Prostate220 - 
Bax, Bak, 
PUMA, Bim, 
Noxa 
Bcl-2, 
Bcl-xL, 
Survivin, 
XIAP 
- - - - - 
Melanoma 
cells230-
232,235,237 
Caspase 3 
and 8 
- Bcl-2 - - - √ √ 
Bis-
dehydroxy-
curcumin 
Colon221 - - - - - - - √ 
Bis-
demethoxy-
curcumin 
Breast222 - - - √ - √ √ - 
Curcumin 
Analogs 
Melanoma107,
238  
Caspase 3, 
7 and 9 
- 
Bcl-2, 
Bcl-xL 
√ √ - - - 
  
Cell Cycle Arrest 
G0/G1 S G2/M 
Curcumin/
Curcumin 
Analogs 
Melanoma234 √ - - 
Colorectal214 - √ - 
Lung217, 
Leukemia218, 
Squamous 
carcinoma219, 
Melanoma236, 
Breast243, 
Bladder242 
- - √ 
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4. PHYSICOCHEMICAL CHARACTERIZATION OF THE 
HOST-GUEST INCLUSION COMPLEXES USING NON-
SYNCHROTRON TECHNIQUES 
4.1. βCD-based host-guest complexes 
The lipophilic inner cavity of βCD provides an opportunity to incorporate the lipophilic parts of 
the guest molecules whereas the hydrophilic compartments of the guest molecule interact with 
the solvent or βCD hydroxyl groups. Therefore, the formation of the βCD complexes depends on 
the polarity of the guest molecule which dictates the geometrical orientation inside the cavity. 
Based on the cavity diameter (6-6.5Å), aromatic moieties have the potential to be inserted into 
the βCD ring through van der Waal forces.180 Other forces that play a role in host-guest inclusion 
complexes of CDs are hydrophobic interactions, dipole-dipole interactions and hydrogen 
bonding. The latter two forces are able to alter the conformational structure of the CD inclusion 
complexes.
246
 No covalent bonds are formed during the inclusion process. Free βCD, free guest 
molecule and the inclusion complex in solution are at equilibrium. Association and dissociation 
of βCD/drug complexes occur continuously with rapid rates in the solution.247 The dissociation 
of the drug from βCD/drug involves mechanisms such as dilution, competitive dislocation of the 
drug from the complex, and drug uptake by cells.
247
 
The most common stoichiometry between CDs and their guests in binary systems is a 1:1 ratio. 
Overall, the binding constant (Kab) of a complex containing a guest molecule and βCD can be 
calculated as: 
aG + bCD → GaCDb 
𝐾𝑎𝑏 =
[𝐺𝑎𝐶𝐷𝑏]
[𝐺]𝑎×[𝐶𝐷]𝑏
                                                                       (4.1) 
Where, [G], [CD] and [GCD] are the molar concentrations of the guest, βCD and inclusion 
complex, respectively. In addition to stoichiometry and binding constant, the structural 
orientation of the guest molecule inside βCD, potential binding sites and the direction that the 
guest enters the cavity can give a better understanding of the host-guest inclusion conformation.  
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4.2. Infrared spectroscopy 
Infrared spectroscopy is an efficient technique to evaluate molecular interactions. The infrared 
photons are not able to excite electrons, but may be large enough to vibrate covanently bonded 
atoms in the forms of stretching and bending. The comparison of the characteristic peaks in the 
spectra of a drug in an inclusion complex and a physical mixture can be employed to elucidate 
the placement of the drug in the βCD molecule. Any shift in the position or absence of the drug 
distinctive peaks such as carbonyl group in the inclusion complex denotes that the drug is 
shielded by βCD.248 
A comparison between the IR spectrum of the inclusion complex of irbesartan and βCD 
expressed the shift in two absorption peaks of the drug corresponding to C═O and C-N groups at 
1731 and 1622 cm
-1
, respectively, as a result of the interaction with the βCD cavity.249 When 
miconazole was included, the two peaks of the drug matching the aromatic ring at 1588 and 1546 
cm
-1
 disappeared in the inclusion complex with βCD.250 
The major challenge with this technique is the lack of the alteration in the drug characteristic 
peaks which makes the interpretation challenging or impractical. For example, the comparison of 
the physical mixture and inclusion of EO-9 (anticancer agent) with HP-βCD did not produce any 
significant changes in the fingerprint region of EO-9 spectrum. The only difference observed was 
the absence of some very weak peaks in the inclusion spectrum.
251
 
There are several studies which compared the FTIR spectra of curcumin inclusion in βCDs with 
free curcumin to confirm the inclusion formation. For instance, the IR spectrum of curcumin in a 
complex with βCD showed alterations to the curcumin peaks at 1602 cm
-1
 corresponding to the 
C=C stretching vibrations of the aromatic rings.
252 Once again, monitoring the peaks associated 
with the aromatic moieties of the guest molecules can provide useful information on the host- 
guest interaction. 
4.3. Thermal analysis: Differential scanning calorimetry and 
thermogravimetry 
Thermal analyses are routinely used to qualitatively investigate the drug/βCD inclusion 
formation.
253
 Any change in the thermal behavior of drug such as melting point, evaporation, 
degradation and polymorphic transition can be used. Differential scanning calorimetry (DSC), 
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recording the endothermic and exothermic events, and thermogravimetry analysis (TGA), 
evaluating mass changes in response to increase in temperature, can be useful tools in evaluating 
the nature of the host-guest interactions.  
The difference in the thermograms of a physical mixture and inclusion sample in DSC, 
demonstrates the accommodation of the drug in the βCD cavity. Three regions are observable at 
βCD thermogram. At around 120 ᵒC a broad peak corresponding to water loss is recognizable, 
following by the thermal degradation region beginning at 250 ᵒC, and the ignition region occurs 
at 300 ᵒC.253 The absence or reduction of the drug melting peak in the inclusion complex 
represents the complete or partial inclusion formation, respectively.
253
 For instance, the DSC 
thermogram of sulfamethoxazole in a complex with HP-βCD revealed the absence of the 
endothermic melting peak of the drug at 170.5 ºC in a freeze dried formulation in comparison to 
a physical mixture.
254
 Moreover, the reduction of the characteristic melting peak of 
benzophenone at 68 ºC in the 1:1 ratio inclusion complex with HP-βCD confirmed that the free 
drug was still available and the inclusion was not complete.
255
 
 
Figure 4.1- Schematic of DSC thermograms of drug, CD, physical mixture and inclusion. 
 
In addition, the shift in the water loss peak of βCD demonstrated the substitution of drug 
molecules in the cavity (Figure 4.1).
256
 In the inclusion of trimethoprim in βCD it was observed 
that the broad water loss peak of βCD shifted from 117.6 ºC to 118.7 ºC in the inclusion complex 
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suggesting the placement of the drug molecule into the cavity, changing the energy of the water 
molecules retained in the cavity.
257
 
A TGA thermogram of βCD shows an initial weight loss (< 100 ᵒC) according to the water 
evaporation succeeded by a major mass loss due to degradation which occurs at 250-400 ᵒC.258 
The incorporation of a drug molecule in βCD, increases the degradation temperature.256 
 
 
Figure 4.2- Schematic of TGA thermograms of drug, CD, physical mixture and inclusion. 
 
For example, the inclusion of pyrimethamine in HP-βCD started to decompose at a higher 
temperature compared to the free drug (190 ⁰C).259 Since in the inclusion complex, the water 
molecules departed from the βCD ring already, the mass loss is less at the water loss region 
(Figure 4.2).
256 
In another thermogravimetric study, the inclusion complexes of glimepiride with 
βCD, HP-βCD and sulfobutylether-βCD (SBE-βCD) also displayed lower water loss than the 
physical mixtures.
260
 Thus, the degree of water loss can be used as an indication of formation of 
inclusion complexes. 
4.4. UV/Visible spectroscopy 
Monitoring the drug chromophore UV spectrum, an increase/decrease in the absorbance peak 
without changing the λmax or a shift in λmax was interpreted as inclusion confirmation. For 
instance, the UV spectrum of purine nucleosides in the presence of βCD showed a decrease in 
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absorption at 205 and 260 nm.
261
 Furthermore, two major absorption peaks of ibuprofen at 258.5 
and 266 nm showed a red shift in the presence of βCD.262 Addition of βCD to diazepam caused a 
shift and decreased the intensity of the UV absorbance peak at 229 nm.
263
 
Evaluation of the UV absorbance of NC 2067 in the presence of the βCD revealed an 
insignificant decrease, while in a βCDgemini surfactant, absorbance decreased significantly up to 
a βCDgemini surfactant: drug mole ratio of 2:1.3  
4.5. Phase-solubility diagram 
To evaluate the interaction between a drug and its carrier Higuchi and Conners suggested a 
model
264
 to describe the βCD in complex with drug molecules (Figure 4.3).265 A-type phase-
solubility diagrams correspond to the profiles in which the solubility of the drug increases with 
the increase of the βCD concentration, resulting in a soluble complex. On the other hand, B-type 
phase solubility indicates the formation of insoluble complexes where the concentration of drug 
decreases at higher βCD concentrations.264 The stoichiometry between drug and βCD can be 
estimated by subcategories of the A-type diagram (AL, AP and AN). The linear correlation 
between drug solubility and βCD concentration in AL profile indicates the 1:1 mole ratio for 
drug: βCD complex. 
 
Figure 4.3- Different phase solubility diagrams of CD inclusion complexes.  
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In AN profile, after a certain concentration of βCD, the positive gradient turns to negative which 
indicates that the drug: βCD ratio is smaller than 1. The AP profile of the complex corresponds to 
the diagram in which, after a certain concentration of βCD, the positive gradient increases, 
suggesting formation of drug/βCD complex at a ratio larger than 1. Thus, based on the phase-
solubility diagram, the stoichiometry of the drug/βCD inclusion complexes can be 
determined.
266-268
 
When the phase-solubility profile is AL type, the inclusion binding constant Ks (or K1:1) can be 
calculated using the diagram slope and intrinsic solubility of the drug (S0) as below: 
𝐾1:1 =
𝑠𝑙𝑜𝑝𝑒
𝑆0(1−𝑠𝑙𝑜𝑝𝑒)
                                                                             (4.2) 
K1:1 value determines the strength of binding between the drug and βCD in the inclusion 
complex as shown in Table 4.1.
269
 
Table 4.1- Inclusion bond strength according to K1:1 
K1:1 value [M
-1
] Bond strength 
<500 Very weak 
500-1000 Weak 
1000-5000 Moderate 
5000-20000 Strong 
>20000 Very strong 
 
The inclusion complex of curcumin and its derivatives with βCD characterized by phase 
solubility diagram and proposed a drug: βCD ratio of 1:2.102,133 
 
4.6. Nuclear Magnetic Resonance (NMR) 
NMR is the most commonly used technique for structural characterization of the drug/βCD 
inclusion complexes by monitoring the chemical shift changes of proton (
1
H-NMR) or carbon 
(
13
C-NMR) atoms of the host (βCD) and/or the guest molecule (drug). 
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4.6.1. 1D proton NMR (
1
H NMR) 
4.6.1.1. Inclusion formation: chemical shift changes 
1
H NMR shifts outline the different hydrogen environment based on the shielding or deshielding 
effect of the atoms located in the neighborhood. Protons of βCD are spatially located internal or 
external of the cavity (Figure 4.4). H3 and H5 are placed inside the cavity in a manner that H3 is 
closer to the wider rim and H5 to the narrower opening. Locations of the H1, H2 and H4 are on the 
outside of the cavity whereas H6,6' are positioned closely on the smaller rim (Figure 4.4). Upon 
inclusion of an organic compound into βCD cavity, the internal protons (H3 and H5) and in some 
cases H6 commonly show upfield chemical shifts compared to the empty βCD. For instance, 
upon an inclusion of a curcumin analog in βCD, chemical shift changes (∆δ=δcomplex-δfree ) of 
0.016 and 0.008 ppm observed for H3 and H5, respectively.
133
 
 
Figure 4.4- Location of the interior and exterior protons of βCD. 
The presence of the π-electron rich groups such as aromatic rings is the main reason for the 
upfield shifts in the inclusion complexes of CDs which is known as an anisotropic effect. The 
upfield shift (shielding effect) in the inclusion complex of a few compounds containing aromatic 
rings with CDs has been demonstrated in the literature.
270-274
 
It is challenging to elucidate conformational parameters of the inclusion complex solely based on 
1D NMR data. However, there are several studies that compared the magnitude of the ∆δ of the 
internal protons to speculate the depth and direction of the guest molecule entrance into βCD 
cavity. Equal values of ∆δH3 and ∆δH5 have been reported as an evidence of the deep placement 
of the guest molecules inside CD ring.
270,275,276
 In others, the alteration in the chemical shift of 
only one of the internal protons (H3 or H5) was applied to describe the superficial interaction.
277
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Moreover, the comparison between the chemical shifts of the internal protons demonstrates the 
direction from which the guest molecules enter the CD cavity. It was shown that in the inclusion 
complex of naringenin with βCD, ∆δH3 (0.03ppm) was greater than ∆δH5 (0.01ppm).
278
 
Conversely, the inclusion of barbigerone in HP-βCD displayed ∆δ values of 0.017 ppm and 
0.042 ppm corresponding to H3 and H5 proposing that the insertion direction was from the 
narrow opening of the cavity.
279
 Similar behavior was observed when omeprazole penetrated into 
the methylated derivative of βCD with chemical shift changes of 0.054 and 0.086 for H3 and H5, 
respectively.
280
 Other evidence that may contribute to the concept of the insertion through the 
narrower rim is the upfield shift in the H6 protons located at the edge of the smaller opening.
280 
The interaction of celecoxib and βCD in freeze dried formulation revealed a significant chemical 
shift in the NMR spectrum for H5 (0.06-0.07 ppm). Moreover, the shift in H3 (0.01 ppm) and 
celecoxib protons (0.01-0.03 ppm) confirmed the deep inclusion of the drug in βCD.271 
Furthermore, in the case of the guest molecules with sufficient aqueous solubility, NMR has the 
potential to discover which part of the guest molecule can interact with the βCD cavity.281 A 1H 
NMR study on digoxin encapsulated within βCD showed that digoxin was incorporated into the 
cavity from its A-ring according to the higher ∆δ of the 19-methyl protons of digoxin in 
comparison to 18-methyl protons.
281
 
4.6.1.2. Determination of the host-guest stoichiometry: Job’s plot 
One of the routine methods used to determine the stoichiometry of the guest inclusion in βCD is 
a continuous variation method known as Job’s plot.282 The modified Job’s plot for NMR studies 
where the host-guest complexation rate is fast, can be calculated by the difference of the 
chemical shifts, ∆δ = δComplex – δHost or Guest which is proportional to the complex concentration. 
Thus, in the case of chemical shift alterations of βCD in inclusion, Δδ × [βCD] can be plotted as a 
function of mole fraction (r). The maximum point in a plotted graph corresponds to the 
stoichiometry of the inclusion complex.
283
 Stoichiometry of 1:1 and 1:2 correspond to the 
maximum point of 0.5 and 0.66, respectively. While, Job’s plot is able to show the 1:2 guest to 
host mole ratio theoretically, the simultaneous presence of GH and GH2 complexes might result 
in erroneous determination of the actual stoichiometry by this method.
284
 
The stoichiometry of several guest molecules such as tulfenamic acid and flufenamic acid, in 
complex with βCD have been calculated as 1:1 mole ratio based on Job’s plot.274,285
 
 Few other 
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studies used Job’s plot on NMR data to confirm the stoichiometry of 1:2 (guest to host mole 
ratio).
286
 
4.6.1.3. Calculation of the binding constant: Scott’s plot 
To calculate the binding constant of the host-guest inclusion with 1:1 mole ratio, adopted form of 
the famous Benesi-Hildebrand equation
287, called Scott’s equation288 (Equation 4.3) can be 
employed as : 
[𝐺]
∆𝛿𝑜𝑏𝑠
=
[𝐺]
∆𝛿𝑚𝑎𝑥
+
∆𝛿𝑚𝑎𝑥
𝐾𝑎
                                         (4.3) 
where [G] is the guest molar concentration, Ka is the binding constant, ∆δobs and ∆δmax are the 
observed chemical shift in the complex and maximum chemical shift change at the saturation 
state, respectively. [G]/∆δobs can be plotted as a function of [G] resulting in the linear curve with 
a slope of 1/∆δmax and intercept of ∆δmax/Ka. The mathematical models to calculate the binding 
constants of more complicated systems such as 1:2 are more challenging and need computer-
based programs. Association constants of the inclusion of fluconazole
273
 and loperamide
272
 in 
βCD at 1:1 mole ratio, were calculated to be 68.7 M-1. 
4.6.2. 1D/2D Rotating frame nuclear Overhauser effect spectroscopy (ROESY) 
In addition to monitoring the chemical shifts, nuclear Overhauser effect (NOE) provides valuable 
information regarding the conformational properties of the cyclodextrin-based inclusion 
complexes. NOE is a change in NMR intensity of a spin when the NMR resonance of the 
neighbor spin is saturated. This phenomenon results from a dipole-dipole cross-relaxation 
between nuclei and depends on the magnetic field and mobility of the molecule in solution. 
NOE-based methods are important techniques to estimate the inter-spin distances. The minimum 
spatial distance between two nuclei should be 4 Å to show NOE cross-linked peaks. In host-
guest complex systems, intermolecular NOEs offer information regarding through space 
interactions of βCD and the organic guest. However, only small molecules with less than 1000 
Da molecular weights show positive NOEs. Macromolecules (more than 5000 Da) provide 
negative but detectable NOE signals. Inclusion complexes of a small molecule in βCD with 
molecular weights in the range of 1000-2000 Da demonstrate unfavorable motional correlations 
which restrict the use of the conventional NOE-based techniques. Rotating frame nuclear 
Overhauser effect spectroscopy (ROESY) is a suitable technique to specifically detect NOE 
signals for βCD host guest inclusion complexes. ROESY provides spin lock in rotating frame 
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which results in the formation of permanent positive NOEs (the intensity of the affected 
resonances increasing).
289 
The 2D ROESY spectrum presents NOE cross-peaks as positive phase 
and diagonal peaks (1D spectrum) as the negative phase. The selective 1D ROESY technique 
applies a discerning irradiation region to excite the peak of interest and trace the possible 
interactive peaks which appear inversely at the spectrum.
290
 
Several studies employed 2D ROESY to evaluate the spatial proximity of guest molecules with 
βCD in form of complex. The ROESY spectrum of naringenin/βCD showed the interaction of 
the C ring protons of naringenin with H3, H5 and H6 of βCD.
278
 In another study, cross-peaks 
corresponding to internal cavity protons of βCD and C, D and E rings of nimbin, elaborated the 
structure of nimbin / βCD complex.291 
 
Inclusion of tryptophan in 6-O-a-D-glucosyl-β-
cyclodextrin (G1-βCD) displayed ROESY cross-peaks between H3 and H5 of the cavity and 
indole protons of tryptophan. Interestingly, another interaction observed between H3 and H5 of 
βCD and protons of β-carbon group in the tryptophan molecule. According to ROESY data, a 
model was built suggesting that one tryptophan molecule interacts with two G1-βCDs as a result 
of deep insertion of the indole ring via the wider rim in one G1-βCD whereas gauche and trans 
protons (β-carbon) penetrated through a wider opening of another G1-βCD molecule.
292
 Based 
on the ROESY spectra, different modes of econazole nitrate / βCD derivatives complexes have 
been explained. Econazole can enter the CD cavity mostly through three different orientations 
involving the interaction of the 4-chlorophenyl moiety, 2,4-dichlorophenyl moiety and imidazole 
ring.
293 
Moreover, a comparative study of the inclusion complexes of gemini surfactants containing 
different spacer lengths (alkyl-a,x-bis(dodecyldimethyl ammonium bromide)) with βCD showed 
that the cross-peak volumes between CD internal protons and Hλ (corresponding to the 7CH2 of 
each hydrocarbon tail) is consistent for gemini surfactants having spacer lengths of 2, 4, 6 and 8 
atoms. However, in the case of the gemini surfactant with a 10 carbon spacer the interaction 
intensity decreased by 5% suggesting the possibility of the interaction of the spacer with the CD 
cavity.
177
 In another study of the inclusion of the gemini surfactant, (dodecyl 
dimethylammonium) diethyl ether (12-EO1-12) dibromide in βCD, the effect of CD 
concentration on the inclusion conformation was assessed. It was observed that, at a lower 
concentration of CD, one hydrocarbon tail located inside the cavity whereas the second tail 
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interacted with the cavity surface. Increasing the concentration of CD resulted in the interaction 
of each tail with a different CD molecule.
173
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5. SYNCHROTRON TECHNIGUES FOR CHARACTERIZATION 
OF HOST-GUEST INCLUSION COMPLEXES AND 
NANOPARTICLES  
As synchrotron-based techniques are significant analytical tools in the characterization of self-
assembling LLPs, this chapter describes the theoretical aspects and applications of the 
synchrotron radiation relevant to nanotechnology. 
5.1. Synchrotron radiation 
Synchrotron radiation (SR) is a brilliant source of electromagnetic radiation ranging from far 
infrared to hard X-rays. SR is generated as a result of acceleration of charged particles, usually 
electrons, which are moving with a speed very close to the speed of light (relativistic velocity).
294
 
 
Figure 5.1- A simplified schematic of the Canadian Light Source beamlines  
 
In practice, a specific magnetic field generated in the storage ring by either the bending magnets 
or insertion devices such as wigglers and undulators bends electron’s trajectory which 
subsequently leads to X-ray radiation.
295
 The decreased electron’s energy due to creation of 
electromagnetic radiation is compensated by radio frequency (RF) cavities.
294
 
The Canadian Light Source (CLS, Saskatoon, Canada) is a third generation SR facility with a 2.9 
Storage ring 
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GeV storage ring (Figure 5.1). The Canadian Macromolecular Crystallography Facility (CMCF) 
located at CLS is composed of 08ID-1 and 08B1-1 beamlines providing X-rays in energy range 
of 5-18 keV, flux of 10
11
 – 1012 ph/s and variety of beam size.296 
5.1.1. X-ray source: bench-top vs synchrotron 
Synchrotron sources of X-ray in comparison to bench-top sources such as X-ray tubes 
demonstrate exclusive properties which make them versatile tools for research in different fields. 
Synchrotron sources of X-ray offer higher flux (10
11
-10
13
 photon/s) in comparison to bench-top 
sources (10
8
 photons/s) resulting in lower data collection time
297,298 
Moreover, SR is well 
collimated with low divergence and high polarity.
299
 The tuneability of SR provides the 
opportunity to select the preferred wavelength and greater use of a multi-wavelength anomalous 
dispersion phasing technique.
297
 The beam size of synchrotron-based X-ray beamlines is usually 
smaller than 100 μm but in some cases it is less than 1 μm.294
 
Moreover, SR has pulsed nature 
including short pulses of beam continuing in a separated bunches in which X-ray beam lasts for 
picoseconds and is divided by nanoseconds breaks.
300
 This property allows time resolved studies. 
From its introduction about 30 years ago SR revolutionized the physicochemical characterization 
of the biological materials such as pharmaceutically important molecules and improved the 
precision and specificity of numerous analysis methods. 
5.1.2 X-ray scattering techniques 
X-ray scattering is an expanding field which has a major role in molecular biology and 
introduction of synchrotrons facilitated detection of weak scattered X-rays from diluted samples. 
Macromolecular crystallography and non-crystalline scattering are major techniques employed in 
biological and medical sciences. 
Synchrotron beamlines revolutionized macromolecular crystallography. As of today, more than 
100,000 crystal structures of macromolecules have been deposited in the Protein Data Bank 
(PDB). The crystal structure determination of drug targets (proteins) provides precious 
knowledge for structure-based drug discovery (SBDD). Today with the development of 
sophisticated software and automation of the SR data collection, a huge amount of data can be 
obtained in a short time and employed in lead discovery and screening of new pharmacologically 
active molecules.
301
 In addition, time-resolved crystallography improves the knowledge of 
molecular dynamics. 
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Non-crystalline scattering techniques such as small angle X-ray scattering (SAXS) advanced 
tremendously with the development of new beamlines at the SR facilities. Synchrotron-based 
SAXS benefits from the high intensity radiation and small sample volume that make it possible 
to characterize supra-atomic structures of nano-materials. 
5.2. Host-guest inclusion characterization by synchrotron X-ray diffraction 
techniques       
5.2.1. X-ray diffraction basics 
When X-ray photons interact with matter, two important phenomena, absorption and scattering, 
occur. In scattering, the photon energy can be either preserved (elastic scattering) or partially 
conveyed to the material (inelastic scattering). Coherently scattered photons interfere with each 
other and create a diffraction pattern.
297 
In 1913, Bragg (the son) described how the scattering 
waves with constructive interference from the atoms of a crystal are able to produce a diffraction 
pattern (Bragg’s law).302 Bragg’s peaks in a diffraction pattern are versatile tools to obtain 
structural information about the scattering element (Figure 5.2). 
 
Figure 5.2- Graphical illustration of the Bragg’s law 
 
Wide angle X-ray scattering (WAXS) is usually defined when scattering angle, 2θ, is larger than 
5ᵒ. Depending if powder or a single crystal of a sample is used, it is defined as a powder X-ray 
diffraction or a single crystal X-ray crystallography. At very low resolution, when the scattering 
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angle is not much bigger than 5
o
, only the interatomic distances in the sample can be observed. 
When the sample diffracts to a higher angle closer to 90
o
, usually called higher crystallographic 
resolution, the crystal structure of the molecule can be determined. In pharmaceutical sciences, 
WAXS can be utilized to determine the atomic structure of drug molecules, drug targets and drug 
carriers. 
 
Figure 5.3- Definition of SAXS and WAXS with respect to scattering angle 
 
On the other hand SAXS is an adaptable tool to characterize molecules in solution under the 
assumption that the molecules do not interact with each other. It is mainly used to study shapes 
of macromolecules and their complexes. In its “high resolution” range, close to 2θ = 5o, SAXS is 
used to study supramolecular arrangements of molecules such as liquid crystals and colloidal 
structures, which are of great pharmaceutical interest since information about the shape and size 
of nano-particulate drug delivery systems (1-100 nm) can be probed (Figure 5.3).
303
 
An ultra-small angle X-ray scattering (USAXS) is covering scattering angles less than 0.1ᵒ and 
can be used to probe large colloidal structures and multi-layer polymer films (Figure 5.3). 
Sometime in the literature a sample to detector distance is used to describe subareas of scattering 
(Table 5.1). According to this definition scattering experiments performed in this thesis would 
belong to middle-angle X-ray scattering (MAXS). 
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Table 5.1- Subareas of  scattering as a function of the sample-detector distance (R), assuming an X-ray wavelength 
of λ~ 1.5 Å.  
Adapted from Ezquerra et al, 2009.
304
  
Subarea R [m] Focus Application 
WAXS 0.05-0.2 Arrangement of atoms Crystallography 
MAXS 0.2-1.0 Liquid-crystalline structure Liquid-crystalline structure, drug delivery 
SAXS 1-3 Nanostructure 2-50 nm Macromolecules in solutions, semi-crystalline 
structure of polymers 
USAXS 6-15 Nanostructure 15 nm- 2 μm Multi-layer polymer films 
 
5.2.2. Single crystal X-ray crystallography 
A crystal is a three-dimensional periodic arrangements of the molecules packed together by 
intermolecular forces. The unit cell is the smallest part of the crystal which represents the 
properties of the whole crystal. Determination of the atomic content of unit cells will lead to 
solve the structure of the crystal.
305
 The unit cell is defined by the crystal lattice made of a, b and 
c vectors, and α, β, and γ angles between vectors, respectively. The unit cell content is composed 
of identical parts called asymmetric units. Seven crystal systems have been defined by the unit 
cell dimensions, angles and symmetry.
306 
There are 230 three-dimensional possible space groups 
that are used by crystallographers to describe crystal structures. However, in macromolecular 
crystallography due to the chiral nature of natural proteins only 65 space groups are possible. 
The most frequently reported space groups in macromolecular crystallography are P21, P212121, 
C2 and C2221.
306
 
 
Figure 5.4- Schematic of single crystal diffraction pattern 
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Upon scattering of the X-ray from a crystal, scattered beams interfere with each other forming a 
diffraction pattern in the form of spots (reflections) on an X-ray detector (Figure 5.4). These 
spots are representative of the discrete beams reflected from atomic planes in the crystal. The 
position and intensity of each reflection provide valuable information about the direction and 
strength of each diffracted beam.
305 
The diffraction pattern contains information about the 
spacing of the reflections called a reciprocal lattice which has inverse properties in comparison to 
the real spacing of the unit cells in the crystal lattice.
305
 Therefore, it is possible to calculate the 
unit cell dimensions from the reciprocal lattice spacing whereas the intensities of reflections are 
used to calculate electron density.
305
  
Each reflection can be assigned to three indices named Miller indices (h, k and l) determining the 
position of each reflection spot at the reciprocal space. Moreover, the intensities of the 
reflections (I(hkl)) are calculated as the square of the amplitude of the structure factors 
(F(hkl)).
305
 The relation between electron density, ρ(xyz), and structure factors, F(hkl), is 
described as a Fourier transform (FT) in Equation 5.1 in which ϕ corresponds to the phase. 
𝜌(𝑥𝑦𝑧) =
1
𝑉
∑ ∑ ∑ |𝐹(ℎ𝑘𝑙)|𝑙𝑘ℎ  cos 2𝜋 (ℎ𝑥 + 𝑘𝑦 + 𝑙𝑧 − 𝜙 (ℎ𝑘𝑙))           (5.1) 
Single X-ray crystallography is capable of providing the most accurate structural information 
about host-guest inclusion complexes. However, crystallization is a rate-limiting step in 
crystallography and growing crystals out of amorphous samples is a tremendous challenge.  
5.2.2.1 X-ray crystallography of the CD-based complexes   
In CD-based host-guest complexes, the molecular weight and properties of the guest play an 
important role in forming complex crystals. In general, appropriate guests can form complexes 
with CDs in the overall shapes of cage or channel  utilizing intermolecular hydrogen binding.
307
 
Crystallography was used to solve the crystal structures of inclusion complexes of small 
molecules with CDs. For example, the structures of the complexes of thymol, carvacrol and 
eugenol with βCD have been solved based on the synchrotron data. In all three complexes, βCD 
formed head-to-head dimers whereas the guest-host stoichiometry was observed as 1:2, 2:2 and 
3:2 for carvacrol, thymol and eugenol, respectively.
308
 In another study, X-ray crystallography 
provided information about the inclusion of menthol isomers in βCD suggesting the formation of 
the 2:2 mole ratio complexes in which βCD showed head to head and guest showed head to tail 
arrangements.
309
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5.2.3. Powder X-ray diffraction 
In comparison to a single crystal, powder samples consist of randomly oriented polycrystalline 
with the grain size of less than 10 µm. Since the crystalline objects in the powder sample are 
randomly oriented, the scattered peaks will extend over the same scattering angle resulting in a 
diffraction pattern made of rings (Figure 5.5). It is almost unfeasible to measure the intensity of 
enough reflections in the powder diffraction pattern to solve large structures. However, some 
methods such as Rietveld method
310
 has been successfully employed to refine the crystal 
structure from powder data. 
 
Figure 5.5- Schematic of powder diffraction pattern 
 
5.2.3.1. Powder X-ray diffraction of the CD-based complexes   
A crystalline powder of a guest molecule produces a diffraction pattern that is a “finger print” of 
the given compound. A diffraction pattern of the physical mixture of the guest molecule and a 
βCD molecule is mostly made of the superimposition of the peaks corresponding to the pure 
components while the diffraction pattern of the inclusion complex is mostly different from each 
component. In some cases the inclusion complex represents an amorphous structure lacking the 
crystallinity peaks of the components.
311,312
 For example, the spray dried formulation of the 
complex of metformin with triacetyl-βCD showed none of the sharp characteristic peaks of the 
two molecules and instead an amorphous solid state was formed.
248
 In other studies the absence 
of the characteristic peaks of the guest in the complex diffraction pattern is observed and a new 
diffraction pattern corresponding to the new solid phase is emerged. The inclusion of iprodione 
in βCD showed new sharp peaks in the inclusion diffractogram at 2θ angles of 11.3 º, 17.7 º and 
26.0 º.
313
 In addition, the complex made of ibuprofen and βCD employing superficial carbon 
dioxide, co-precipitation and freeze-drying methods resulted in new peaks at 2θ angle of 6.82º, 
7.3º and 7.35º, respectively.
314
 
 
 
 50 
 
Moreover, powder X-ray diffraction data can be employed directly to solve the crystalline 
structure of CD-based complexes. Rietveld refinement
315,316
 is the most commonly used 
technique to determine the crystal structure based on the nonlinear least squares method. In this 
technique instead of obtaining the discrete integrated intensities or structure factors from 
diffraction pattern (direct method), a calculated profile is fitted to the experimental data.
317
 In 
addition, the quality of the diffraction data plays an important role in the attainment of Rietveld 
refinement.
317
 Although Rietveld refinement has been used for various CD-based structures, 
there are only a few examples that successfully employed powder diffraction data to solve the 
crystal structure of the complexes of organic molecules with CDs. The crystal structure of a 
lipoic acid complex with βCD having 98 non-hydrogen atoms has been solved and the guest 
molecule configuration in the cavity has been explained in detail.
318
 Similarly, the guest 
conformation, mode of inclusion and crystal packing of atenolol
319
 and mefenamic acid
320
 
complexes with βCD have been determined from the high resolution synchrotron powder 
diffraction data. 
5.3. Characterization of nanoparticles using synchrotron SAXS/WAXS 
Contrary to X-ray diffraction from crystalline material, non-crystalline materials such as partially 
ordered systems will not develop reflection spots but partial or full diffraction rings similar to 
powder diffraction pattern which can be used to characterize the partially ordered system.  
In the case of monodisperse systems such as diluted solutions of nanoparticles where particles do 
not interact with each other, the scattering pattern is presented as a plot of scattering intensity I(s) 
[arbitrary units] versus the wave vector (s) in reciprocal space. The scattering vector (s) is the 
difference between incident and scattered beam and calculated as Equation 5.2. 
𝑠 = 2𝑠𝑖𝑛𝜃/𝜆                                       (5.2) 
where, 2θ and λ are the scattering angle and the  beam wavelength, respectively. 
Several studies in the literature have used momentum transfer, q, (calculated as 2π times the 
magnitude of s therefore, 
𝑞 = 4𝜋𝑠𝑖𝑛𝜃/𝜆                                               (5.3) 
The SR brightness and associated equipment such as very long vacuum tubes and very sensitive 
X-ray detectors  evoke SAXS as a versatile and robust technique to characterize nano-systems.
321
 
Currently, the submicron size of the synchrotron beam enables the use of samples as small as 10 
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μl which is critical for biological applications.322 Furthermore, time-resolved SAXS studies can 
be performed applying the pulsed nature of the SR.
323 
According to the storage ring magnets, the 
average time to do a SAXS experiment at synchrotron beamlines is between seconds and 
minutes. 
5.3.1. Pharmaceutical applications of SAXS/WAXS 
Among the wide range of samples that can be characterized by SAXS/WAXS, nanoparticles, 
colloidal systems and macromolecules in solutions are of great importance from a 
pharmaceutical point of view. Three different regions in the SAXS pattern can be applied to 
determine characteristics such as size, shape and surface of a dispersed system. A SAXS curve at 
lower angles (Guinier area), provides information to calculate an approximate molecule size 
(radius of gyration).
324
 The radius of gyration is the root mean square distance of all scatterers 
from a common center of the mass. At higher angles in the SAXS pattern, the surface properties 
can be obtained based on Porod’s rule325 which describes the scattering from the interface in the 
two-phase systems. The region that extends towards higher resolution, determines the internal 
structure of the particles according to the Bragg’s peak positions. 
5.3.1.1. Characterization of the lipid-based nanoparticles by SAXS/WAXS 
Lipid-based nanoparticles including nano-dispersed particles (matrix-based), liquid crystals and 
membrane-based lipid nano particulate systems such as liposomes have been characterized 
extensively using X-ray diffraction techniques particularly SAXS/WAXS as a golden technique. 
The peaks available in SAXS/WAXS curves are associated with the crystal lattice and the 
relative positions of the periodic peaks can describe the phase behavior of the lipid nanoparticles. 
Table 5.2 shows the most common lyotropic liquid crystalline mesophases based on the relative 
Bragg’s peak positions corresponding to their space groups.326 
Table 5.2- Ordinary crystalline mesophases featuring peak position ratios.
326
 
Mesophase type Peak position ratios 
Lamellar 1:2:3:4, etc 
Inverted Hexagonal √3:√4:√7:√12, etc 
Cubic 
(Bicontinuous) 
√2:√4:√6:√8:√10, etc 
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A lamellar crystalline phase is commonly formed by the lipid bilayers stacking on top of each 
other with a water layer in between.
327
 The inverted hexagonal phase is a 2D cylindrical structure 
composed of micelles packing parallel in a hexagonal lattice.
328
 Various types of cubic phases 
reported so far in which bicontinuous cubic consists of lipid bilayers in 3D structure containing 
water channels.
329
 
SAXS/WAXS patterns were used extensively to determine the LLC mesophases to improve the 
design and development of new drug delivery systems.
41,330,331
 The inverted hexagonal 
mesophase of glyceryl monooleate LLC was studied in the presence of a skin penetration 
enhancer peptide for transdermal delivery of diclofenac.
332 
It was found that the release rate of 
propranolol from cubic phases is more slowly compared to the other phases employing the 
SAXS/WAXS technique.
333 
Moreover, an interesting study evaluated the effect of different drug 
molecules loaded in LLC phases on the structure by building computational models and 
subsequently confirming them by synchrotron SAXS/WAXS measurements.
334
 Synchrotron 
time-resolved SAXS was able to discover the phase transformations occurring under different 
situations such as transformation from cubic to hexagonal
335
 or lamellar to cubic phases
336
. 
Furthermore, SAXS/WAXS was employed to characterize the phase behavior of the solid lipid 
nanoparticles (SLN). For instance, the lamellar structure of cetyl palmitate was determined 
according to the Bragg’s peak positions of 001, 002 and 003 in a manner that s-values for the 
first peak was half and one-third of the second and third peaks, respectively.
337
  
In other studies the effect of the drug loaded into nanoparticles on phase transition has been 
investigated. Increasing the concentration of diclofenac, decreased the bilayer distance in 
phospholipid liposomal formulation and new micellar structures have been formed.
338
 
A fast growing subcategory of lipid-based nanoparticles is the development of lipoplexes. 
Lipoplexes mostly consist of cationic liposomes in combination with nucleic acids as non-viral 
gene delivery vectors.
339
 The study of structure-transfection relationship of different cationic 
liposomes/DNA formulations suggested that with the increase in the concentration of dendritic 
cationic lipids, the characteristic lamellar phase peaks changed to a novel self-assembly model 
called hexagonal tubular phase with higher transfection efficacy in comparison to lamellar and 
inverted hexagonal phases commonly observed in lipoplexes.
340 
In another research, the gene 
silencing activity and phase transition of SiRNA/DOTAP/DOPE formulations were evaluated. It 
was found that increasing the DOPE concentration resulted in the phase transition from lamellar 
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to inverted hexagonal.
341
 
5.3.1.2. Characterization of gemini-based nanoparticles by SAXS/WAXS 
As mentioned before, cationic gemini surfactants can form complexes with nucleic acids and act 
as gene delivery vectors. The structure determination of various plasmid/amine substituted 
gemini surfactant/DOPE complexes were performed using SAXS/WAXS data. The results 
showed that the increased transfection efficacy in formulations containing gemini surfactants 
with pH-sensitive imine-based spacers can be correlated to the formation of less ordered phases 
other than the hexagonal phase. The main Bragg’s peak observed for 12-7NH-12 gemini 
surfactant was at q of 0.105 Å
-1
 corresponding to d-spacing of 59.6 Å. The presence of another 
strong peak at q of 0.117 Å
-1
 along with several weak peaks confirmed the formation of other 
phases.
166 
In another study, the phase behavior of lipoplexes consisting of glucose-based gemini 
surfactants showed three different morphologies called as lamellar, condensed lamellar and 
inverted hexagonal at pH range of 8.8 to 3 and the inverted hexagonal phase showed higher 
fusogenic activity.
342
 The co-existence of condensed lamellar and lamellar phases was reported 
in alkane-α,ω-diyl-bis(alkyldimethylammonium bromide) gemini/DOPE/DNA complexes which 
is related to the ionic strength (NaCl solution), surface charge density and the sample preparation 
method.
343
 Moreover, it was observed that SiRNA complexes with bis(quaternary 
ammonium)bromide gemini surfactants having a 12 hydrocarbon tail and different spacer lengths 
(s=3, 6, 12) formed a micellar sandwich model. Gemini surfactant self-assembly structures were 
globular with different radii of gyration dependent on spacer length.
344
 The structural behavior of 
phytanyl substituted gemini surfactants complexes with DNA obtained by SAXS/WAXS data 
and correlated to their transfection efficiency and cytotoxicity in OVCAR-3 cells.
345
 
In addition, phase diagrams of gemini surfactants can be determined through monitoring the 
changes in SAXS/WAXS pattern. The investigation of a ternary system of various gemini 
surfactant/octanol/water demonstrated the coexistence of four anisotropic phases as hexagonal, 
hexagonal/lamellar, lamellar and lamellar/micelle.
346
 In another study, two zwitterionic 
bis(alkyltriazolium sulfobetaine) gemini surfactants showed an inverse discontinuous micellar 
cubic phase that was highly stable at a wide range of surfactant concentration and temperature.
347
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6. RESEARCH FOCUS 
6.1. Rationale for the study 
The majority of the anticancer agents synthesized every year, have poor water solubility leading 
to a low in vivo bioavailability. The use of organic solvents in anticancer formulations is limited 
due to their high cytotoxicity. However, nanotechnology revolutionized anticancer drug delivery 
by introducing various tunable nano-sized delivery agents. In brief, anticancer agents 
encapsulated by nano- drug delivery systems offer higher efficiency and lower resistance.  
In our research group, novel lipid-based drug delivery agents, βcyclodextrin-gemini surfactants 
(βCDgemini surfactants), have been synthesized by attaching βcyclodextrin to various gemini 
surfactants.
3
 βcyclodextrin (βCD), a ring-shaped oligosaccharide having seven α-D-
glucopyranose units is able to incorporate hydrophobic molecules and form host-guest inclusion 
complexes.
277
 The gemini surfactants employed to build these delivery agents, belong to imino 
substituted bisquaternary ammonium gemini surfactants extensively used as gene delivery 
vectors.
153
 Previously, it was shown that the nano-structures formed by self-assembly of the 
gemini surfactant could insert foreign genes into mammalian cells.
166
 The βCDgemini surfactants 
were designed to benefit simultaneously from βCD as a solubilizing agent and gemini surfactants 
as self-assembling agents. 
Curcumin, the active ingredient of turmeric rhizome showed anticancer activity, but its potential 
to be used as a drug was hampered by a high IC50 value in cancer cell lines and low in vivo 
bioavailability.
94
 To modify the characteristics of curcumin, various curcumin analogs have been 
synthesized. Dr. Dimmock and his colleagues synthesized a variety of curcumin analogs showing 
high in vitro cytotoxicity towards various cancer cell lines, including colon cancer and 
melanoma.
111
 Despite formidable efforts in oncology research, treatment of melanoma, the 
deadliest type of skin cancer, remains largely ineffective. This is mostly due to the 
chemoresistance
48
 to conventional chemotherapy agents and low penetration of drugs into the 
skin cells. Thus we proposed to utilize the knowledge on the curcumin analogs to develop new 
potential therapies for melanoma. We selected a curcumin analog, named NC 2067, which 
previously showed high in vitro cell toxicity towards A375 melanoma cell line and minimal 
toxicity to normal human keratinocytes. The high lipophilicity of NC 2067 (log P value of 4.6)
2
 
is an issue which can restrict its in vivo bioavailability. We previously reported that to overcome 
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this drawback, βCDgemini surfactant as a delivery agent for NC 2067 could be employed.3 It 
was confirmed that NC 2067 in presence of βCDgemini surfactant was able to retain its 
anticancer activity in vitro and increased caspase 3 and 7 in A375 melanoma cells.
3
 
In my research, I developed a series of formulations of NC 2067 and βCDgemini surfactants by 
varying the linker structure, βCDgemini surfactant moiety, the mole ratios between the 
anticancer agent to delivery agent and addition of helper lipid. The main purpose of my 
dissertation was the physicochemical characterization and evaluation of the anticancer activity of 
these formulations. The host-guest inclusion complexes of NC 2067 with βCD and βCDgemini 
surfactant were characterized using different synchrotron and non-synchrotron techniques. The 
nano-structural behavior of the formulations was evaluated to further understand the aggregation 
of the complexes formed by NC 2067 and various βCDgemini surfactants. Finally, the 
mechanism of cell death triggered by the formulations was assessed by flow cytometry in A375 
melanoma cells. 
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6.2. Hypothesis 
A curcumin analog, NC 2067 will interact with cyclodextrin-gemini surfactant-based delivery 
agents and its in vitro cytotoxic activity will increase in A375 melanoma cells. 
6.3. Objectives 
Overall objectives 
- To characterize drug/βCDgemini surfactant conjugates using different techniques. 
- To evaluate the anticancer activity mechanism of these formulations in melanoma cell line. 
 
 Specific objectives 
1. Physicochemical characterization 
1.1. To incorporate a selected drug (NC 2067) into βCDgemini surfactant complex 
1.2. To develop formulations by varying the mole ratio between the drug and delivery agent, 
using βCDgemini surfactants with various gemini surfactant tails, having ester or amide 
bonds between the βCD and gemini surfactant moiety and addition of helper lipid 
1.3. To characterize the βCDgemini surfactants 
1.4. To confirm the formation of the inclusion of NC 2067 in βCD or βCDgemini surfactant 
qualitatively using different analytical techniques 
1.5. To use advanced techniques such as synchrotron single crystal X-ray diffraction or 2D 
ROSEY NMR to understand the structural properties of the drug/βCD and drug/βCDgemini 
surfactant inclusion complexes 
1.6. To use synchrotron small- and wide angle X-ray scattering (SAXS/WAXS) to evaluate 
the supramolecular arrangement of drug/βCDgemini surfactant delivery systems in solution 
 
2. Molecular mechanism of the anticancer activity 
2.1. To calculate the cell toxicity (IC50) of different drug/βCDgemini surfactant formulations 
towards melanoma cell line 
2.2. To elucidate the type of cell death mechanism and cell cycle arrest behavior of different 
drug/βCDgemini surfactant formulations using flow cytometry-based assays in melanoma 
cells 
 57 
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This published manuscript describes the physicochemical characterization and in vitro 
cytotoxicity of NC 2067 complexes with βCD and βCDgemini surfactant. I used synchrotron-
based powder X-ray diffraction, Fourier transform infrared spectroscopy and thermogravimetric 
analysis to confirm the inclusion formation in NC 2067 complexes with βCD and βCDgemini 
surfactant. Synchrotron-based small- and wide angle X-ray scattering and dynamic light 
scattering employed to characterize the nano-structures of NC 2067/βCDgemini surfactant 
complexes. Moreover, I determined the cellular toxicity of NC 2067/βCDgemini surfactant 
complexes towards A375 melanoma cells. 
The co-authors of this paper synthesized the anticancer agent, NC 2067 and the delivery agent, 
βCDgemini surfactant. 
 
This manuscript addresses the following specific objectives of my research  
1.1. To incorporate a selected drug (NC 2067) into βCDgemini surfactant complex 
1.2. To develop formulations by varying the mole ratio between the drug and delivery agent 
and having ester or amide bonds between the βCD and gemini surfactant moiety 
1.4. To confirm the formation of the inclusion of NC 2067 in βCD or βCDgemini surfactant 
qualitatively using different analytical techniques 
1.6. To use synchrotron small- and wide angle X-ray scattering (SAXS/WAXS) to evaluate 
the supramolecular arrangement of drug/βCDgemini surfactant delivery systems in solution 
2.1. To calculate the cell toxicity (IC50) of different drug/βCDgemini surfactant formulations 
towards melanoma cell line 
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7.1. Abstract 
Purpose:  Curcumin analogs, including novel compound NC 2067, are potent cytotoxic agents 
that suffer from poor solubility, and hence, low bioavailability. Cyclodextrin-based carriers can 
be used to encapsulate such agents.  In order to understand the interaction between the two 
molecules, the physicochemical properties of the host-guest complexes of NC 2067 with 
βcyclodextrin (βCD) or βcyclodextrin-gemini surfactant (βCDgemini surfactant) were 
investigated for the first time. Moreover, possible supramolecular structures were examined in 
order to aid the development of new drug delivery systems. Furthermore, the in vitro anticancer 
activity of the complex of NC 2067 with βCDgemini surfactant nanoparticles was demonstrated 
in the A375 melanoma cell line.  
Methods: Physicochemical properties of the complexes formed of NC 2067 with βCD or 
βCDgemini surfactant were investigated by synchrotron-based powder X-ray diffraction, 
Fourier-transform infrared spectroscopy and thermogravimetric analysis. Synchrotron-based 
small- and wide angle X-ray scattering and size measurements were employed to assess the 
supramolecular morphology of the complex formed by NC 2067 with βCDgemini surfactant. 
Lastly, the in vitro cell toxicity of the formulations toward A375 melanoma cells at various drug-
to-carrier mole ratios were measured by cell viability assay. 
Results: Physical mixtures of NC 2067 and βCD or βCDgemini surfactant showed 
characteristics of the individual components, whereas the complex of NC 2067 and βCD or 
βCDgemini surfactant presented new structural features, supporting the formation of the host-
guest complexes. Complexes of NC 2067 with βCDgemini surfactants formed nanoparticles 
having sizes of 100-200 nm. NC 2067 retained its anticancer activity in the complex with 
βCDgemini surfactant for different drug-to-carrier mole ratios, with an IC50 (half-maximal 
inhibitory concentration) value comparable to that for NC 2067 without the carrier.  
Conclusions: The formation of host-guest complexes of NC 2067 with βCD or βCDgemini 
surfactant has been confirmed and hence the βCDgemini surfactant shows good potential to be 
used as a delivery system for anticancer agents. 
 
 
Keywords: host-guest complex, gemini surfactant, cyclodextrin, curcumin analog, small-angle X-
ray scattering 
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7.2. Introduction 
With the advances of combinatorial chemistry, many new anticancer agents are synthesized 
every year in an effort to combat different cancers. The major challenge with some compounds is 
their low water solubility, which results in poor absorption through biomembranes and leads to 
low bioavailability. Organic solvents (dimethylsulfoxide [DMSO]) and surfactants 
(Cremophor®) are used in laboratory experiments and formulations to enhance the solubilization 
of these molecules. However, DMSO is not safe for in vivo use because it has its own influence 
on the cells and the US Food and Drug Administration has not yet approved the use of DMSO as 
a delivery agent except for the treatment of interstitial cystitis.
348
 In addition, Cremophor used in 
conventional chemotherapy formulations is associated with fatal hypersensitivity reactions.
1
 
Therefore, different nanotechnology-based drug delivery systems have been developed to 
increase the solubility of the hydrophobic anticancer compounds and enhance their efficiency. 
Curcumin, the active ingredient of turmeric rhizome, and its analogs are some examples of 
poorly soluble drug candidates in aqueous medium. While they show strong in vitro anticancer 
activity towards different cancer cell lines
3,91,97,107,108,349,350
 their lipophilicity (high logP value) is 
a limitation for in vivo applications. Various nanotechnology-based drug delivery systems, such 
as liposomes
95,96
, solid lipid nanoparticles
97,98,351
, polymer-based nanoparticles
99,349,352
 and 
mesoporous nanoparticles
353
, have been developed to encapsulate curcumin and its analogs so as 
to enhance solubilization and deliver them to cancerous cells. Beta-cyclodextrin (βCD) (Figure 
7.1A) is a well-known carrier for insoluble drugs in the pharmaceutical industry. It is capable of 
encapsulating a lipophilic guest molecule in its hydrophobic internal cavity to form a complex 
and its hydrophilic outer surface leads to improved guest solubility in an aqueous 
environment.
123
 Complexes of curcumin or curcumin analogs and βCD have been created 
previously to increase the water solubility of the drug.
103,133,354-357
 Curcumin analogs with the 
1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore structure have been synthesized and their cell 
toxicity toward various cancer cell lines has been demonstrated.
108,111
 Among these structures, 
NC 2067 (Figure 7.1B) demonstrated high in vitro cell toxicity towards melanoma and colon 
cancer cell lines.
3,226
 Its high logP value of 4.6
2
 and the presence of aromatic ring moieties in its 
structure suggest that NC 2067 is a good candidate for encapsulation by βCD. Beta cyclodextrin-
gemini surfactant (βCDgemini surfactant) is a novel carrier composed of βCD attached by an 
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ester or amide linker to a cationic gemini surfactant (Figure 7.1C and 7.1D, respectively). They 
were synthesized in order to create a suitable substitute for a solubilizing agent,
3
 hypothesizing 
that the hydrophobic βCD cavity can accommodate NC 2067 while the gemini surfactant tail 
possibly could contribute to a supramolecular association that would enhance diffusion into 
biomembranes.  
In a previous study
3
, we have shown that NC 2067 in a complex with βCD or βCDgemini 
surfactant in a 1:2 mole ratio exhibited high in vitro cell toxicity toward A375 melanoma cell 
line. Moreover, based on UV spectroscopy findings, we have also suggested a hypothetical 
model of the interaction of the NC 2067 molecule with βCD and βCDgemini surfactant.3 
However, understanding the nature of the physicochemical interactions between NC 2067 and 
βCD or βCDgemini surfactant is necessary to confirm whether inclusion complexes are formed. 
Furthermore, examination of the structural behavior of the nanoparticles made of NC 2067 in a 
complex with the βCDgemini surfactant should help to optimize the use of these nanoparticles as 
delivery agents for poorly soluble anticancer agents such as NC 2067.  
The objective of the current work is to determine to what degree inclusion of NC 2067 in βCD or 
βCDgemini surfactant can occur. Moreover, the nanoparticulate behavior of NC 2067 in a 
complex with βCDgemini will be assessed more comprehensively. Finally, the effect of 
variations in drug-to-carrier mole ratio and linker structure on the size and anticancer activity of 
the nanoparticulate systems are investigated.  
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Figure 7.1- Chemical structures of (A) βCD, (B) NC 2067, (C) βCDgemini surfactant (ester linker) and (D) 
βCDgemini surfactant (amide linker).  
Abbreviations: βCD, βcyclodextrin; βCDgemini surfactant, βcyclodextrin-gemini surfactant. 
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7.3. Materials and methods 
7.3.1. Preparation of inclusion complexes  
Curcumin analog NC 2067 was synthesized as described previously.
111
 βCD was purchased from 
Alfa Aesar (Haverhill, MA, USA). βCDgemini surfactants with ester or amide linkages were 
synthesized previously.
3
 All other chemicals were purchased from Sigma-Aldrich (Oakville, ON, 
Canada). Complexes of NC 2067 with βCD or βCDgemini surfactant were created as follows. 
Solutions of βCD and βCDgemini surfactant in water (10 mM) and NC 2067 in methanol (2 
mM) were combined to obtain mole ratios of drug to delivery agent of 0.5, 1.0 and 2.0 and 
shaken overnight. The solvent mixture was removed by rotary evaporation under vacuum. These 
powders were used for the powder diffraction, thermogravimetric analysis (TGA), and Fourier-
transform infrared (FTIR) spectroscopy experiments. For all other studies, the residue was 
reconstituted in water and shaken overnight. Physical mixtures were made by blending the 
appropriate amount of powders of NC 2067 and βCD or βCDgemini surfactant. 
7.3.2. Characterization of the complex of NC 2067 with βCD or βCDgemini surfactant 
7.3.2.1. Powder X-ray diffraction measurements 
The powder samples of NC 2067 and its physical mixtures and complexes with βCD or 
βCDgemini surfactant were loaded into capillaries (MiTeGen, Ithaca, NY, USA). Powder X-ray 
diffraction patterns were obtained at beamline 08B1-1 (Canadian Macromolecular 
Crystallography Facility-bend magnet) at the Canadian Light Source Inc (CLS, Saskatoon, 
Canada) using X-ray energy of 12 keV at room temperature.
358
 Data collection was performed at 
a sample-to-detector distance of 280 mm with 30-second exposure time. Data processing was 
carried out employing X-ray analysis software for partially ordered and disordered systems 
(Alaidi, personal communication), automating Fit2d.
359
 
7.3.2.2. FTIR spectroscopy 
Infrared spectra of the powder samples of NC 2067 and its physical mixtures and complexes 
with βCD or βCDgemini surfactant, embedded in a KBr matrix, were scanned over the 4,000–
400 cm
−1 
region and recorded by using a Bruker IFS 66v/S Fourier-transform spectrometer 
(Bruker Optics, Billerica, MA, USA) at Mid-IR beamline at the CLS. 
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7.3.2.3. TGA study 
The thermal behavior of NC 2067 and its physical mixtures and complexes with βCD or 
βCDgemini surfactant was evaluated using TGA. The scans were carried out employing a TGA 
Q500 instrument (TA instruments, New Castle, DE, USA) under nitrogen at a heating rate of 
5⁰C/min. 
7.3.2.4. Small- and wide angle X-ray scattering measurements 
Small- and wide angle X-ray scattering (SAXS/WAXS) measurements were performed at the 
BL4-2 beamline at Stanford Synchrotron Radiation Lightsource (SSRL, Stanford, CA, USA) at 
an energy of 11 keV and a sample-to-detector distance of 1.1 m at 20-second exposure time. 
Diffraction intensity versus q (scattering vector) plots were obtained by radial integration of the 
two-dimensional patterns using X-ray analysis software for partially ordered and disordered 
systems. The concentration of βCDgemini surfactant in all samples was fixed at 10 mM.  
7.3.2.5. Size measurements 
Particle sizes in solution were measured using a Zetasizer Nano ZS instrument (Malvern 
Instruments, Malvern, UK). Results are reported as the mean of three to five measurements ± 
standard deviation. 
7.3.3. Cell viability assay 
A375, human amelanotic melanoma cells (American Type Culture Collection, CRL-1619) were 
seeded at a density of 1 x 10
4
 cells per well in 96-well tissue culture-treated plates. Cells were 
treated with the formulations at drug concentrations of 0.01–200 µM in quadruplicate wells for 
48 hours to produce a balanced four-parameter curve. The experiments were conducted in 
triplicate. After treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 
Invitrogen, Burlington, ON, Canada) at 450 μg/mL was added to each well and the plates were 
incubated for 2 hours at 37 ᵒC.  Absorbance at 550 nm was recorded using a Synergy BioTek 
plate reader. The values of the half-maximal inhibitory concentration (IC50) for all samples were 
calculated using the four-parameter curves generated by the Gen5 software from BioTek. 
7.3.4. Statistical analysis 
Statistical analysis was performed using SPSS (version 19.0). One-way analysis of variance and 
Scheffe’s comparison were used. The level of significance was considered at p<0.05 value. 
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7.4. Results 
7.4.1. Physicochemical characterization of the host-guest inclusion complexes of NC 2067 in 
βCD and βCDgemini surfactant 
7.4.1.1. Powder X-ray diffraction analysis  
To confirm the formation of the complexes of NC 2067 and βCD or βCDgemini surfactant, 
analysis of powder diffraction patterns of the complexes were compared to the patterns of the 
physical mixtures of NC 2067 and βCD or βCDgemini surfactant. Because of the structure of the 
linker (amide or ester) in βCDgemini surfactant should have a minimal influence on the host-
guest complexes, only βCDgemini surfactant with the ester linker was evaluated. Moreover, 
qualitative analysis of the host-guest complexes will not change with different drug-to-carrier 
mole ratios and hence, the 1:2 mole ratio was selected for these experiments. Diffractograms of 
βCD, NC 2067, their physical mixture, and the complex they formed are illustrated in Figure 
7.2A. The βCD and NC 2067 diffractograms (Figure 7.2A-a and -b, respectively) display several 
peaks representative of a crystalline structure. The physical mixture of NC 2067 and βCD 
(Figure 7.2A-c) shows a pattern resembling the superposition of the NC 2067 and βCD peaks, 
with the most intense peaks of NC 2067, at 2θ angles of 3.9⁰, 12.8⁰, 13.2⁰, 13.9⁰ and 18.8⁰, 
being most evident. Conversely, in the diffraction pattern of the complex of NC 2067 with βCD 
(Figure 2A-d), a new diffraction pattern emerges, with peaks in different positions such as 1.9º, 
9.3º and 12.2º, which is not found in diffractograms of NC 2067 or βCD (All the peak positions 
are presented in Table S1). 
Diffractograms of βCDgemini surfactant, NC 2067, their simple physical mixture and their 
complex are illustrated in Figure 7.2B. The diffused diffraction pattern of βCDgemini surfactant 
(Figure 7.2B-a) is representative of an amorphous structure.  In the physical mixture of NC 2067 
and βCDgemini surfactant (Figure 7.2B-c) and as seen in the NC 2067 and βCD physical 
mixture (Figure 2A-c), the strongest peaks of NC 2067 are visible (at 2θ angles of 3.9⁰, 12.8⁰, 
13.2⁰, 13.9⁰ and 18.9⁰).  On the contrary, the diffractogram of the complex of NC 2067 with 
βCDgemini surfactant (Figure 7.2B-d) illustrates an expected amorphous structure similar to that 
of βCDgemini surfactant, confirming the formation of a complex between NC 2067 and the 
βCDgemini surfactant. 
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Figure 7.2- Diffractograms of (A) βCD (a), NC 2067 (b), Physical mixture (c) and inclusion complex of NC 2067 
and βCD (d); and (B) βCDgemini surfactant (a), NC 2067 (b), Physical mixture (c) and inclusion complex of NC 
2067 and βCDgemini surfactant (d). 
Abbreviations: au, arbitrary unit; βCD, βcyclodextrin; βCDgemini surfactant, βcyclodextrin-gemini surfactant. 
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7.4.1.2. FTIR spectroscopy  
Further evaluation of the complex between the drug and βCD or βCDgemini surfactant (using 
the ester linker as a model) was carried out by comparison of the FTIR spectra (Figure 7.3) of 
NC 2067, βCD, βCDgemini surfactant, their complexes, and physical mixtures. Generally, in the 
physical mixtures of NC 2067 and βCD or βCDgemini surfactant (Figure 7.3A-c and 7.3B-c), the 
infrared peaks of NC 2067 and βCD or βCDgemini surfactant are detectable, whereas in the 
complexes of NC 2067 with βCD or βCDgemini surfactant (Figure 7.3A-d and B-d), some peaks 
of the NC 2067 are missing or very weak. For example, the three bands corresponding to the 
aromatic ring conjugated with the alkene C=C bond of NC 2067 in the 1,450-1,600 cm
-1
 range 
are still detectable in the physical mixture at 1,468, 1,489 and 1,512 cm
-1
, whereas in the 
complexes, they are very weak or undetectable. The peak of NC 2067 at 1,671 cm
-1
, 
corresponding to the α,β-unsaturated ketone stretch, is still present in the physical mixture, 
whereas it is less intense in the complex. Moreover, there are several peaks of NC 2067 at 694 
cm
-1
, 1,278 cm
-1
, 1,433 cm
-1
 and 3,022 cm
-1
,
 
which disappear after complexation of NC 2067 
with βCD but are observable in the physical mixture. Similarly, the peaks of NC 2067 at 694 cm-
1
, 1433 cm
-1
, 1608 cm
-1
, 1631 cm
-1
and 3,022 cm
-1
 are lacking in the complex of NC 2067 with 
βCDgemini surfactant but observable in their physical mixture. The disappearance of the NC 
2067 peaks at 694 cm
-1
, corresponding to the monosubstituted aromatic ring, and at 3,022 cm
-1
, 
corresponding to the C-H stretch of the aromatic ring, from the complexes supports the theory 
that one or both aromatic rings conjugated with the alkene bond in the NC 2067 structure are 
involved in the inclusion. On the other hand, a peak at 1,248 cm
-1
, corresponding to the aryl alkyl 
ether group (side chain in NC 2067 structure), can be detected in all physical mixtures and 
complexes with βCD and βCDgemini surfactant, thus suggesting that this side chain is not 
involved with the βCD moiety in the complex (Figure 7.3). 
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Figure 7.3- FTIR spectra of (A) βCD (a), NC 2067 (b), physical mixture (c) and inclusion complex of NC 2067 and 
βCD (d); (B) βCDgemini surfactant (a), NC 2067 (b), physical mixture (c) and inclusion complex of NC 2067 and 
βCDgemini surfactant (d).  
Note: Expansions for the 1,720-1,380 cm
-1
 region are illustrated in the insets. 
Abbreviations: au, arbitrary unit; βCD, βcyclodextrin; βCDgemini surfactant, βcyclodextrin-gemini surfactant; 
FTIR, Fourier-transform infrared. 
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7.4.1.3. TGA study  
Thermal behavior of the complexes and physical mixtures of NC 2067 and βCD or βCDgemini 
surfactant (using ester linker) was investigated to further corroborate the results obtained from 
powder X-ray diffraction and FTIR studies. The thermal profile of βCD (Figure 7.4A) showed a 
water loss of 10% from 30⁰C to 70 ⁰C and degradation occurring in the range of 275⁰C to 315 
⁰C, with a concomitant 65% weight loss, which is in agreement with a previous report.258 The 
physical mixture displayed 8% water loss in the same temperature range as βCD whereas no 
water loss was recorded in the complex in this range (Figure 7.4A). Thermal decomposition of 
NC 2067 began at 218 ⁰C, while the complex of NC 2067 with βCD showed delayed onset of the 
degradation, shifting to a higher temperature of 240 ⁰C (Figure 7.4A). The thermogram 
corresponding to βCDgemini surfactant (Figure 7.4B) did not show the initial water loss at or 
below 70 ⁰C. The complex of NC 2067 with βCDgemini surfactant showed marginally less water 
loss in comparison to βCDgemini surfactant alone. Moreover, the degradation temperature of NC 
2067 in the complex increased to 232 ⁰C (Figure 7.4B).   
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Figure 7.4- TGA thermograms of (A) βCD, NC 2067, physical mixture and inclusion complex of NC 2067 and 
βCD; and (B)  
βCDgemini surfactant, NC 2067, physical mixture and inclusion complex of NC 2067 and βCDgemini surfactant. 
Abbreviations: βCD, βcyclodextrin; βCDgemini surfactant, βcyclodextrin-gemini surfactant; TGA, 
thermogravimetric analysis. 
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7.4.2. Nanoparticulate behavior of NC 2067 in complex with βCDgemini surfactant 
7.4.2.1. Size measurements of nanoparticles 
Because a complex of NC 2067 with βCD will not form nanoparticles, only the size of 
nanoparticulate systems of NC 2067 in a complex with the βCDgemini surfactant (ester and 
amide linkers) in water at three different drug-to-carrier mole ratios (1:0.5, 1:1 and 1:2) was 
measured. All the nanoparticles had sizes in the range of 101-199 nm, with a polydispersity 
index ≤ 0.3 (Table 7.1). The average size of the nanoparticles formed by NC 2067/βCDgemini 
surfactant (ester linker at 1:2 mole ratio) was significantly different (p<0.05) from the size of 
particles in other formulations. The size of the nanoparticles at 1:0.5 mole ratio was significantly 
higher than that at the other two mole ratios for both ester and amide linker groups. βCDgemini 
surfactant size measurements provided variable values with high polydispersity index, 
suggesting the inhomogeneous nature of the aggregations of free βCDgemini surfactant in 
solution. 
Table 7.1- Size of different nanoparticulate formulations and corresponding PDI. 
NC2067/βCDgemini 
surfactant nanoparticles 
NC 2067-to-βCDgemini 
surfactant mole ratio 
size (nm) ± SD PDI 
Ester linker 
1:0.5 160 ± 3 0.1 
1:1 140 ± 1 0.2 
1:2 101 ± 2 0.3 
Amide linker 
1:0.5 199 ± 6 0.3 
1:1 131 ± 3 0.2 
1:2 131 ± 1 0.2 
Note: Sizes are the average of three to five measurements ± SD. 
Abbreviations: βCD, βcyclodextrin; βCDgemini surfactant, βcyclodextrin-gemini surfactant; PDI, polydispersity 
index; SD, standard deviation. 
 
7.4.2.2. SAXS/WAXS measurements 
To evaluate the lipid phase behavior of the nanoparticles, we assessed the SAXS/WAXS pattern 
of the complexes of NC 2067 with βCDgemini surfactant (ester linker) at three different drug-to-
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carrier mole ratios (1:0.5, 1:1 and 1:2) (Figure 7.5). Surprisingly, the βCDgemini surfactant, 
alone, showed a broad peak pattern in the SAXS region (q < 0.1 Å
-1
), corresponding to the 
formation of aggregates, without showing any peak in the WAXS region (Figure 7.5A). 
Moreover, the scattering pattern of different concentrations of βCDgemini surfactant (1-30 mM) 
in the q range of 0.02-0.2 Å
-1 
did not alter in position (data not shown). Once again, because the 
nature of the linker has minimal effect on the self-assembling behavior of the gemini surfactants, 
we focused on the ester linker. Interestingly, adding NC 2067 to the βCDgemini surfactant at 
different mole ratios (1:0.5, 1:1 and 1:2) resulted in a flattening of the peak corresponding to the 
free βCDgemini surfactant phase and, simultaneously, appearance of a peak at q of 0.27 Å-1 in 
the scattering pattern (Figures 7.5B-D). Furthermore, at higher q or 2θ angles, some peaks at q of 
0.42 Å
-1
, 0.56 Å
-1
, 0.66 Å
-1
 and 0.8 Å
-1
 (corresponding to 2θ angles of 4.3⁰, 5.7⁰, 6.8⁰ and 8.3⁰, 
respectively) are observed for the complexes of NC 2067 and βCDgemini surfactant with higher 
drug-to-carrier mole ratio. These peaks correspond to the most intense peaks observed in the 
powder X-ray diffraction pattern of the free NC 2067.  
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Figure 7.5- SAXS/WAXS patterns of (A) βCDgemini surfactant; and complexes of NC 2067 with βCDgemini 
surfactant at three different mole ratios of (B) 1:2, (C) 1:1 and (D) 1:0.5. Arrows show the peaks corresponding to 
precipitated NC 2067. 
Abbreviations: βCD, βcyclodextrin; βCDgemini surfactant, βcyclodextrin-gemini surfactant; SAXS/WAXS, small- 
and wide-angle X-ray scattering. 
 
7.4.3. Cell activity of NC 2067 /βCDgemini surfactant formulations 
Our aim was to evaluate the effect of various NC 2067/βCDgemini surfactant nanoparticulate 
formulations, made at different drug-to-carrier mole ratios and with different linkers, on the cell 
viability of the A375 cell line to complete our previous study.
3
 
7.4.3.1. In vitro activity of NC 2067 in complexes with βCDgemini surfactants having different linkers  
To evaluate the efficiency of the anticancer agent encapsulated in the carrier, we assessed the 
ability of NC 2067, in the form of a complex with βCDgemini surfactant, to kill A375 melanoma 
cells (Table 7.2). NC 2067 in the complex with βCDgemini surfactant (having both amide and 
ester linkers), at 1:2 mole ratio, showed strong cytotoxic effects, with IC50 values of 2.1 ± 0.3 μM 
and 2.0 ± 0.25 μM, respectively, comparable to the values reported in previous work.3 The IC50 
values of NC 2067 in βCDgemini surfactants having different linkers were similar (P>0.05).  
In order to gain some estimate of the contribution of the delivery agent (βCDgemini surfactant) 
to the overall toxicity shown by the inclusion complexes (Table 2), the toxicity of the 
βCDgemini surfactants (both ester and amide linker) was evaluated at a 200 μM carrier 
concentration. This concentration is approximately 50-fold higher compared to the carrier 
concentration at the IC50 values shown in Table 2 for the complexes. The toxicity of βCDgemini 
surfactant with amide linker (95% ± 0.5%) was significantly (P<0.05) greater than that of 
βCDgemini surfactant with an ester linker (18% ± 6%) (Table 7.2). 
7.4.3.2. In vitro activity of NC 2067 in complex with βCDgemini surfactant in different drug-to-delivery 
agent mole ratios 
We next determined whether the ratio of the drug to delivery agent had any influence on the 
overall efficiency of the nanoparticles. In a previous study, a 1:2 mole ratio of NC 
2067/βCDgemini surfactant was evaluated.3 Here, we assessed whether lower amounts of the 
delivery agent could be used for intracellular delivery of the NC 2067. Because the intrinsic 
toxicity of amide linker was high, we eliminated it from further study. Comparison of the NC 
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2067 in βCDgemini surfactant (ester linker) at three different drug-to-carrier mole ratios (1:0.5, 
1:1 and 1:2) showed comparable efficiency, with IC50 values in the range of 2.0-2.4 μM (Table 
7.2). Although the three different drug-to-carrier mole ratio formulations showed significantly 
higher IC50 in comparison to NC 2067 dissolved in DMSO, they showed high enough toxicity 
toward A375 melanoma cell line and were significantly more efficient than mephalan (P<0.05).  
 
Table 7.2- IC50 values of melphalan in acidified ethanol and NC 2067 in DMSO and various βCDgemini surfactant 
formulations and percentage intrinsic toxicity of the βCDgemini surfactants. 
Anticancer 
agent 
Delivery 
agent/Solvent 
Mole ratio of drug 
to delivery agent 
IC50 [μM] ± SD 
% toxicity of βCDgemini 
surfactant [ 200 µM] ± SD  
 
Melphalan Acidified ethanol NA 40 ± 9 NA 
NC 2067 
DMSO NA 0.5 ± 0.1 NA 
βCDgemini 
surfactant (amide 
linker) 
1:2 2.1 ± 0.3 94.6 ± 0.5 
βCDgemini 
surfactant (ester 
linker) 
1:0.5 2.2 ± 0.2 18 ± 6 
1:1 2.4 ± 0.4 
 
1:2 2.0 ± 0.25  
 
Abbreviations: βCD, βcyclodextrin; βCDgemini surfactant, βcyclodextrin-gemini surfactant; DMSO, dimethyl 
sulfoxide; IC50, half-maximal inhibitory concentration; SD, standard deviation; NA, not applicable. 
 
7.5. Discussion 
The comparative analysis of the powder X-ray diffraction patterns of complexes formed between 
NC 2067 and βCD or βCDgemini surfactant, their physical mixtures and the individual 
components leads to the conclusion that the complex is a new structure with altered diffraction 
pattern in comparison to its components, whereas the physical mixture pattern is the overlay of 
the guest, NC 2067, and the hosts, βCD or βCDgemini surfactant. Similar to these results, it has 
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been shown that the inclusion of iprodione in βCD displayed new sharp peaks in the 
diffractogram of the inclusion complex.
313
 Furthermore, a complex formed by ibuprofen and 
βCD, using supercritical carbon dioxide, coprecipitation, and freeze-drying methods, resulted in 
new peaks, confirming the formation of complexes.
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Based on the comparison of the FTIR spectra of the complexes of NC 2067 in βCD or 
βCDgemini surfactant and their physical mixtures, it has been observed that the peaks 
corresponding to the aromatic ring conjugated with the alkene C=C bond of NC 2067 are 
available in physical mixtures, whereas in the complexes, they are weakened or disappear. We 
hypothesize that the NC 2067 complex with βCD or βCDgemini surfactant arises from the 
complexation of the 1,5-diaryl-3-oxo-1,4-pentadienyl pharmacophore moiety and not from the 
side chain moiety substituted on the 4-piperidineone nitrogen atom.  
TGA study on NC 2067 complexed with βCD showed no water loss at 30 ºC -70 ºC in 
comparison to βCD, which lost 10% of its weight in the same temperature region. This 
phenomenon could be attributed to the fact that NC 2067, accommodated in the βCD cavity, 
displaced the water from the cavity, similar to a number of inclusion systems in βCD.260,360 
Furthermore, it was observed that βCDgemini surfactant weight did not decrease due to water 
loss, supporting the argument that inclusion of the hydrocarbon tail of the gemini surfactant in 
the βCD cavity could have displaced the water molecules commonly located in the βCD ring. 
This finding is consistent with other studies that show the βCD cavity has the affinity to 
accommodate the tail of the gemini surfactants and other double-chain surfactants.
173,176-178,361,362
 
Moreover, the thermal degradation of NC 2067 complexes formed with βCD or βCDgemini 
surfactant started at higher temperatures in comparison to that of free NC 2067, suggesting the 
formation of a more stable complex. Similar thermal behavior was observed in the case of 
complexation of sulfamethoxazole with hydroxypropyl-βCD, wherein the degradation 
temperature of the pure compound shifted from 200 ⁰C to 243 ⁰C in the complex, confirming 
that the inclusion complex is more stable than the drug.
254
 It is hypothesized that NC 2067 was 
shielded by the βCD ring and required a higher temperature to degrade due to greater 
stabilization of the drug in the complexes in comparison to NC 2067 alone.  
Overall, it seems that the potential for the gemini surfactant tail to locate whitin the βCD cavity 
of the βCDgemini surfactant competes with inclusion of NC 2067 and creates a more 
complicated system in comparison to the binary system consisting of NC 2067 and βCD. Further 
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studies of the possible inter- and intramolecular self-inclusion behavior of βCDgemini surfactant 
will be carried out by using proton nuclear magnetic resonance spectroscopy to elucidate the 
intimate interaction between the guest and host. 
Among the formulations, NC 2067/βCDgemini surfactant (ester linker) at a 1:2 mole ratio 
showed average size of 101 nm, which is optimal for cellular uptake, because particles in the 
nanometer range can evade the reticulo-endothelial system
13
 and enter the cells by endocytosis.
22
 
An additional benefit of the nano-carriers for anticancer agents is that the presence of 
nanoparticles in the endosomes prevents the expulsion of the drug through efflux pumps, 
overcoming the dominant mechanism of resistance toward anticancer agents.
363
 
The SAXS/WAXS data of free βCDgemini surfactant showed a diffused pattern that did not 
change by increasing the concentration. Based on the affinity of the βCD cavity to accommodate 
the gemini tail(s) of the βCDgemini surfactant, the gemini moiety will be unavailable to form 
supramolecular assembly in the traditional manner of the gemini surfactants.
153
 Moreover, 
contrary to the case of studies with free gemini surfactants, the constant mole ratio of gemini 
surfactant to βCD moiety in βCDgemini surfactant compounds leads to the result that increasing 
the concentration of βCDgemini surfactant does not enhance self-assembly to form micellar 
structures. This can explain the fact that specific conductivity vs concentration profiles of the 
βCDgemini surfactant (results not shown) do not have a sharp break point, the critical micelle 
concentration, consistent with that of gemini surfactant, alone. A similar type of aggregate of a 
long-tailed gemini surfactant with βCD molecules was investigated by small-angle neutron 
scattering.
364
 In the SAXS/WAXS pattern of NC 2067/βCDgemini surfactant complexes 
(different mole ratios) a new peak emerged. This change in the scattering pattern may be related 
to the partial displacement of the gemini hydrophobic tail by the NC 2067 from the βCD cavity, 
providing the gemini surfactant moiety freedom to self-assemble as traditional surfactants. This 
conclusion is consistent with other observations demonstrating that the gemini monomers, in the 
presence of βCD, are initially involved in complexation with βCD until the point that the βCD 
cavity is saturated by gemini surfactant. This phenomenon delays the routine self-assembly of 
gemini surfactant, resulting in a higher CMC.
174
 Similarly, in our system, addition of NC 2067 
competes for inclusion in the βCD cavity, possibly replacing the gemini tail(s) from the βCD 
cavity to some extent, and drives the self-assembly behavior of the gemini surfactant moiety. We 
speculate that the presence of NC 2067 in the cavity of the βCDgemini acts as a ‘promoter’ to 
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release the gemini tail from the βCD cavity and to form a more organized and repetitive 
supramolecular structure with interplanar distances of 22.9 Å (corresponding to q of 0.27 Å
-1
). 
At this point, the peaks observed in complexes of NC 2067 and βCDgemini surfactant are too 
few for assignment of a specific supramolecular arrangement, resulting in the hypothesis that the 
new supramolecular arrangement is formed, partially and that it coexists with the previous self-
inclusion arrangements. Moreover, at 0.5:1 and 1:1 mole ratios of NC 2067/βCDgemini 
surfactant, some peaks related to free NC 2067 became visible. The presence of these peaks is 
possibly related to the precipitation of NC 2067 in the formulations having lower βCDgemini 
surfactant-to-NC 2067 mole ratio. On balance, characterization of the βCDgemini surfactant-
based nanoparticles suggests that self-inclusion could occur. 
The low IC50 values of the NC 2067 in complexes with βCDgemini surfactants having amide or 
ester linkages indicate a high potency toward cancer cell lines. The intrinsic toxicity of the 
βCDgemini with amide linker was significantly higher than that with the ester linker and could 
be related to the ability of the amide linker to form hydrogen bonds with the hydroxyl groups of 
proteins,
365,366
 interfering with cellular homeostasis and resulting in an increase in cellular death. 
Because the long-term goal is to design nanoparticulate formulations for targeted cancer therapy, 
the intrinsic toxicity of a carrier is a major concern. Therefore, the βCDgemini surfactant with 
amide linker was excluded from several of the studies in this work. NC 2067/βCDgemini 
surfactant (ester linker) at different mole ratios showed similar IC50 values, which indicates that 
mole ratio alteration does not change the formulation’s efficiency. 
Although βCD is considered as a safe excipient and is used in the pharmaceutical industry, some 
reports suggest that it can remove cholesterol from the cellular membranes of Caco-2 cells, 
leading to membrane perturbation.
130
 Moreover, the presence of a guest molecule in the βCD 
cavity could decrease its affinity to attach to cell membrane components.
129,130
 Gemini 
surfactants, due to their concentration, spacer length, charge density of the head group, and 
geometrical packing parameters, have shown different cytotoxicity toward normal skin cell lines 
such as human keratinocytes and human dermal fibroblasts.
367
 Even though both components of 
the βCDgemini surfactant compound have the capability to be cytotoxic, our study showed that 
the conjugated βCDgemini surfactant is not toxic for A375 melanoma cell line and shows 
potential as an inert delivery agent. 
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7.6. Conclusion 
Different analytical techniques such as powder X-ray diffraction, FTIR spectroscopy and TGA 
support the complexation of NC 2067 with βCD or βCDgemini surfactant. Evidence of the 
interaction of the aromatic ring(s) of NC 2067 with the interior of the βCD cavity was provided 
from FTIR studies. Although SAXS/WAXS results suggested that βCDgemini surfactant alone 
did not show common micellar self-assembly, the presence of NC 2067 initiated the formation of 
a new supramolecular arrangement. Attention-grabbing self-inclusion behavior of βCDgemini 
surfactant has been suggested from analysis of TGA thermograms. NC 2067/βCDgemini 
surfactant nanoparticulate formulations containing different linker types and drug-to-delivery 
agent mole ratios did not affect the anticancer activity towards A375 melanoma cell line. In the 
future, more in-depth evaluation of the NC 2067/βCDgemini surfactant aggregation will be 
performed; techniques such as two-dimensional nuclear magnetic resonance spectroscopy, 
rotating frame Overhauser effect spectroscopy, and single-crystal X-ray crystallography will be 
utilized to provide more geometrical details regarding the host-guest complex structures. 
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7.9. Supplementary material 
S1- Most intense peaks in diffractograms of CD, NC 2067, physical mixture and their inclusion 
complex powder samples (20 peaks have been shown). 
 βCD NC 2067 Physical mixture Inclusion complex 
2θ[⁰] d [Å] 2θ[⁰] d [Å] 2θ[⁰] d [Å] 2θ[⁰] d [Å] 
1 8.35 7.10 3.89 15.22 3.93 15.07 1.95 30.36 
2 7.01 8.45 4.07 14.55 13.89 4.27 13.95 4.25 
3 12.95 4.58 13.91 4.27 13.17 4.50 14.41 4.12 
4 11.29 5.25 12.87 4.61 11.85 5.00 13.33 4.45 
5 13.81 4.30 13.03 4.55 12.79 4.64 15.87 3.74 
6 12.51 4.74 13.25 4.48 8.39 7.06 14.83 4.00 
7 11.77 5.04 13.41 4.42 12.51 4.74 12.47 4.76 
8 11.61 5.11 12.67 4.68 11.49 5.16 12.27 4.83 
9 15.07 3.94 16.13 3.68 7.19 8.24 11.75 5.05 
10 10.15 5.84 10.57 5.61 16.07 3.70 11.45 5.18 
11 14.23 4.17 1.51 39.21 10.51 5.64 16.53 3.59 
12 17.89 3.32 11.91 4.98 15.75 3.77 8.35 7.10 
13 2.91 20.34 18.91 3.14 16.89 3.52 20.47 2.91 
14 16.61 3.58 15.95 3.72 9.89 5.99 10.25 5.78 
15 9.71 6.10 20.09 2.96 15.31 3.88 9.33 6.35 
16 16.11 3.69 17.03 3.49 13.65 4.35 18.81 3.16 
17 7.63 7.76 11.55 5.13 18.81 3.16 7.07 8.38 
18 7.81 7.59 15.01 3.96 13.47 4.40 19.39 3.07 
19 17.53 3.39 5.19 11.41 18.03 3.30 21.59 2.76 
20 5.97 9.92 9.89 5.99 14.33 4.14 18.37 3.24 
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In this manuscript we used NMR techniques to elucidate the self-inclusion behavior of the 
βCDgemini surfactant. One- and two-dimensional rotating frame Overhauser spectroscopy 
(ROESY) was employed to further comprehend the geometrical interaction of NC 2067 with 
βCD and βCDgemini surfactant. I prepared all samples and performed experiments except for 
ROESY samples which Dr. Karoyo helped me in running the samples. 
 
This manuscript addresses the following specific objectives of my research  
1.3. To characterize the βCDgemini surfactants 
1.5. To use advanced techniques such as 2D ROSEY NMR to understand the structural 
properties of the drug/βCD and drug/βCDgemini surfactant inclusion complexes 
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8.1. Table of Contents 
 
 
 
 
 
A scheme of various equilibrium processes of the interaction of a curcumin analog (NC 2067) 
with βCD and βCDgemini surfactant based on 1D/2D 1H NMR studies.  
 
  
 83 
 
8.2. Abstract  
Host systems based on βcyclodextrin (βCD) were employed as pharmaceutical carriers to 
encapsulate a poorly soluble drug, curcumin analog (NC 2067), in order to increase its water 
solubility. βCD was chemically conjugated with an amphiphilic gemini surfactant with the 
ability to self-assemble and to form nanoscale supramolecular structures. The conjugated 
molecule, βCDgemini surfactant, was shown to be a promising drug delivery agent. In this 
report, its physicochemical properties were assessed in aqueous solution using 1D and 2D 
1
H 
NMR spectroscopy. The results showed that the apolar hydrocarbon domain of the gemini 
surfactant was self-included within the βCD internal cavity. The host/guest complexes composed 
of native βCD or βCDgemini surfactant with NC 2067 were examined using 1D/2D ROESY 
NMR methods. The stoichiometry of βCD/NC 2067 complex was estimated using Job’s method 
via 
1
H NMR spectroscopy. The binding geometry of NC 2067 within βCD was proposed using 
molecular docking and further supported by 1D and 2D ROESY NMR results. Addition of NC 
2067 to βCDgemini surfactant revealed minimal changes to the overall structure of the 
βCDgemini surfactant system.  
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8.3. Introduction 
βcyclodextrin (βCD; Figure 8.1a) is a toroidal-shaped macrocyclic oligosaccharide 
comprised of seven -D-glucopyranose units with a hydrophilic outer surface and hydrophobic 
internal cavity. βCD and its derivatives have been used widely in pharmaceutical formulations as 
solubilizing and stabilizing agents. The non-covalent interactions between the βCD host and a 
hydrophobic drug molecule can result in the formation of stable host/guest inclusion 
complexes.
246,277,368,369
 Moreover, CD-based nanoparticles were recently designed by grafting 
CDs onto polymers
140,142
, incorporating CDs into liposomes
370
 and through synthesis of 
amphiphilic βCDs143. 
Curcumin is an active ingredient of turmeric rhizome and has variable pharmacological 
activity such as anti-cancer and anti-inflammatory properties; however, curcumin suffers from 
poor solubility, instability, and low bioavailability. βCD and its derivatives have been utilized in 
various studies as carriers for curcumin delivery.
100,252,371-373
 Recently Jahed et al. evaluated the 
structure of βCD/curcumin inclusion complex by NMR spectroscopy and molecular modeling.372 
They reported that the aromatic rings of curcumin interact with the internal cavity protons of 
βCD through hydrophobic forces.  In another study, the inclusion complex of a curcumin analog 
in βCD at the 2:1 host/guest mole ratio showed an increased in vivo anti-cancer activity.133 
Molecular docking of this complex revealed that the most stable configuration occurred when the 
curcumin analog was included through its aromatic rings containing the difluoro and 
methoxy/hydroxyl groups, where several hydrogen bonds were formed with βCD.133  
In this study, we selected a curcumin analog NC 2067 (Figure 8.1b), as a model guest 
compound with low water solubility (logP = 4.6) that was previously reported to have high cell 
toxicity toward the A375 melanoma cell line.
3
 A novel modified βCD-based carrier named 
βCDgemini surfactant (cf. Figure 8.1c) was designed to enhance the solubility and bioavailability 
of NC 2067.
3
 This bifunctional surfactant was formed by covalently linking βCD to a gemini 
surfactant (12-7NH-12) through a succinyl group at the primary hydroxyl group of βCD. In a 
previous study
374
, the physicochemical characterization of the inclusion complexes of NC 2067 
with βCD and βCDgemini surfactant, respectively, was carried out in the solid state using 
powder X-ray diffraction (PXRD), thermogravimetric analysis (TGA) and Fourier transform 
infrared spectroscopy (FTIR).  
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Herein, we report an NMR study in aqueous solution to examine the geometry of the CD-
based host/guest systems. The molecular level interactions in solution were elucidated using 
complexation-induced shifts (CIS) data of the 
1H nuclei located within the βCD cavity, in the 
presence and absence of NC 2067. In particular, nuclear Overhauser enhancement (NOE) 
spectroscopy in the rotating frame (i.e. ROESY) proved to be useful in probing through-space 
interactions between the host and guest, especially when the proximity of the nuclei are within 4-
5 Å.
289
 ROESY is exclusively employed for NOE enhancements in molecules with intermediate 
(~1000-2000 Da) molecular weight range for host/guest complexes of βCD and small molecules 
or in molecule systems where the tumbling rates (correlation time) make the measurable NOEs 
zero or close to zero using conventional NMR methods.
375
 ROESY has previously been used to 
probe the spatial molecular arrangement of the guest in the bound state with CD hosts.
291-
293,372,376
 For example, three modes of inclusion of econazole nitrate with βCD derivatives were 
demonstrated based on the correlation of the βCD interior 1H nuclei with 4-chlorophenyl, 2,4-
dichlorophenyl and imidazole rings, respectively, using NMR results derived from ROESY 
experiments.
293
  
The structure of βCD and βCDgemini surfactant, respectively, with NC 2067 in the bound 
state was investigated using 
1
H NMR and 1D selective/2D ROESY NMR spectroscopy. 
Furthermore, NMR ROESY results were used to monitor changes in the conformation of the 
self-included gemini surfactant within the βCD cavity upon addition of NC 2067. 1D/2D NMR 
results were used to provide evidence for the formation of a ternary complex between 
βCDgemini surfactant and the NC 2067 drug system. 
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Figure 8.1- Molecular structures of a) βCD, b) NC 2067 and c) βCDgemini surfactant. 
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8.4. Experimental 
8.4.1. Materials 
βCDgemini surfactant and NC 2067 were synthesized as described elsewhere.3,111 βCD 
was purchased from Alfa Aesar (Haverhill, MA, USA). All other chemicals were purchased from 
Sigma-Aldrich (Oakville, ON, Canada). Complexes of NC 2067 with βCD or βCDgemini 
surfactant were prepared as described previously.
374
 Samples of βCD or βCDgemini surfactant 
(host) with NC 2067 (guest) were prepared in 2:1 (host/guest) mole ratios by employing variable 
concentration ratios (2.5:1.25, 5:2.5 and 10:5 mM). The samples were then reconstituted in D2O, 
shaken overnight and analyzed using NMR spectroscopy. The NMR spectrum of Gemini 
surfactant (12-7NH-12) was obtained at 15 mM. 
8.4.2. NMR Spectroscopy 
1D/2D 
1
H ROESY NMR spectra in solution were recorded on a 500 MHz 3-channel 
Bruker Avance spectrometer in D2O at 298 K. Chemical shifts (δ) are reported in ppm with 
respect to trimethylsilane (TMS; δ 0.0 ppm) as external standard and residual water (HOD; δ 
4.79) as an internal standard. Complexation-induced chemical shift (CIS) values were calculated 
as Δδ = δ free – δ complex. 
1D selective and 2D ROESY spectra were obtained at variable parameters which were 
optimized as follows; spin-lock time of 350 ms, recycle delay of 3 s with 8 scans and 1k data 
points. 
8.4.3. Determination of the Stoichiometry 
A series of ten βCD/NC 2067 sample mixtures were prepared in D2O. The concentration of 
βCD in the samples was varied from 1 to 10 mM with 1 mM increments, where the sum of the 
mole concentrations of the βCD/NC 2067 mixtures in each sample was kept constant at 10 mM. 
The mole fraction r (0 < r < 1) was determined from the respective mole quantities and volume 
as shown by the equation below; 
 
𝑟 =
𝑛𝛽𝐶𝐷
𝑛𝛽𝐶𝐷+𝑛𝑁𝐶 2067
                  (8.1) 
where, n is the moles of the various components. Chemical shift changes (Δδ) of the internal 
protons (H3 and H5) of βCD were evaluated in each sample and a graph of Δδ × 𝑛𝛽𝐶𝐷 versus 
mole fraction (r) was used to create the Job plot.
377
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8.4.4. Molecular Modeling 
8.4.4.1 3D Structure Optimization  
The molecular structure of βCD was downloaded from the Worldwide Protein Data Bank (PDB: 
DB03995). The molecular structure of NC 2067 was based on an unpublished single X-ray 
crystallographic study [Appendix 13.1]. Structures were loaded in the Molecular Operating 
Environment (MOE)
378
 software and hydrogen atoms were subsequently added. The structures 
were minimized geometrically using the force field function of Merck Molecular Force Field 
(MMFF94X) and applied in the MOE at a RMS (root-mean-square) gradient of 0.001 Å. 
8.4.4.2. Docking 
Docking with MOE consists of five stages: conformational analysis, placement, rescoring 
(1), refinement and rescoring (2). In the conformational analysis, a series of torsion angles were 
applied to the rotatable bonds of the guest (ligand). The alpha triangle was used as a placement 
method in which the ligand atom triplets and triplets of receptor alpha sphere centers are 
superimposed. For two stages of scoring, the affinity dG scoring function was used to estimate 
the impact of enthalpy on the free energy of binding. At the refinement stage the conventional 
molecular mechanics force field (MMFF94X) was applied for energy minimization. For the first 
docking run NC 2067 and βCD were set as ligand and receptor, respectively. To estimate the best 
pose from this run, another βCD was added for the second docking step. Both runs were set to 
produce 100 poses which were listed and ranked in a database by their relative scoring level in a 
fashion that the lowest score was the criteria for the optimized complex. At the end of the cycle, 
the energy of the docked poses was minimized once again. 
 
8.5. Results & Discussion 
8.5.1.
 1H NMR and 1D/2D ROESY Characterization of βCDgemini Surfactant 
To characterize the structure of the bound and unbound host systems, 
1
H NMR CIS values and 
NOE effects were used to characterize the βCDgemini surfactant system in the solution, as 
described below. 
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8.5.1.1. 
1H NMR Spectrum of βCDgemini Surfactant 
As a prelude to obtaining 
1
H NMR spectrum of the βCDgemini surfactant, 1H NMR 
spectra of βCD and gemini surfactant (12-7NH-12) were acquired in D2O for comparison. The 
structures of βCD and βCD-conjugated gemini surfactant are shown in Figure 8.1a and 8.1c and 
that of 12-7NH-12 is shown in Figure 8.2c. The 
1
H NMR spectra are presented in Figure 8.3. 
The chemical shifts (δ) of the βCD protons (both interior and exterior; cf. Figure 8.2b) in D2O are 
shown in Table 1 and are in good agreement with literature values.
379,380
  Positive Δδ values 
indicate upfield shifts and negative Δδ values downfield shifts. 
In the 
1
H NMR spectrum of the βCDgemini surfactant (Figure 8.3c), the βCD cavity 
internal protons (H3 and H5) showed considerable upfield shift (cf. Table 8.1). The Δδ values for 
H3 (0.094 ppm) and H5 (0.172 ppm) indicate a partial or complete inclusion of the gemini 
surfactant moiety within the βCD cavity creating considerable shielding effects. This is in 
agreement with results for well-defined inclusion complexes formed between βCD and alkyl 
carboxylate anions.
381
 Moreover, the 
1
H NMR spectrum of the external surface protons (H4) of 
the βCD moiety for the βCDgemini conjugate displayed downfield shifts (Δδ = -0.03 ppm) 
indicating a deshielding effect for these protons. This might be related to the proximity of a 
quaternary ammonium head group near the exterior surface of βCD or a combination of 
conformational effects of the macrocycle. A similar phenomenon was observed in complexes of 
βCD with gemini surfactants such as 12-OE1-12
173
 and 12-s-12
177
. Furthermore, the H6 protons 
at the narrower rim of the βCD cavity showed an upfield shift of 0.019 ppm (cf. Table 8.1). This 
may suggest that the inclusion of the gemini surfactant occurs through the narrower rim of the 
CD host and is consistent with the grafting of the gemini surfactant at the primary end of the 
βCD, at the O6 position, as was confirmed previously.
3
 
 The 
1
H NMR  values (ppm) of the gemini surfactant (12-7NH-12; cf. Figure 8.2c) are 
assigned as listed in Table 8.2. These results are in good agreement with previous proton 
assignments of similar gemini surfactant species.
177
 As shown in the spectra of Fig. 3, most of 
the proton nuclei of the gemini surfactant tail (e.g. Hγ, Hλ, and Hω) are significantly broadened in 
the βCDgemini surfactant conjugate relative to the free gemini surfactant (Figure 8.3, shown by 
asterisks). These observations are consistent with changes in the motional dynamics and 
hydration states between the bulk solvent and the βCD cavity, and provide further evidence for 
the interaction of the gemini surfactant with the βCD cavity. The results are similar to a previous 
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study of a mono-substituted βCD with an amphiphilic moiety containing an alkenyl chain, where 
self-inclusion of the amphiphilic moiety was reported.
181
  
Self-inclusion for this system is supported by previous thermogravimetric results of 
βCDgemini surfactant system.374 It was observed that the TGA thermogram of the βCDgemini 
surfactant did not show any significant water loss at lower temperature (~70 °C) when compared 
to βCD. This difference in hydration suggested that the βCD cavity in βCD-conjugated gemini 
surfactant was devoid of hydrate water due to self-inclusion of the gemini surfactant moiety. As 
well, it was found that increasing the concentration of βCDgemini surfactant did not show any 
overt break point in a plot of specific conductivity vs concentration that is often typical of regular 
surfactants that undergo self-assembly to form supramolecular structures (e.g., micelles, vesicles 
or rods). It was herein hypothesized that the βCD cavity was likely fully or partially occupied by 
whole or a segment of the alkyl chain of the gemini surfactant moiety, precluding the anticipated 
self-assembly phenomenon. Moreover, results from small- and wide angle X-ray scattering did 
not provide evidence that the gemini surfactant moiety of βCDgemini surfactant underwent 
formation of self-assembled structures.
374
 The latter is in contrast to the formation of self-
assembled structures for non-conjugated (conventional) gemini surfactants.
382
 A 1D/2D ROESY 
NMR study was undertaken to further characterize the structure of the βCD-conjugated gemini 
surfactant. 
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Figure 8.2- a) Numbering of the carbon atoms for the -D-glucopyranosyl unit of βCD, b) the relative location of 
interior and exterior protons of βCD and c) proton assignment of gemini surfactant (12-7NH-12).  
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Figure 8.3- 
1
H NMR spectra of a) βCD, b) gemini surfactant (12-7NH-12) and c) βCDgemini surfactant obtained in 
D2O at 298 K. Broadened resonance lines of the hydrocarbon tail (Hω, Hλ and Hγ) of the gemini moiety are shown 
by asterisks.  
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Table 8.1 - Chemical shifts (ppm) for the protons of βCD in free form and in βCDgemini surfactant in D2O at 298 
K.  
 
βCD 
βCDgemini 
surfactant 
δ 
(ppm) 
δ 
(ppm) 
Δδ 
(ppm) 
H1 d 5.001 5.003 -0.002 
H2 dd 3.580 3.582 -0.003 
H3 t 3.898 3.804 0.094 
H4 t 3.516 3.546 -0.030 
H5 m 3.803 3.631 0.172 
H6 m 3.809 3.790 0.019 
Δδ = δβCD - δ βCDgemini surfactant 
d = doublet; dd = doublet of doublets; t = triplet; 
m= multiplet. 
Multiplicity of the protons corresponds to the spectral 
signatures of βCD hydrate. 
 
Table 8.2- Chemical shifts (ppm) for the 
1
H nuclei of gemini surfactant (12-7NH-12) in D2O at 298 K. 
 Chemical shifts of gemini surfactant (12-7NH-12) [ppm] 
Hω 6H (CH3)2 0.826 
Hλ 28H (CH2)14 1.248 
Hγ 8H (CH2)4 1.327 
Hβ 4H (CH2)2 1.727 
Hβ΄+ γ΄ 4H (CH2)2 + 4H (CH2)2 2.151 
Hη 12H (CH3)4 3.064 
Hα 4H (CH2)2 3.292 
Hα΄ 4H (CH2)2 3.366 
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8.5.1.2. 1D/2D ROESY Spectrum of βCDgemini Surfactant 
A 2D ROESY spectrum for the βCDgemini surfactant system was obtained to further 
investigate the self-inclusion phenomenon and the results are shown in Figure 8.4. Well-defined 
cross-peaks were observed between the internal protons of βCD (H3 and H5) and the protons of 
the gemini hydrocarbon tails (Hω, Hλ and Hγ) (cf. Figure 8.4). Such results suggest that the 
gemini apolar alkyl chain interacts with the βCD cavity and are consistent with the 1D 1H CIS 
effects described previously (cf. Section 8.4.1.1). Similarly, it was previously shown using 2D 
ROESY that the alkyl tail or spacer of a gemini surfactant is included in the cavity of native 
βCD.173,177 
 
Figure 8.4- Expansion of the 2D ROESY spectrum of βCDgemini surfactant showing the dipolar cross-peaks 
between βCD cavity nuclei (H3, H5) and the gemini alkyl tail (Hω, Hλ and Hγ).  
The greater sensitivity of the 1D ROESY technique offers an option to further confirm the 
self-inclusion of the gemini tail within the βCD cavity by selectively irradiating the nuclei of 
interest. The 1D ROESY results for the βCDgemini surfactant in aqueous solution at 298 K are 
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shown in Figure 8.5. The inversion of the βCD nuclei between 4.0-3.5 ppm was observed due to 
irradiation of the regions that correspond to Hω (1.0-0.5 ppm) and Hλ+γ (1.5-1.0 ppm) in Figure 8. 
5a and b, respectively. Similarly, the excitation of the region corresponding to Hβ (1.8-1.5 ppm) 
showed observable interactions with the βCD cavity nuclei (cf. Figure 8.5c). This interaction was 
not evident in the 2D ROESY spectrum and may be attributed to the relatively weak through 
space interactions and the conditions under which the ROESY results were obtained for Hω and 
Hλ+γ. Hβ (2CH2) is located closer to the gemini polar head group (cf. Figure 8.2c)  and has 
weaker interactions with the βCD internal cavity as evidenced by through space interactions with 
the methyl groups (Hη) on the quaternary ammonium head groups at  ~ 3ppm (cf. Figure 8.2c, 
interaction denoted by an asterisk in Figure 8.5).  
 
Figure 8.5- 1D ROESY spectra of βCDgemini surfactant (10 mM) with irradiation of various nuclei a) 1.0-0.5 ppm 
(Hω), b) 1.5-1.0 ppm (Hλ and Hγ), c) 1.8-1.5 ppm (Hβ) and d) 1D 
1H NMR spectrum of βCDgemini surfactant. 
Arrows show inverted peaks due to interaction with βCD cavity. 
 
 
 
  
1.0 – 0.5 ppm: H
ω
 
A 
B 
 
 
1.5-1.0 ppm: H
λ+γ
 
1.8-1.5 ppm: H
β
 
a) 
b) 
c) 
d) 
* 
 96 
 
8.5.1.3. Self-inclusion of the βCDgemini Surfactant 
The inclusion of the gemini alkyl tail(s) may occur due to self-inclusion (intra-molecularly) 
or by associative interaction between two βCDgemini (inter-molecularly). To understand the 
nature of the interactions, the chemical shifts of the βCD internal protons (H3 and H5) were 
monitored as a function of concentration of the βCDgemini surfactant. The correlations between 
concentration and chemical shift changes are shown in Figure 8.6, where Δδ (ppm) were 
computed by subtracting the chemical shift values of unbound βCD from those of βCD-
conjugated gemini surfactant. The chemical shift data are presented as supplementary 
information (S1). The following observations were noted from Figure 8.6; 
(a) No correlations were observed between the chemical shifts changes of H3 and H5 and the 
concentration of βCDgemini surfactant (cf. Figure 8.6). The foregoing observation suggests that 
the self-inclusion process of βCDgemini surfactant occurs intramolecularly such that increasing 
the concentration of βCDgemini surfactant does not lead to proportionately higher chemical 
shifts of the internal cavity nuclei, as compared with intermolecular association phenomena. 
(b) Even though no correlation was observed between the chemical shifts changes of H3 with 
incremental amount of βCDgemini surfactant, increasing the concentration from 1.8 mM to 15 
mM yielded a subtle change of  Δδ = 0.013 ppm for H5 (cf. Figure 8.6). The weak concentration 
dependence in Fig. 6 could also be interpreted as evidence that intramolecular association (self-
inclusion) occurs between the gemini surfactant and βCD cavity. 
We concluded from the above scenarios and the results of Fig. 6 that increasing the concentration 
of βCDgemini surfactant did not affect the magnitude of the chemical shifts of H3 and H5 
significantly. This result indicates that intramolecular interactions occur between βCD and parts 
of the gemini surfactant.  The subtle chemical shift changes observed for H5 between the highest 
and lowest concentration of βCDgemini surfactant cannot be used to unequivocally characterize 
intermolecular interactions.  
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Figure 8.6- Chemical shift changes of H3 and H5 observed at incremental concentrations of βCDgemini surfactant (1 
to 15 mM). 
 
 
8.5.2.
 1H NMR and 1D/2D ROESY Characterization of βCD/NC 2067 Complexes 
8.5.2.1.
 1H NMR Spectrum of βCD/NC 2067 Complexes 
The 
1H NMR spectra of the complexes of  βCD and  NC 2067 at a host/guest mole ratio of 
2:1 at different concentrations were obtained and compared to free βCD (Figure 8.7). The 1H 
NMR spectrum of NC 2067 in D2O could not be acquired due to its poor solubility in water. The 
upfield shifts of the cavity protons of βCD (i.e., H3 and H5) in Figure 8.7 indicate a shielding 
effect due to the inclusion of NC 2067 within the host cavity.  
A comparison of the βCD/NC 2067 complex at the highest concentration (10/5 mM) (cf. 
Figure 8.7d) showed significant upfield shifts of ~0.040 and 0.072 ppm for the H3 and H5 cavity 
protons, respectively (cf. Table 8.3). This is due to the shielding effects of the apolar phenyl 
moieties of NC 2067, the anisotropic effect of the π-electrons of the aromatic rings and 
displacement of cavity bound water.
270-272,274
 Increasing the concentration of βCD/NC 2067 from 
2.5:1.25 to 10:5 mM resulted in an increase in the magnitude of Δδ for both H3 and H5 
suggesting a concentration dependent insertion of NC 2067 in the βCD cavity. Although the 
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inclusion process showed negligible effect on the exterior protons (H1, H2 and H4) of βCD, as 
expected, the H6 protons at the narrow face of the cavity also showed an upfield shift of Δδ ~ 
0.02-0.03 ppm (Table 8.1). This could be accounted for due to changes in rotamer populations of 
the CH2 (C6) due to approach of the NC 2067 aromatic moiety near the annular hydroxyl 
groups.
383
 The results herein indicate that NC 2067 interacts with the βCD cavity without 
affecting the CIS values of the external cavity protons. 
 
 
Figure 8.7. Expansion of 
1
H NMR spectra of a) free βCD, and βCD/NC 2067 host/guest complexes at various 
concentrations of b) 2.5/1.25 mM, c) 5/2.5 mM and d) 10/5 mM collected in D2O at 298 K. Asterisks correspond to 
the chemical shifts of H3 and H5 for various concentrations of  βCD/NC 2067. 
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Table 8.3 - Chemical shifts (ppm) for the 
1H nuclei of unbound βCD and in the bound state with NC 2067 at various 
concentrations.  
 
βCD 
 (15 mM) 
βCD/ NC 2067 
2.5/1.25 mM 5/2.5 mM 10/5 mM 
δ Δδ δ Δδ δ Δδ 
H1 5.001 4.991 0.010 4.992 0.009 4.995 0.006 
H2 3.580 3.573 0.007 3.574 0.006 3.580 0.000 
H3 3.898 3.868 0.030 3.860 0.038 3.858 0.040 
H4 3.516 3.513 0.003 3.514 0.002 3.519 -0.003 
H5 3.803 3.753 0.050 3.735 0.068 3.731 0.072 
H6 3.809 3.778 0.031 3.774 0.035 3.778 0.031 
Δδ = δβCD - δ βCD/NC 2067 
 
8.5.2.2. Stoichiometry of βCD/NC 2067 Complexes 
The stoichiometry of the host/guest complex of βCD with NC 2067 was determined using 
the continuous variation (Job's plot) method.
282
 A series of βCD/NC 2067 samples was prepared 
with different host to guest mole fractions (0 <r <1) and the total concentration was maintained 
constant. A plot of Δδ .nβCD vs mole fraction (r) is shown in Figure 8.8. The plots showed a 
maximum value for H3 and H5 protons of βCD when r  0.67, which corresponds to host/guest 
mole ratio of 2:1 βCD/NC 2067.283 The 2:1 host/guest stoichiometry is reasonable since there are 
two styryl ring systems (cf. Figure 8.1b) which can be potentially included by two βCD hosts. 
1D/2D ROESY results were studied to further understand the structure of the complexes formed 
between βCD and the drug (NC 2067). 
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Figure 8.8- Job’s plot of βCD/NC 2067 inclusion complex showing an approximate 2:1 host/guest mole ratio in the 
complex. Lines on the graph serve as a guide and have no other physical meaning. 
8.5.2.3. 1D/2D ROESY Spectra of βCD/NC 2067 Complexes 
The 2D ROESY spectrum of βCD/NC 2067 was obtained at 2:1 host/guest ratio (cf. Figure 
8.9). As mentioned above, a detailed assignment of the protons of the aromatic rings of free NC 
2067 was precluded due to the poor solubility of the drug in D2O. However, in the presence of 
βCD the solubility was enhanced such that the 1H NMR signatures were observed in the range of 
8.0-6.5 ppm, downfield from the βCD protons (~5.3-3.0 ppm; cf. Figure 8.9). Moreover, the well 
resolved 1D spectrum in Figure 8.9 allowed for the assignment of the NC 2067 peaks to its 
respective aromatic and alkenic protons. The 2D ROESY spectrum of the βCD/NC 2067 
complex showed cross-peaks between H3 and H5 protons of the βCD cavity and the styryl 
protons of NC 2067 (H2΄ and H1΄; Figure 8.9). All aryl protons (ortho-, meta- and para-) of the 
styryl group interacted strongly with H3 protons of the βCD host. The presence of strong cross-
peaks for the H3 protons of βCD was reported elsewhere for the inclusion of fluconazole within 
βCD through its difluorophenyl moiety.273 Moreover, it was recently shown from a 2D ROESY 
study of polymer/dye systems that the phenyl moiety of p-nitrophenol was bound by the βCD 
cavity for a CD-based copolymer.
384
  
Increasing amount of NC 2067 
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In general, the NC 2067 guest reported herein displays interaction with the cavity protons 
of βCD at the position of the styryl, alkene and benzoyl groups (cf. Figure 8.9).  It is not 
straightforward in this case to unequivocally characterize a well-defined geometry of the bound 
drug based on the intensity of the cross-peaks for the different nuclei due to the broadening of 
the guest signatures. Therefore, the use of molecular modeling may provide an insight regarding 
the topology of the drug in the bound state with βCD. 
 
 
 
Figure 8.9- 2D ROESY spectrum of βCD/NC 2067 at a 2:1 host/guest mole ratio (10:5 mM), showing cross-peaks 
between βCD internal cavity protons and NC 2067 protons. 
 
The 2D ROESY technique is prone to sensitivity issues when the solubility of the 
host/guest system is limited or the fraction of bound species is low. Therefore, the host/guest 
interactions of βCD/NC 2067 system were further examined using 1D selective ROESY. Various 
spectral regions of the host or guest were irradiated and the through space interactions between 
NC 2067 and βCD were monitored as inverted signals, as shown in Figure 8.10. Excitation of the 
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region corresponding to the aromatic and alkenic nuclei of NC 2067 (~8.0-6.5 ppm) showed 
interactions with the βCD cavity (~4.0-3.5 ppm) region (cf. Figure 8.10a) confirming that the 
aromatic and alkenic nuclei are bound by the βCD cavity. These results were further confirmed 
by irradiation of the NC 2067 alkenic guest region (~8.0-7.6 ppm), styryl nuclei (~7.6-7.2 ppm) 
and the benzoyl moiety (~7.2-6.5 ppm), as shown in Figure 10b, c, and d, respectively (denoted 
by arrows). 
 
 
Figure 8.10- 1D ROESY spectrum of βCD/NC 2067 at the 2:1 host/guest mole ratio (10:5 mM) with irradiation at 
resonance regions between a) 8.0-6.5 ppm (H2ʹ, H1ʹ, H5ʹ and H4ʹ), b) 8.0-7.6 ppm (H2ʹ), c) 7.6-7.2 ppm (H1ʹ), d) 7.2-
6.5 ppm (H5ʹ and H4ʹ); and e) 1D 
1H NMR spectrum of βCD/NC 2067. Arrows show the inverted peaks due to 
interactions with βCD cavity. 
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8.5.2.4. Molecular Modeling and Mode of Binding of βCD/NC 2067 complexes   
Molecular docking results were performed by MOE to illustrate feasible structures of the 
complexes for the βCD-drug system. The results were used to complement the experimental 
findings from the 1D/2D ROESY findings and to establish a better understanding of the 
complex. The initial docking (NC 2067 and βCD set as ligand and receptor, respectively) of the 
1:1 host/guest mole ratio showed the most stable binding mode in which the NC 2067 molecule 
is included within the cavity of βCD with one of the styryl groups (cf. Figure 8.11a). This styryl 
ring is distally remote to the side chain containing the quaternary ammonium group. The non-
covalent interactions that occur between the styryl ring of the drug and the βCD cavity (H3 
nuclei) are reasonable based on favorable van der Waals interactions and hydrophobic 
association. Moreover, the inclusion complexes in which the NC 2067 was inserted in the βCD 
cavity through the narrower rim were more stable (lower energy of 1.5 kcal/mol) relative to other 
“poses” where the penetration was performed from the wider side of the cavity and this may be 
understood on the basis of the dipole moment of the βCD macrocycle.  It should be noted that 
hydration contributions may negate such small energy differences.  
The second docking was achieved using the best pose of the first docking attempt in 
conjunction with a second molecule of βCD which resulted in a series of poses. The lowest 
energy (best) pose indicated that the second βCD may encapsulate the unbound styryl ring and 
the benzoyl ring of the drug at the 2:1 host/guest mole ratio (cf. Figure 8.11b). βCD may 
encapsulate a second styryl ring and benzoyl ring, whilst minimizing steric hindrance between 
each binding site due to the spatial proximity (~4 Å) between the two rings. In addition, the 
internal diameter of the βCD cavity (6.5 Å) affords inclusion of these two aromatic rings of NC 
2067.  The modeling results are in good agreement with the 1D/2D ROESY data (cf. Section 
8.2.2.3) and the size-fit requirements of the βCD cavity (6.5 Å) and guest. The interaction of the 
benzoyl ring (H4ʹ and H5ʹ; 7.2-6.5 ppm) occurs with the cavity protons of the second βCD, 
according to NMR results in Figures 8.9 and 8.10. 
In Figure 8.11b, the terminal quaternary ammonium of the side chain of NC 2067 is 
located outside of the βCD cavity to enable hydration in the solvent phase. However, the 
carbonyl groups of NC 2067 are positioned between the two βCD rings and form hydrogen 
bonds with the C6-OH of βCD. Hydrogen bonds between C3-OH and C2-OH at the wider rim and 
C6-OH at the narrow rim were observable. It is important to note that the orientation of βCD in 
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the βCD/NC 2067 complex is tail to tail which may also be stabilized by host-host and water 
mediated H-bonding interactions. 
Finally, the MOE calculations provide a basis for rationalizing the size-fit relationship for 
this host/guest system, however, the global minimum energy for this system may require a fuller 
account of hydration phenomena. For example, hydrophobic effects are anticipated to be an 
important driving force in complex formation judging by the relatively low water solubility of 
the guest (NC 2067).
385
 
 
 
Figure 8.11. The most stable conformation of βCD/NC 2067 complex at a) 1:1 and b) 2:1 host/guest mole ratios. 
The βCD host is presented as the wire frame model and NC 2067 guest is presented as the ball and stick model. 
 
a b 
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8.5.3. 
1H NMR and 1D/2D ROESY Characterization of NC 2067/ βCDgemini surfactant 
Complexes  
8.5.3.1.
 1H NMR spectrum of NC 2067 / βCDgemini surfactant Complexes 
In order to elucidate the molecular interactions between the βCDgemini surfactant with 
NC 2067, the 
1H NMR spectra of different concentrations of βCDgemini surfactant/NC 2067 at 
the 2:1 host/guest mole ratio were measured and compared with the free βCD and βCDgemini 
surfactant. The chemical shifts data are shown in Table 8.4 and the 
1
H NMR spectra are provided 
as supplementary information (S2). A detailed assignment of the 
1
H nuclei of the gemini 
surfactant moiety of the βCDgemini surfactant was difficult to fully resolve due to the spectral 
broadening and overlap of the nuclei. The addition of NC 2067 to βCDgemini surfactant did not 
significantly alter the chemical shifts of the βCDgemini surfactant nuclei at various host/guest 
concentrations. This is in contrast to the βCDgemini surfactant (Section 8.2.1) and βCD/NC 
2067 (Section 8.2.2) systems which display significant CIS values for H3 and H5 nuclei. The 
variation in the H3 and H5 CIS values for the βCDgemini surfactant/NC 2067 system are less 
apparent. The formation of a ternary complex (βCDgemini surfactant/ NC 2067) may result in 
less pronounced chemical shift changes due to the disordered nature of the complex and the 
likelihood that the drug is bound in an outer-sphere arrangement. Based on the known binding 
affinity of βCD/surfactant systems,28  the binding affinity of the self-included alkyl chain of the 
βCDgemini system is likely 103 L/mol or greater. By contrast, the binding affinity of the 1:1 
complex for the βCD/NC 2067 guest system must be less than or equal to this value since the 
drug binding by the βCDgemini surfactant does not displace the self-included alkyl tail upon 
formation of the ternary complex (i.e. βCDgemini surfactant/NC 2067). 1D/2D ROESY 
measurements were carried out to study the possibility of competing interactions between the 
gemini surfactant alkyl chain and NC 2067 within the βCD cavity of the βCDgemini 
surfactant/NC 2067complex. 
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Table 8.4 - Chemical shifts (ppm) for the 
1H nuclei of βCD in βCDgemini surfactant, alone without drug and at 
various concentrations of βCDgemini surfactant/NC 2067. 
 
βCDgemini 
surfactant 
βCDgemini surfactant/NC 2067 
2.5 /1.25 mM 5/2.5 mM 10/5 mM 
δ [ppm] δ [ppm] Δδ [ppm]  δ [ppm] Δδ [ppm] δ [ppm] Δδ [ppm] 
H1 5.003 4.999 0.003 5.002 0.001 5.005 -0.002 
H2 3.582 3.593 -0.010 3.593 -0.011 3.589 -0.007 
H3 3.804 3.790 0.014 3.784 0.020 3.802 0.002 
H4 3.546 3.542 0.004 3.547 -0.001 3.544 0.003 
H5 3.631 3.649 -0.019 3.639 -0.009 3.635 -0.004 
H6 3.790 3.780 0.010 3.794 -0.004 3.793 -0.003 
Δδ= δβCDgemini surfactant - δ βCDgemini surfactant/ NC 2067 
 
8.5.3.2. 1D/2D ROESY Results of βCDgemini surfactant/NC 2067 Complexes 
The 2D ROESY spectrum of βCDgemini surfactant/NC 2067 (Figure 8.12) shows cross-
peaks between 
1H nuclei of the alkyl chain of the βCDgemini surfactant (Hλ, Hγ and Hω) and the 
βCD cavity, similar to the free βCDgemini surfactant in the absence of the drug. However, in 
contrast to the 2D ROESY results of βCD/NC 2067 system, no interactions of the aromatic 
protons of the guest drug (8.0-6.5 ppm) with βCD host protons were observed. This reinforces 
the possibility that the gemini alkyl chain has greater affinity for βCD as described above. By 
contrast, aromatic ring-containing compounds ordinarily show binding constants of an order of 
lower magnitude.
372,386
 The most notable feature of the 2D ROESY results of βCDgemini 
surfactant/NC 2067 system in Figure 8.12 are compared with the results of the single component 
βCDgemini surfactant in Figure 8.5. The absent (or very weak) interaction of Hω (gemini tail) 
with H5 (βCD cavity) is evidenced by the absence of relevant cross-peaks, and provides indirect 
evidence that the drug may interact with βCDgemini surfactant, further indicating the biological 
benefit of the complexation.
3,374
 The apparent lack of observable interactions between the drug 
and βCDgemini surfactant host indicates that a non-inclusion ternary complex is formed. It is 
well established that ternary complexes comprised of a βCD host and two different guest 
molecules are known in the case of the co-inclusion complexes of pyrene and alcohols with 
βCD.387 Therefore, the absence of well-defined cross-peaks between the βCD interior and drug 
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protons are consistent with the possible formation of a ternary complex, as described above. In a 
previous study by Udachin et al., it was shown that aromatic guests such as pyrene can form 
non-inclusion complexes within the peripheral hydroxyl region of βCD, whereas 1-octanol can 
be encapsulated within the CD cavity interior according to single crystal X-ray studies.
388
 Based 
on the structure of such ternary complexes, the absence of through space interactions may be 
expected due to their disordered nature, in agreement with the broadened lines of NC 2067 in the 
presence of βCDgemini surfactant (cf. Figure 8.12).  
 
Figure 8.12- 2D ROESY spectrum of βCDgemini surfactant/NC 2067 at the 2:1 host/guest mole ratio (20:10 mM), 
showing cross peaks between the βCD cavity nuclei and the gemini surfactant alkyl tail. 
Once again, due to the higher sensitivity of the 1D- versus 2D-ROESY technique, an 
evaluation of the molecular interactions was estimated from the 1D ROESY spectra for the 
βCDgemini surfactant/NC 2067 system (Figure 8.13). Irradiation of the aromatic region (8.0-6.5 
ppm) did not result in any spectral inversion (Figure 8.13a). Similarly, irradiation of the 
individual areas corresponding to styryl protons of NC 2067 at 8.0-7.6 ppm (H2´) and 7.6-7.2 
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ppm (H1´), did not significantly perturb the resonance lines in the 1D spectrum (Fig. 13b,c). 
However, irradiation of the benzoyl group at 7.2-6.5 ppm (H4ʹ and H5ʹ) resulted in the inversion 
of the spectral region corresponding to H5, H2 and H4 (Figure 8.13d). Irradiation of the gemini 
tail nuclei (Hω, Hλ+γ and Hβ) between 1.0-0.5 ppm, 1.5-1.0 ppm and 1.8-1.5 ppm, respectively, 
resulted in an inversion of the βCD nuclei (cf. Figure 8.13e, f, and g). These results are consistent 
with those for the βCDgemini surfactant in the absence of drug (Figure 8.5). It appears that the 
addition of the NC 2067 to βCDgemini surfactant did not reveal any notable spectral changes; 
however, there is a strong possibility of a weak interaction with the cavity due to formation of a 
ternary complex as revealed by the interaction of the benzoyl moiety. The gemini surfactant 
alkyl chain shows stronger affinity for βCD cavity as described above. 
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Figure 8.13- 1D 
1H ROESY spectra of βCDgemini surfactant/NC 2067 with irradiation of variable spectral regions 
between a) 8.0-6.5 ppm (aromatic protons), b) 8.0-7.6 ppm (H2ʹ), c) 7.6-7.2 ppm (H1ʹ), d) 7.2-6.5 ppm (H5ʹ and H4ʹ), 
e) 1.8-1.5 ppm (Hβ), f) 1.5-1.0 ppm (Hλ and Hγ),  g) 1.0-0.5 ppm (Hω) and h) 1D 
1H NMR spectrum of βCDgemini 
surfactant/NC 2067 (no irradiation). Arrows show the inverted peaks due to dipolar through space interactions 
within the complex. 
 
The high in vitro activity of the NC 2067 manifested in formulations containing 
βCDgemini surfactant3,374 is related to the formation of a weakly bound inclusion complex, in 
agreement with the idea of a ternary complex for the drug and βCDgemini surfactant. The 
formation of a ternary complex accounts for the weak interactions, structural disorder of the 
complex, solubilization phenomena and bioavailability of NC 2067 with A375 melanoma cells, 
as depicted in Scheme 8.1. In addition, the promising results of the in vitro studies such as low 
toxicity of βCDgemini surfactant374 and the ability to solubilize the drug and increase the 
bioavailability with the A375 melanoma cell line illustrate the utility of the βCD-conjugated 
gemini surfactant to act as a unique drug delivery agent. 
 
 
Scheme 8.1- Illustration of various equilibrium processes for CD and CDgemini surfactant 
systems;  1:1 and 2:1 host/guest complex formation for CD and NC 2067 (Drug), self-inclusion 
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of the alkyl chains of the gemini moiety according to K1 and the formation of a ternary complex  
between the self-included form of CDgemini surfactant and NC 2067 (Drug) according to K2. 
Solvent is not shown for the sake of clarity. K2 is assumed to be less than K1 on the basis of the 
greater extent of inclusion complex formation for K1. 
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8.6. Conclusions 
In conclusion, three systems were characterized (βCDgemini surfactant, βCD/NC 2067, and 
βCDgemini surfactant/NC 2067) in order to study the structure of NC 2067 (drug) in βCD-
conjugated gemini surfactant complexes. The alkyl tail of the gemini surfactant moiety 
undergoes intramolecular self-inclusion within the internal cavity of βCD of the βCDgemini 
surfactant system. The structure of the NC 2067 guest in its complexed form with βCD was 
evaluated using 1D/2D NMR techniques. The stoichiometry of βCD/NC 2067 system was 
estimated to be a 2:1 host/guest complex according to the Job continuous variation method. 
Moreover, 1D/2D ROESY spectra and molecular modeling indicated that NC 2067 was included 
by two βCD molecules through its styryl and/or benzoyl groups. By contrast, the addition of NC 
2067 to the βCDgemini surfactant resulted in only subtle measurable changes to the system374, 
and that favorable βCDgemini surfactant self-inclusion still persists. The drug (NC 2067) is 
weakly bound to the βCDgemini surfactant system and likely forms a ternary complex (cf. 
Scheme 1, in agreement with other related systems
387,388
, including the known stability of loosely 
bound facial complexes for βCD/guest systems.389 
The results of this study reveal the behavior of a poorly soluble drug molecule in the 
presence of complexing/solubilizing agents and represent a major step forward in the design of 
delivery agents that are safe for the formulation of hydrophobic cytotoxic agents. Future steps 
will be taken to modify the structure of the βCDgemini surfactant conjugate to control self-
inclusion phenomena whilst promoting drug encapsulation by βCD to afford effective delivery to 
the target cells. Moreover, grafting of pH-sensitive moieties that facilitate the intracellular 
release of the drug from the βCDgemini carrier will also be considered.  
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8.8. Supplementary Data 
Table S1. Chemical shift changes of H3 and H5 of various concentrations of βCDgemini 
surfactant relative to βCD. 
 
Δδ relative to βCD [ppm] 
βCDgemini 
surfactant 
concentration 
[mM] 
H3 H5 
15.0 0.085 0.153 
11.1 0.085 0.152 
8.8 0.084 0.150 
7.2 0.085 0.150 
6.2 0.086 0.149 
5.4 0.086 0.148 
4.3 0.085 0.147 
3.2 0.085 0.144 
2.5 0.084 0.144 
2.1 0.083 0.142 
1.8 0.085 0.140 
Δδ= δβCD-δβCDgemini surfactant 
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Figure S2-   Expansion of 
1
H NMR spectra of a) free βCD, b) free βCDgemini surfactant, 
βCDgemini surfactant/NC 2067 complexes at various concentrations of c) 2.5/1.25 mM, d) 5/2.5 
mM and e) 10/5 mM  in D2O collected at 298 K. 
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In this manuscript βCDgemini surfactants having various chain length and degree of unsaturation 
of the tail of the gemini surfactant moiety were used in NC 2067/βCDgemini surfactant 
formulations and their nanostructural behavior in solution was evaluated. Moreover, the cell 
death mechanism associated with the formulations toward A375 melanoma cells was assessed. 
The co-authors of this manuscript contributed in the synthesis of NC 2067 and running the flow 
cytometer. 
 
This manuscript addresses the following specific objectives of my research, 
1.2. To develop formulations by varying the mole ratio between the drug and delivery agent, 
using βCDgemini surfactants with various gemini surfactant tails  
1.3. To characterize the βCDgemini surfactants 
1.6. To use synchrotron small- and wide angle X-ray scattering (SAXS/WAXS) to evaluate 
the supramolecular arrangement of drug/βCDgemini surfactant delivery systems in solution 
2.1. To calculate the cell toxicity (IC50) of different drug/βCDgemini surfactant formulations 
towards melanoma cell line 
2.2. To elucidate the type of cell death mechanism and cell cycle arrest behavior of different 
drug/βCDgemini surfactant formulations using flow cytometry-based assays in melanoma 
cells 
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9.1. Abstract 
Lipid-based nanoparticles are widely used to encapsulate lipophilic anticancer agents to enhance 
their bioavailability and efficacy. We evaluated the nano-structural behavior of a curcumin 
analog encapsulated by gemini surfactant-based carriers. Furthermore, the cell death mechanism 
of the curcumin analog in presence of the delivery agents was evaluated. 
The aggregation behavior of the curcumin analog with various βCDgemini surfactants were 
investigated using synchrotron-based small- and wide angle X-ray scattering and size 
measurements. Finally, the in vitro cytotoxicity and cell death mechanism of the formulations 
were measured by cell viability assay and flow cytometry, respectively. 
We showed that the addition of a curcumin analog to βCDgemini surfactants having various 
chain length and degree of unsaturation formed nano-sized structures. Moreover, these 
formulations induced apoptosis without any influence on cell cycle in A375 melanoma cells. 
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9.2. Introduction 
To increase the accumulation of a chemotherapeutic agent at cancer site, and minimize non-
specific distribution in the body, a novel approach is to encapsulate the active agent into 
nanoparticles.
390
   Drugs encapsulated into nanoparticles preferentially accumulate in tumors due 
to the enhanced permeability and retention effect that permits extravasation of the nanoparticles 
into the tumor through the leaky vasculature.
391
 In addition, barriers such as the epithelial tight 
junctions might be overcome by the utilization of nanoparticles.
392
  
Amphiphilic lipids such as surfactants containing hydrophilic and hydrophobic parts are 
frequently employed for the delivery of anticancer drugs.
36
 They can self-assemble in aqueous 
media and subsequently build ordered nanoparticulate structures known as lyotropic liquid 
crystals (LLC). Nanostructured LLCs can be distinguished from micelles or vesicular lipid 
aggregations by the presence of the internal molecular organization in LLC structure. 
Nanoparticles built of LLC mesophases are able to incorporate different small molecule 
anticancer agents
40,41
 to enhance their bioavailability via various routes of administration. 
Gemini surfactants as amphiphilic lipids have the potential to form lyotropic liquid crystalline 
mesophases in excess of water.
157,158
 Nature and length of the hydrocarbon tail impact the phase 
behavior of gemini surfactants.
162,163
 A new class of cationic gemini surfactants named as 
βCDgemini surfactant has been synthesized by addition of βcyclodextrin (βCD) to different 
cationic gemini surfactants (12-7NH-12, 16-7NH-16 and 1:18-7NH-18:1)
3
 (Figure 9.1) in our 
laboratory. The presence of the βCD that can encapsulate hydrophobic molecules renders 
βCDgemini surfactant a promising carrier for insoluble anticancer agents such as curcumin 
analogs.
3,133-136
  
A variety of curcumin analogs were synthesized with anticancer activity towards melanoma cell 
lines.
107,239
 Molecular mechanism associated with the anti-melanoma activity of curcumin and its 
analogs toward different cell lines has been reported in the literature, as some form of 
apoptosis.
107,231,237,238
 
Apoptosis is the targeted cell death mechanism induced by the chemotherapeutic agents in 
cancer treatment. This programmed type of cell death, is naturally occurring in a variety of cells 
to maintain homeostasis. Apoptotic morphological changes involve nuclear cell shrinkage
182
, 
cytoskeleton disintegration
183
, chromatin condensation
184
, DNA fragmentation
185
, membrane 
budding and formation of the apoptotic bodies. Moreover, during apoptosis, phosphatidylserine 
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(PS), an aminophospholipid located on the inner-leaflet of the cell membrane, is externalized and 
localized on the surface of the cell membrane.
186
 Curcumin analogs showed to induce apoptosis 
in melanoma cells mainly through mitochondrial mediated pathway activating caspase-3, -7 and 
-9.
3,107,109
 For example, the proapoptotic effect of a curcumin analog, named DM1, was reported 
to be implemented in A375 melanoma cell line by downregulation of the antiapoptotic Bcl-2 
proteins (e.g. Mcl-1 and Bcl-xL) and the inactive form of caspase-3 and upregulation of the 
active form of caspase-9.
238
 
In this paper, our aim is to assess the proapoptotic effect of NC 2067 (Figure 9.1D), a model 
curcumin analog, that showed high in vitro cell toxicity towards A375 melanoma cell line.
3
 In 
addition, we previously introduced a formulation made of NC 2067 complex with βCDgemini 
surfactant surfactant-12 (Figure 9.1A) so as to overcome the poor solubility associated with the 
anticancer agent.
3
 We reported that NC 2067 in βCDgemini surfactant- based nanoparticulate 
formulation retained its high in vitro activity toward A375 cell line and increased the executioner 
caspases (-3 and -7).
3
 Furthermore, we evaluated the physicochemical properties and 
nanoparticulate behavior of the formulation of NC 2067/βCDgemini surfactant-12 extensively.374 
Herein, cell death mechanism of the formulation comprised of the βCDgemini surfactants 
(Figure 9.1) are assessed using flow cytometry. Moreover, we evaluated the correlation between 
chain length and degree of unsaturation of the tail of the gemini surfactant moiety and the 
behavior of the lipid-based nanoparticulate formulations.  
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Figure 9.1- Chemical structures of βCDgemini surfactants A) -12, B) -16, C) -18:1; synthesized by the attachment 
of βCD to different gemini surfactant moieties and D) NC 2067. 
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9.3. Materials and Methods 
9.3.1. Preparation of inclusion complexes  
NC 2067 and βCDgemini surfactants were synthesized as described previously.111,3 All other 
chemicals were purchased from Sigma-Aldrich (Oakville, ON, Canada). Complexes of NC 2067 
with βCDgemini surfactants (-12, -16 and -18:1) were formulated as described previously.374  
9.3.2. Size measurements 
Particle sizes in solution were measured by using a Zetasizer Nano ZS instrument (Malvern 
Instruments, UK). Results are reported as the mean of 3-5 measurements ± standard deviation. 
9.3.3. Small- and wide-angle X-ray scattering (SAXS/WAXS) measurements 
SAXS/WAXS measurements were performed at the BL4-2 beamline at Stanford Synchrotron 
Radiation Lightsource (SSRL, Stanford, CA, USA). The samples containing NC 
2067/βCDgemini surfactant complexes with constant concentration of surfactant  (10 mM) were 
studied at energy of 11 keV, a sample to detector distance of 1.1 m and exposure time of 20 
second. Diffraction intensity versus q (scattering vector) plots were obtained by radial integration 
of the 2D patterns using GSAS-II software.
393
  
9.3.4. Cell viability assay 
A375, human amelanotic melanoma cells (American Type Culture Collection, CRL-1619) were 
seeded at a density of 1 x 10
4
 cells per well in 96-well tissue culture-treated plates. Cells were 
treated with the formulations at cytotoxic agent concentrations of 0.01–200 µM in quadruplicate 
wells for 48 h to produce a balanced 4-parameter curve. The experiments were conducted in 
triplicate. After treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
Invitrogen, Burlington, ON, Canada) at 450 μg/mL was added to each well and the plates were 
incubated for 2 h at 37 ᵒC.  Absorbance at 550 nm was recorded using a Synergy BioTek plate 
reader. The IC50 values for all samples were calculated using the 4-parameter curves generated 
by the GEN5 software from BioTek. 
9.3.5. Apoptosis analysis using flow cytometry  
Cells were seeded in 6-well plates at a density of 25 x 10
4
 cells /well and incubated for 24 hours 
at 37 
ᵒ
C in a humidified incubator with 5% CO2 before treatment.  Treatments of NC 2067 
formulations and melphalan as a control at the IC50 concentrations were applied and the cells 
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were incubated for 24 hours. After treatment, the cells in triplicate were detached from the plates 
with trypsin, combined and resuspended in 500 µL Dulbecco’s phosphate-buffer saline (DPBS, 
Sigma, Oakville, ON, Canada) containing calcium and magnesium.  Early stage of apoptosis was 
measured by the externalization of the phosphatidylserine (PS) to the outer leaflet of the cell 
membrane using Annexin V-FITC Apoptosis Detection Kit (BioVision, AB, Canada). Late 
stages of apoptosis were detected by the loss of cell membrane integrity, permitting the 
permeation of propidium iodide (PI) (Sigma, Oakville, ON, Canada) into the cell. Cells were 
incubated with 5µL FITC-conjugated annexin V for 15 minutes in the dark followed by the 
addition of 5 µL PI.  Cells were analyzed with a FACScalibur flow cytometer (Becton 
Dickinson, San Jose, CA, USA) with excitation from the 488 nm laser and simultaneous 
monitoring of green fluorescence from the annexin V in the 530/30 nm filter and propidium 
iodide red fluorescence in the 585/42 filter. 
9.3.6. Evaluation of mitochondrial membrane potential (ΔΨm) 
We used two different mitochondrial fluorescent dyes named JC-1
394
 ((5,5′,6,6′-tetrachloro-
1,1′,3,3′- tetraethylbenzimidazolylcarbocyanine iodide) and TMRM395 (tetramethylrhodamine 
methyl ester) to probe mitochondrial membrane potential loss.  
Cells seeded in 6-well plates (25 x 10
4
 cells/well) and after 24 h of incubation at 37̊C in a 
humidified incubator with 5% CO2, they were treated with formulations at IC50 concentration. 
After 12 and 24 hours of incubation, JC-1 (2.5 μg/ml) or TMRM (0.5 μM) added to each well 
and incubated at 37̊C for 20 min. CCCP (80 μM) was added at the same time as JC-1. 
Immediately, media removed from wells and cells were washed twice by DPBS to remove the 
dyes remaining outside of the cells. Then cells were trypsinized and harvested. Cell pellets 
resuspended in 500 μl DPBS, filtered and analyzed with a FACScalibur flow cytometer with 
excitation from the 488 nm argon laser and emission in the 585/42 and 530/30 nm filters. The 
percentage of the green fluorescence of JC-1 monomers and intensity of the red fluorescence of 
TMRM were employed to identify the cells with mitochondrial membrane potential drop. 
9.3.7. Fluorescence microscopy 
Cells were seeded in 96-well plate (1 x 10
4
 cells/well) and kept under cell culture conditions (37 
ᵒ
C in a humidified incubator with 5% CO2). Cells were treated with formulations at concentration 
of IC50 for 24 hours. Then cells were stained by 4,6-diamidino-2-phenylindole (DAPI, Life 
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technologies Inc., Burlington, Canada) at concentration of 30 μM and further incubated for 2 
hours . Cells were washed with PBS twice and imaged by fluorescence microscopy. 
9.3.8. Cell cycle analysis using flow cytometry 
Cell cycle analysis was performed by seeding 25 x 10
4
 cells / well in 6-well plates and incubated 
for 24 hours at 37 
ᵒ
C in a humidified incubator with 5% CO2 before treatment.  The cells were 
treated with NC 2067 formulations and melphalan at the IC50 concentration for 24 h. Sodium 
butyrate (2 mM), a compound arresting the cell cycle in G1 phase and resveratrol (30 μM) 
arresting the cells in S phase were used as positive control. Both adherent and floating cells were 
collected using trypsin and versene.  Approximately 1x10
6
 cells were suspended in 300 µL PBS.  
Cold 100% ethanol was added drop by drop until final concentration of 70% was obtained.  Cells 
were incubated for 24 hours at -20 
ᵒ
C.  The ethanol was removed by centrifugation at 1500 rpm 
for 10 minutes at 4 
ᵒ
C.  The pellet was resuspended in 1000 µL PBS containing 0.3 mg/mL 
RNase.  PI was added to a final concentration of 20µg/ml.  Cells were analyzed with a 
FACScalibur flow cytometer  (Becton Dickinson, San Jose, CA, USA) with excitation from the 
488 nm laser and emission in the 585/42 filter. Cell cycle analysis was performed on ModFit LT 
(Verity Software House, Topsham, ME, USA). 
9.3.9. Statistical analysis 
Statistical analysis was performed using SPSS (version 19.0). One-way analysis of variance, 
Scheffe comparison was used. The level of significance was considered at p<0.05 value. 
 
9.4. Results and Discussion  
9.4.1. Size measurements of βCDgemini surfactant-based nanoparticles 
We previously measured the size of the NC 2067/βCDgemini surfactant-12 systems at different 
drug to delivery agent ratios.
374
  In the current work, we investigated the effect of the tail length 
and degree of unsaturation on the size of the nanoparticles by using different βCDgemini 
surfactants. Surprisingly, we observed that free βCDgemini surfactant-18:1 was able to form 
nanoparticles with average size of 117±5 nm at 2 mM concentration. βCDgemini surfactant-16 
showed inconsistent values in size measurements with high polydispersity index (PDI) value. 
This finding is similar to the size measurement of free βCDgemini surfactant-12374 suggesting a 
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heterogeneity of the aggregations made of free βCDgemini surfactants having 12 and 16 carbon 
containing saturated tails. Formulations comprised of NC 2067 complexes with various 
βCDgemini surfactants (-16 and -18:1) at 1:2 drug to delivery agent mole ratio formed 
nanoparticles in a size range of 90-131 nm (Table 9.1) comparable to the size of NC 
2067/βCDgemini surfactant-12 systems.374 
The use of nanoparticles in cancer drug delivery systems, is highly advantageous since nano-
sized particles facilitate drug delivery of the chemotherapeutics at cellular level by enhanced 
cellular uptake mechanisms such as endocytosis.
23
 Nanoparticles similar to macromolecules 
bypass the transport systems that are used by small molecules such as diffusion or protein-
channel mediated pathways, due to their greater size.
396
  Moreover, nanoparticles showed to have 
the potential to contribute to reverse the multidrug resistance (MDR).
24
  The pH-sensitive 
nanoparticles have been developed to fuse with lysosomal membrane and consequently release 
the drug into cytoplasm. Therefore, efflux pumps which are located in the cell membrane cannot 
excrete it out of the cell.
27
 
Table 9.1-Size of different βCDgemini-based nanoparticles (average of 3-5 measurements ± standard deviation, SD) 
and corresponding polydispersity index (PDI). 
βCDgemini surfactant-based 
nanoparticles 
Size [nm] ± 
SD 
PDI 
βCDgemini surfactant-18:1 117 ± 5 0.2 
NC 2067/βCDgemini surfactant-12* 101 ± 2 0.3 
NC 2067/βCDgemini surfactant-16 90 ± 7 0.3 
NC 2067/βCDgemini surfactant-18:1 131 ± 3 0.4 
*Data is adopted from our previous study.
374
 
 
9.4.2. SAXS/WAXS measurements of βCDgemini surfactant based formulations  
In our former work, we found that in βCDgemini surfactant-12, the hydrocarbon tail interacts 
with βCD cavity resulting in self-inclusion behavior. Moreover, the supramolecular behavior of 
the free βCDgemini surfactant -12 at 10 mM concentration showed a diffused scattering pattern 
which is in good agreement with the self-inclusion behavior.
374
 Herein, we monitored 
SAXS/WAXS patterns of free βCDgemini surfactants at various concentrations (1-30 mM) to 
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better understand their aggregation behavior. As previously reported, βCDgemini surfactant-12 
showed a broad peak (at q less than 0.1 Å
-1
) corresponding to the diffused scattering and 
increasing the concentration of the surfactant did not change the aggregation behavior in this 
system. Similar results were observed for βCDgemini surfactant-16 and -18:1 (data is not 
shown). This is further evidence that, self-inclusion of the alkyl tail of the gemini surfactant in 
the βCD cavity in the βCDgemini surfactants will prevent supramolecular assembly in aqueous 
media and formation of lyotropic liquid crystals. 
The scattering behavior of formulations containing complexes of NC 2067 and βCDgemini 
surfactants (16 and 18 hydrocarbon tails) at various drug to carrier mole ratios (1:0.5, 1:1 and 
1:2) (Figure 9.2B,C) examined  and compared to the similar systems comprising of βCDgemini 
surfactant-12 (Figure 9.2A)
374
. We formerly demonstrated that the SAXS/WAXS pattern of NC 
2067/βCDgemini surfactant-12 at various drug to delivery agent mole ratios (1:0.5, 1:1 and 1:2) 
showed a new peak at q of 0.27 Å
-1
 (velvet arrows) corresponding to a d-spacing of 23 Å formed 
in the system upon the addition of NC 2067 (Figure 9.2A)
374
. The appearance of the other peaks 
at higher q are associated with the precipitated form of NC 2067 in the systems (black arrows-
Figure 9.2A) expressly observable in systems with lower amount of βCDgemini surfactant-12, 
1:0.5 and 1:1 mole ratios, respectively (Figure 9.2A).
374
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Figure 9.2- SAXS/WAXS patterns of the formulations containing A) βCDgemini surfactant-12 [reproduced from 
Poorghorban et al, 2015], B) βCDgemini surfactant-16 and C) βCDgemini surfactant-18:1. 
 
SAXS/WAXS study of free βCDgemini surfactants (-16 and -18:1) displayed diffused scattering 
patterns which were different in shape in comparison to βCDgemini surfactant-12 (Figure 9.2B, 
C). The addition of NC 2067 to βCDgemini surfactant-16 resulted in flattening of the broad peak 
corresponding to the free βCDgemini surfactant-16 and appearance of the new peaks at higher q 
range corresponding to NC 2067 precipitated in the samples (black arrows, Figure 9.2B). 
Conversely, no peaks detected at higher q values in the scattering patterns of the formulations 
composed of NC 2067/βCDgemini surfactant-18:1 at various mole ratios. We speculate that the 
interaction of NC 2067 with βCDgemini surfactant-18:1 is different from the other two 
βCDgemini surfactants even at lowest amount of the delivery agent (mole ratio of 1:0.5) leading 
to a better solubilization of the cytotoxic agent. This could be related to the monounsaturated 
nature of the hydrocarbon tail of βCDgemini surfactant-18:1 which alters its geometry. It is well 
documented the monosaturation of the acyl chain can disturb the lipid bilayers by providing a 
kink in the structure.
397
 We hypothesized that the self-inclusion behavior possibly is less robust 
in the case of the free βCDgemini surfactant-18:1 due to the “bend” in the structure and 
geometrical hindrance. A weaker interaction of the gemini-18:1 tail with βCD cavity could be 
favorable for more efficient insertion of the NC 2067 into βCD cavity. Furthermore, the direct 
interaction of NC 2067 with the unsaturated bonds of βCDgemini surfactant-18:1 might also 
increase the solubility of NC 2067.  According to the better interaction of NC 2067 with 
βCDgemini surfactant-18:1, either CD cavity or gemini surfactant moiety, NC 2067 was 
solubilized more even at 1:0.5 mole ratio. 
Monitoring the NC 2067/βCDgemini surfactant-16 and NC 2067/βCDgemini surfactant-18:1 
systems at various mole ratios, we detected the peak at q of 0.27 Å
-1
 (velvet arrow, Figure 9.2B 
and C). Unlike the βCDgemini surfactant-12 containing systems, this peak was observed only for 
the systems with the lowest amount of the delivery agent at mole ratio of 1:0.5. The presence of 
this peak indicates the formation of a new phase in the βCDgemini surfactant containing systems 
upon addition of NC 2067 which is not governed by the length and nature of the gemini 
surfactant hydrocarbon tail.  
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9.4.3. Molecular mechanism of the anticancer activity of NC 2067 complexes with different 
βCDgemini surfactants  
9.4.3.1. In vitro activity of NC 2067 complexes with βCDgemini surfactants having different 
hydrocarbon tails (-12, -16 and -18:1)  
We previously showed the anticancer activity of NC 2067/βCDgemini surfactant-12 in which 
βCDgemini surfactant-12 synthesized by structurally different linkers (ester and amide) and drug 
to carrier mole ratios were various as well. Herein, we extended our study by the in vitro 
assessment of the other two βCDgemini surfactant (-16 and -18:1) containing systems to 
understand the effect of the acyl chain length and unsaturation of the hydrocarbon tail on cellular 
toxicity.  
The in vitro activity of NC 2067 complexes with three different βCDgemini surfactants (16 and 
18:1 hydrocarbon tail) (Table 9.2) at 1:2 drug to carrier mole ratio, toward A375 melanoma cell 
line was determined and compared to the previous results of βCDgemini surfactant-12374. IC50 
values (half-maximal inhibitory concentration) used as an indicator of the ability of NC 2067 to 
kill cancerous cells. The IC50 values of all NC 2067/βCDgemini surfactant formulations were 
calculated as less than 3 μM suggesting the high toxicity toward A375 melanoma cells (Table 
9.2).  No significant difference was observed by comparing the IC50 values for the various 
βCDgemini surfactant containing systems (P>0.05).  
To evaluate the safety of the delivery agents, the βCDgemini surfactants (-16 and -18:1), the 
intrinsic toxicity was evaluated at 200 μM concentration. We observed that the intrinsic toxicity 
of free βCDgemini surfactant-16 was significantly (P<0.05) higher than the βCDgemini 
surfactants -12 and -18:1 (Table 9.2). This observation possibly related to the fact that 
βCDgemini surfactant-16 was less soluble and precipitated easily in cell culture media (visual 
examination by light microscopy not shown).  
The IC50 value for NC 2067/βCDgemini surfactants (-16 and 18:1) were comparable to our 
previous study on βCDgemini surfactant-12 based systems.374  
Low IC50 values of NC 2067/βCDgemini surfactant (-12, -16 and -18:1) formulations showed 
that an anticancer activity of NC 2067 can be retained in these systems and the chain length and 
unsaturation of the gemini surfactant tail did not alter their in vitro efficiency toward A375 cell 
line. However, the comparison of the intrinsic toxicity of the free βCDgemini surfactants (-12, -
16 and -18:1) (Table 9.2) revealed that βCDgemini surfactant-16 is the least appropriate carrier 
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due to its significantly higher cellular toxicity and βCDgemini surfactant-12374 and -18:1 showed 
low intrinsic toxicity. The cytotoxicity of the gemini surfactant moiety of βCDgemini surfactant-
12 (12-7NH-12) reported to be high in rabbit epithelial cells.
165
 Moreover, other gemini 
surfactant derivatives comprised of the substitution of various amino-acids on gemini surfactant-
12 (12-7NH-12) revealed low cell viability as well.
165
 However, as we reported previously 
βCDgemini surfactant-12 showed low intrinsic toxicity whereas βCD grafted gemini surfactants 
with exception of -16 tail showed favorable low cytotoxicity as drug delivery agents. 
Table 9.2- IC50 values of NC 2067 complexes with three different βCDgemini surfactants (12, 16, 18:1 hydrocarbon 
tail) at 1:2 drug to delivery agent mole ratio and % intrinsic toxicity of the free βCDgemini surfactants.  
NC 
2067/βCDgemini 
surfactant drug 
delivery systems 
IC50 [μM] ± SD 
% toxicity of βCDgemini surfactant [ 
200 µM] ± SD  
-12* 2.0 ± 0.25 18 ± 6 
-16 2.63 ± 0.17 80 ± 0.8 
-18:1 2.65 ± 0.14 22.6 ± 2.1 
*Data is adapted from our previous study.
374 
9.4.3.2. Proapoptotic activity of NC 2067 complexes with βCDgemini surfactants having different 
hydrocarbon tails (-12, -16 and -18:1)  
Cytotoxic drugs can destroy cancer cells by apoptosis, necrosis or autophagy. We formerly 
reported an increase in the caspase -3 and -7 in A375 cells upon treatment with NC 2067 
formulations.
3
 Here in, we examined the mode of cell death in melanoma cells treated with the 
NC 2067 in presence of the βCDgemini surfactant-based carrier to differentiate apoptosis from 
necrosis. Early signs of apoptosis can be tracked by the translocation of PS on the outer cell 
leaflet. We evaluated the effect of NC 2067 complexes with different βCDgemini surfactants (12, 
16 and 18:1) toward A375 melanoma cell line by measuring the PS exposed on the cell surface 
using flow cytometry. An anti-melanoma agent, melphalan was used as a positive control. 
We observed that the untreated cell population was healthy (96.6% of cells); both early and late 
apoptotic cells combined represented 3% of the total population and only 0.4% was in a necrotic 
state (Table 9.3). The NC 2067 complexes with different βCDgemini surfactants (-12, -16 and -
18:1) at 1:2 drug to carrier mole ratio or dissolved in 1% DMSO at IC50 values showed an 
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increased population of apoptotic cells (late and early) and decreased healthy populations (Table 
9.3). The percentage of the necrotic population did not alter significantly compared to the 
untreated cells suggesting that NC 2067 did not induce necrosis in A375 melanoma cells. 
Melphalan, an antimelanoma drug on market, showed similar proapoptotic behavior at its IC50 
concentration with 31.3% of cells undergoing apoptosis. The early apoptotic population of cells 
treated with NC 2067/βCDgemini surfactant-12 (8.7%) was comparable to melphalan (9.8%) 
(Table 9.3). The majority of the cells treated with free βCDgemini surfactants (-12 and -18:1) or 
1% DMSO were healthy (93.3-95.3%) whereas treatment with free βCDgemini surfactant-16 
resulted in the increase in necrotic/apoptotic population (Table 9.3). This observation is in good 
agreement with the high intrinsic toxicity of free βCDgemini surfactant-16 obtained with MTT 
assay (Table 9.2). 
Moreover, cells stained with DAPI showed chromatin condensation (Figure 9.3A, yellow 
arrows) after 24 hour of treatment with NC 2067/βCDgemini surfactant-12 formulation while 
cells treated with free βCDgemini surfactant-12 did not show signs of apoptosis in fluorescent 
micrographs (Figure 9.3B).   
These results suggested that NC 2067 complexed with different βCDgemini surfactants (-12, -16 
and -18:1) at 1:2 mole ratio was able to preserve its ability to trigger cell death via apoptosis, at a 
comparable level to NC 2067 dissolved in 1% DMSO. Our finding is in good agreement with 
other studies showing the proapoptotic activity of curcumin and its analogs in melanoma cells 
through regulation of the mediators of intrinsic or extrinsic apoptosis pathways.
107,109,231,238
  
Autophagy is a cellular degradation process in which cellular organelles will be eaten by 
autolysosomes in response to various stimuli such as chemotherapeutics.
398
 Even though 
autophagic mechanism of cell death is not defined entirely, there are several studies confirmed 
the cross talks between apoptosis and autophagy. 
399,400
 There are reports in the literature 
showing that curcumin is able to induce autophagy in various cancer cells.
401-403
 Moreover, it 
was shown that autophagy and apoptosis can occur simultaneously by curcumin and its 
analogs.
400,404-406
 However, caspases are not related to autophagic cell death mechanism whereas 
in apoptotic modes of cell death, they have crucial role.
398
 The caspase-dependent cell death 
mechanism of NC 2067/βCDgemini surfactant-12 in A375 melanoma cells3 supports our finding 
regarding apoptosis involvement in cell death mechanism. There is an essential need to perform 
more experiments to confirm whether autophagy occurred simultaneously with apoptosis. 
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Furthermore, we evaluated the mitochondrial membrane potential loss of A375 melanoma cells 
treated with NC 2067 formulations as an indicator to discriminate the intrinsic (mitochondrial 
mediated) apoptosis from extrinsic pathway. NC 2067 in presence of βCDgemini surfactants or 
0.1% DMSO did not alter the mitochondrial membrane potential. 
Albeit curcumin and its analogs mainly induce apoptosis in cancer cells in a mitochondrial-
dependent manner
109,212,214,215,238
 and NC 2067 decreased mitochondrial membrane potential in 
HCT-116 colon cancer cell line
226
, our findings did not confirm the loss of the mitochondrial 
membrane potential in A375 melanoma cells. This result is consistent with few studies verifying 
the non-mitochondrial dependent apoptosis induced by curcumin in melanoma cells.
231,232
 
Finally, free βCDgemini surfactants (-12 and -18:1) showed minimal proapoptotic activity in 
A375 melanoma cell line.  
  
 
 
Table 9.3 - Apoptotic cell death induced by NC 2067 complexes with different βCDgemini surfactants (12, 16 and 
18:1) after 24 hours of treatment at IC50 concentrations toward A375 melanoma cell line (samples were pooled from 
triplicates). 
 
Populations percentage 
Untreated Melphalan 
NC 2067 in 1% 
DMSO 
NC 2067 
/βCDgemini 
surfactant 
βCDgemini 
surfactant 1% 
DMSO 
-12 -16 -18:1 -12 -16 -18:1 
Healthy 96.6 68 88.6 76 86 91.7 93.3 88.8 94.2 95.3 
Early 
Apoptotic 
0.6 9.8 1.8 9.85 2.5 2.8 1 1.6 0.5 0.5 
Late 
Apoptotic 
2.4 21.5 9.2 13.4 10.7 4.9 5 8.1 5 3.8 
Necrotic 0.4 0.7 0.4 0.69 0.8 0.6 0.7 1.5 0.3 0.4 
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Figure 9.3- Biexponential apoptotic rate of (annexin V-FITC/PI dual staining) and fluorescence micrographs (DAPI 
staining) in A375 melanoma cells treated with A) NC 2067/βCDgemini surfactant-12 and B) free βCDgemini 
surfactant-12 for 24 hours. Yellow arrows show chromatin condensation. 
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9.4.3.3. Cell cycle analysis of NC 2067 complexes with βCDgemini surfactants having different tails 
(12, 16 and 18:1)  
We used flow cytometry based analysis to evaluate the effect of NC 2067 complexes with 
various βCDgemini surfactants on the cell cycle distribution. The fluorescence intensity of cells 
stained by PI indicates DNA concentration in different cell cycle phases. Sodium butyrate
407
 and 
resveratrol
408
, specific cell cycle arresters at G0/G1 and S phases, respectively, were used as 
positive controls (data not shown). Cells treated by NC 2067 complexes with different 
βCDgemini surfactants (12, 16 and 18:1) or NC 2067 dissolved in 1% DMSO showed minimal 
effect on the cell cycle phases comparable to untreated cells (Table 9.4). NC 2067/βCDgemini 
surfactant-16 increased the cell population in G2/M and S-phases moderately (P=0.05) while 
decreasing the cells at G0/G1 phase.  Conversely, NC 2067/ 1% DMSO and 1% DMSO showed 
slight increase of the population in G0/G1 phase in comparison to healthy cells (Table 9.4). Since 
rise in the cell population at G0/G1 phase by these two samples are similar, the effect is 
undoubtedly caused by 1% DMSO. The ability of 2% DMSO to arrest cell cycle at G0/G1 phase 
by inhibiting the gene expression in fibroblast cells, is well documented.
409
  Melphalan arrested 
cells predominately at S-phase of the cell cycle at 76.3%, a 52.3% increase over the untreated 
population.  This finding is consistent  with literature proposing the anticancer mechanism of the 
melphalan in melanoma cell lines.
410
 There are reports showing that curcumin treatment is able 
to arrest cancer cells at G0/G1
232,244
, S
213
 and G2/M
219,227,236
 phases at various cancer cell lines 
such as melanoma cell lines. However, NC 2067 most likely exerted its effect by thiol alkylation 
without interfering with DNA.
113,114
 Some of the existing anticancer therapeutic agents that 
target amino and hydroxyl groups on nucleic acids result in genotoxic outcomes.
115
 Free 
βCDgemini surfactants (12, 16 and 18:1) did not influence cell cycling (Table 9.4). 
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Table 9.4- Cell cycle analysis of A375 cells treated with NC 2067/βCDgemini surfactant (-12, 16 and 18:1) 
formulations after 24 hours at IC50 concentrations in comparison to NC 2067 dissolved in 1% DMSO and model 
drug melphalan (samples were pooled from triplicates).  
 Cell Cycle Untreated Melphalan 
NC 2067 in 
1% DMSO 
NC 2067 /βCDgemini 
surfactant 
βCDgemini 
surfactant 1% 
DMSO 
-12 -16 -18:1 -12 -16 -18:1 
G0/G1 68 16.3 73.9 65.1 48.4 62.6 64.5 62 65 74.5 
G2/M 8 7.3 8 0.3 14.9 8 8 8 8 8 
S 24 76.3 18.1 34.6 36.7 29.4 27.5 30 27 17.5 
 
9.5. Conclusion 
Overall, NC 2067 complexes with βCDgemini surfactants (12, 16 and 18:1) formed nano-sized 
aggregations that were able to trigger non-mitochondrial apoptosis without affecting cell cycle 
distribution in A375 melanoma cells. Despite the fact that the self-inclusion behavior of 
βCDgemini surfactants (12, 16 and 18:1) hinder the formation of LLC phases, SAXS/WAXS 
patterns of the NC 2067/βCDgemini surfactant nanoformulations showed that upon addition of 
NC 2067 to the system new phase was formed. To understand the molecular mechanism of cell 
death induced by these formulations further investigations will be required. 
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In this manuscript, the influence of the addition of 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) on assembling of the nanostructures formed of NC 2067 with 
various βCDgemini surfactants was evaluated using SAXS/WAXS. In addition, the in vitro 
anticancer activity of the formulations was assessed in A375 melanoma cells. I made all the 
formulations, performed experiments and analyzed data. 
 
This manuscript addresses the following specific objectives of my research 
1.2. To develop formulations by addition of helper lipid  
1.6. To use synchrotron small- and wide angle X-ray scattering (SAXS/WAXS) to evaluate 
the supramolecular arrangement of drug/βCDgemini surfactant delivery systems in solution 
2.1. To calculate the cell toxicity (IC50) of different drug/βCDgemini surfactant formulations 
towards melanoma cell line 
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10.1. Abstract 
Helper lipids such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) are commonly 
used in the gene delivery formulations composed of cationic surfactants in order to increase the 
transfection efficiency and lower the cytotoxicity associated with gemini surfactants. 
βCyclodextrin-gemini surfactant-based formulations were designed to increase the solubility of 
the model lipophilic anticancer agent, NC 2067, and enhance its delivery to A375 melanoma 
cells. The influence of the addition of DOPE was evaluated on the anticancer activity and nano-
structural arrangements of the NC 2067/βCyclodextrin-gemini surfactant complexes. 
Size measurements and SAXS/WAXS were used to compare the nanoparticulate behavior of the 
formulations upon addition of DOPE. Cell viability assay was employed to track the alterations 
in the efficiency of NC 2067 formulated with βCyclodextrin-gemini surfactants and DOPE 
towards A375 melanoma cells. 
It was found that the addition of DOPE did not significantly alter the IC50 of the NC 2067 in the 
formulations whereas it increased the intrinsic toxicity of the βCyclodextrin-gemini surfactant. 
Moreover, formulations containing DOPE formed nano-sized particles and their scattering 
pattern was not drastically different from their DOPE-free counterparts. 
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10.2. Introduction 
Cationic lipid-based nano-formulations are widely used for the delivery of the drug small 
molecules
411
 and nucleic acids
412,413
. It was shown that the self-assembling behavior of these 
nanoparticles play an important role in the enhancement of the efficiency of the chemotherapy 
and gene therapy. The fusion of the lipid moieties of such formulations with biomembranes 
increases the delivery of the drugs and genes into the target cells, but not all cationic lipids 
possess fusogenic properties.  
Helper lipids are neutral lipids which commonly added to cationic liposomes to increase the 
transfection efficiency. Among the helper lipids, DOPE (1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine) (Figure 10.1), a neutral phospholipid extensively studied to improve the 
transfection efficiency of the cationic lipid formulations in gene therapy.
414,415
 It was shown that 
in comparison to other helper lipids, DOPE enhanced the transfection to higher extend.
416
 
DOPE can destabilize lipid bilayers and disturb endosomes resulting in the release of nucleic 
acids into cytosol.
415,417
 From the structural point of view, the cone-shaped DOPE forms the 
inverse hexagonal phase (HII
C
) in lipoplexes.
328,418
 Studies showed that DOPE was able to 
contribute to the formation of various lipid-based supramolecular arrangements that enhanced 
the fusogenic activity of the nanoparticles and improved the cellular uptake.
341
  
Previously, DOPE was added to lipoplexes containing gemini surfactants in order to improve the 
transfection compared to the formulations lacking DOPE.
419
 βCDgemini surfactants are new 
class of dicationic gemini surfactants built by attachment of gemini surfactants (m-7NH-m) to 
βcyclodextrin.3 We previously demonstrated that βCDgemini surfactants can be employed as 
delivery agents for hydrophobic anticancer agents such as a curcumin analog (NC 2067).
374
 
Moreover, the nanoparticulate behavior, anticancer activity and cell death mechanism of 
formulations comprised of NC 2067 and βCDgemini surfactants with various chain length and 
degree of unsaturation of the alkyl tail were examined. In the current study, our aim is to 
evaluate the effect of the addition of DOPE to NC 2067/βCDgemini surfactant formulations on 
the structural properties and cytotoxicity activity. 
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Figure 10.1- Molecular structure of DOPE. 
 
10.3. Materials and Methods 
10.3.1. DOPE preparation 
DOPE (Avanti Polar Lipids, Alabaster, AL, USA) and α-tocopherol (Spectrum, Gardena, CA, 
USA) in 1:0.2 weight ratios were dissolved in 100% ethanol (Commercial Alcohols Inc., 
Brampton, ON, Canada) and deposited as a thin film on a round-bottomed flask. The lipid was 
lyophilized overnight, to remove traces of solvent, and resuspended at 1 µmol/ml concentration 
in 9.25% w/v isotonic sucrose (Spectrum) solution (pH 9) by sonication, then filtered through 
0.45 µm Acrodisc® filters.413 
10.3.2. Preparation of inclusion complexes  
NC 2067 and βCDgemini surfactants were synthesized as described previously.111,3 All other 
chemicals were purchased from Sigma-Aldrich (Oakville, ON, Canada). Complexes of NC 2067 
with βCDgemini surfactants (-12, -16 and -18:1) were formulated as described previously374 and 
reconstituted in DOPE (1 mM). 
10.3.3. Size measurements 
Particle sizes in solution were measured by using a Zetasizer Nano ZS instrument (Malvern 
Instruments, UK). Results are reported as the mean of 3-5 measurements ± standard deviation. 
10.3.4. Small- and wide-angle X-ray scattering (SAXS/WAXS) measurements 
SAXS/WAXS measurements were performed at the BL4-2 beamline at Stanford Synchrotron 
Radiation Lightsource (SSRL, Stanford, CA, USA) at 20 s exposure time. The samples 
containing NC 2067/βCDgemini surfactant complexes dispersed in DOPE with constant 
concentration of gemini surfactant  (10 mM) studied at energy of 11 keV and a sample to 
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detector distance of 1.1 m. Diffraction intensity versus q (scattering vector) plots were obtained 
by radial integration of the 2D patterns using GSAS-II software.
393
  
10.3.5. Cell viability assay 
A375, human amelanotic melanoma cells (American Type Culture Collection, CRL-1619) were 
seeded at a density of 1 x 10
4
 cells per well in 96-well tissue culture-treated plates. Cells were 
treated with the formulations at cytotoxic agent concentrations of 0.01–200 µM in quadruplicate 
wells for 48 h to produce a balanced 4-parameter curve. The experiments were conducted in 
triplicate. After treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
Invitrogen, Burlington, ON, Canada) at 450 μg/mL was added to each well and the plates were 
incubated for 2 h at 37 ᵒC.  Absorbance at 550 nm was recorded using a Synergy BioTek plate 
reader. The IC50 values for all samples were calculated using the 4-parameter curves generated 
by the GEN5 software from BioTek. 
10.3.6. Statistical analysis 
Statistical analysis was performed using SPSS (version 19.0). One-way analysis of variance, 
Scheffe comparison was used. The level of significance was considered at p<0.05 value. 
 
10.4. Results and Discussion 
10.4.1. Size measurements of NC 2067/βCDgemini surfactant-12 dispersed in DOPE at 
different mole ratios 
The size of nano-particulate systems of NC 2067/βCDgemini surfactant-12 at three different 
drug to carrier mole ratios (1:1, 1:2 and 1:0.5) in the presence of DOPE (1 mM) was measured 
and compared to previous results in which the nano-formulations were dispersed in water
374
 
(Table 10.1). At 1:2 mole ratio, the average size of the nanoparticles dispersed in DOPE of 
109±6 nm was comparable to the same formulation without DOPE (P>0.05). However, at the 
ratios of 0.5:1 and 1:1 the nanoparticles dispersed in DOPE showed sizes of 93±1.3 and 87±0.6 
nm, respectively, which were significantly smaller in comparison to formulations dispersed in 
water (P<0.05). All formulations containing DOPE exhibited the average size under 110 nm with 
a polydispersity index (PDI) of ≤ 0.3.  DOPE at 1 mM concentration formed nanoparticles with 
the size of 97 ± 0.3 nm (Table 10.1). 
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Table 10.1- Size of different nanoparticulate formulations (average of 3-5 measurements ± standard deviation, SD) 
and corresponding polydispersity index (PDI). 
 
 
Dispersion 
media 
Mole ratio of drug to delivery 
agent 
size [nm] ± SD PDI 
NC2067/βCDgemini 
surfactant-12 
nanoparticles 
  Water* 
1:0.5 160 ± 3 0.1 
1:1 140 ± 1 0.2 
1:2 101 ± 2 0.3 
DOPE 
1:0.5 93 ± 1 0.2 
1:1 87 ± 1 0.2 
1:2 109 ± 6 0.3 
DOPE (1 mM) Water NA 97 ± 0.3 0.2 
 * Data is adapted from our previous study.374 
 
10.4.2. SAXS/WAXS measurements of NC 2067 complexes with different βCDgemini 
surfactants (12, 16 and 18:1) dispersed in DOPE at different mole ratios 
We evaluated the SAXS/WAXS pattern of the complexes of NC 2067 with βCDgemini 
surfactants (12, 16 and 18:1) at three different drug to carrier mole ratios (1:0.5, 1:1 and 1:2) 
dispersed in DOPE (Figure 10.2). Free βCDgemini surfactant-12 and -16 dispersed in DOPE 
showed diffused scattering pattern (Figure 10.2A and B) comparable to the similar βCDgemini 
surfactants dispersed in water discussed in section 9.4.2, Figure 9.4.  Interestingly, the free 
βCDgemini surfactant-18:1 dispersed in DOPE showed a different scattering pattern with peaks 
at q10, q11 and q20 of 0.095, 0.166 and  0.192 Å
-1
, respectively, corresponding to inverted 
hexagonal phase (1:√3:√4) (velvet arrows in Figure 10.2C).  The two-dimensional inverted 
hexagonal phase is well-defined for DOPE in solution.
420
 Moreover, the peak at q of 0.095 Å
-1
 
retained in the scattering pattern of NC 2067/βCDgemini surfactant-18:1 at 1:2 mole ratio in the 
presence of DOPE (Figure 10.2C). As well, a peak at q of 0.27 Å
-1
 appeared in the scattering 
pattern of NC 2067/βCDgemini surfactant-18:1 at 1:0.5 mole ratio dispersed in DOPE (Figure 
10.2C; orange arrow) which is related to the new phase forming by addition of NC 2067 to the 
lipid system.  
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Furthermore, another peak detected at higher q of 0.43 Å
-1
, corresponding to NC 2067 powder 
diffraction pattern (d=15 Å) which arises from drug precipitation in formulations comprised of 
NC 2067 complexed with βCDgemini surfactants (-16 and 18:1) containing lower amount of 
delivery agent (1:0.5 and 1:1 mole ratios) (Figure 10.2-A and B; black arrows). The same 
observation was reported previously for NC 2067/βCDgemini surfactant-12 surfactant in 
water.
374
 
 
Figure 10.2- SAXS/WAXS patterns of formulations dispersed in DOPE containing A) βCDgemini surfactant-12, B) 
βCDgemini surfactant-16 C) βCDgemini surfactant-18:1. 
 
Overall, the scattering pattern of free βCDgemini surfactants (-12 and -16) dispersed in DOPE 
(Figure 10.2-A and B) were similar to the delivery agents dispersed in water. In contrast to the 
formulations dispersed in water, addition of NC 2067 did not result in the formation of new 
phase. In case of the βCDgemini surfactant-18:1 dispersed in DOPE, the dominant inverted 
hexagonal phase, characteristic to DOPE, was detected. The formulation prepared of NC 
2067/βCDgemini surfactant-18:1 dispersed in DOPE at the highest βCDgemini surfactant mole 
ratio (1:2) still showed the DOPE hexagonal phase (first peak) while at the lowest amount of the 
delivery agent to drug (mole ratio of 1:0.5) a new phase related to the NC 2067 was detectable.  
̶̶ ̶  ̶   βCDgemini surfactant 
̶̶ ̶  ̶  1:0.5 mole ratio NC 2067/βCDgemini surfactant 
̶̶ ̶  ̶  1:1 mole ratio NC 2067/βCDgemini surfactant 
̶̶ ̶  ̶  1:2 mole ratio NC 2067/βCDgemini surfactant 
A 
DOPE 
B C 
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Based on our knowledge regarding the self-inclusion behavior of βCDgemini surfactants, the 
addition of DOPE to these formulations did not change the lipid phase behavior of the system 
drastically. Moreover, this can be related to the low concentration of DOPE used (1 mM). 
We previously discussed in section 9.4.2 that the complex of NC 2067/βCDgemini surfactant-
18:1 dispersed in water showed different scattering pattern compared to the other complexes. We 
speculate that the mono-unsaturated oleyl chains of βCDgemini surfactant-18:1 behave 
differently from the saturated tail resulting in a weaker self-inclusion behavior, thus forming 
LLC more readily. Addition of DOPE to this surfactant in the absence of NC 2067 resulted in the 
formation of the inverted hexagonal phase corresponding to DOPE. This observation supports 
the previous finding regarding the higher possibility that the gemini surfactant hydrocarbon tails 
are available to interact with DOPE in βCDgemini surfactant-18:1. 
 
10.4.3. In vitro activity of NC 2067/βCDgemini surfactant-12 dispersed in DOPE at 
different mole ratios  
The delivery efficacy of various formulations of NC 2067/βCDgemini surfactant-12 dispersed in 
DOPE (1mM) at three different drug to carrier mole ratios (1:0.5, 1:1, 1:2) was assessed and IC50 
values were calculated. The in vitro activity of formulations dispersed in DOPE at each mole 
ratio was not significantly different from the similar formulations dispersed in water
374
 (P>0.05) 
(Table 10.2). 
The intrinsic toxicity of βCDgemini surfactant-12 dispersed in DOPE was significantly higher 
than the free βCDgemini surfactant-12 (P<0.05) (Table 10.2). However, the overall cell viability 
in the βCD-substituted gemini surfactants is significantly higher than in their amino acid-
substituted counterparts.
165
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Table 10. 2- IC50 values of NC 2067 in various βCDgemini surfactant-12 formulations and % intrinsic toxicity of 
the βCDgemini surfactants. 
 
Dispersion 
media 
Mole ratio of drug 
to delivery agent 
IC50 [μM] ± SD 
% toxicity of 
βCDgemini 
surfactant [ 200 
µM] ± SD 
NC2067/βCDgemini 
surfactant-12 
nanoparticles 
Water* 
1:0.5 2.2 ± 0.2 
18 ± 6 1:1 2.4 ± 0.4 
1:2 2.0 ± 0.25 
DOPE 
1:0.5 1.8 ± 0.3 
32 ± 4 1:1 2.0 ± 0.35 
1:2 2.0 ± 0.2 
* Data is adapted from our previous study.
374
 
 
 
10.5. Conclusion 
In conclusion addition of DOPE to NC 2067/βCDgemini surfactant-12 complexes did not change 
their nano-size or nano-structural behavior at 1:2 mole ratio. Moreover, DOPE was able to 
change the scattering pattern of βCDgemini surfactant-18:1 surfactant to inverted hexagonal 
phase though it did not alter the other two βCDgemini surfactants behavior in solution. Further 
studies needed to elucidate the effect of DOPE on βCDgemini surfactant-based formulations.  
  
 144 
 
11. GENERAL DISCUSSION AND FINAL CONCLUSIONS 
Numerous novel anticancer agents are designed and synthesized yearly in order to treat variety of 
cancers, the major public issue worldwide. Advancements of nano-based drug delivery systems 
revolutionized cancer therapy. One innovative approach is the utilization of nano-formulations to 
increase the solubility of poorly soluble anticancer agents and, consequently, enhance their 
bioavailability.  
Curcumin, the active ingredient of turmeric rhizome, is a natural polyphenol with various 
pharmacological activities. The anticancer activity of curcumin has been confirmed in different 
cancer cells. Several curcumin analogs were designed and synthesized to improve the anticancer 
activity of curcumin. Dr. Dimmock and his colleagues synthesized series of curcumin analogs, 
named NC compounds with high in vitro cytotoxicity towards various cancer cells.
111,226
 Among 
them NC 2067 was shown to have high in vitro cell toxicity towards A375 melanoma cells with 
low IC50 value (less than 1 μM).
3
 The main challenge of this anticancer agent was the low water 
solubility (log P = 4.6)
2
 which is not favorable for in vivo efficacy. 
To address the solubility and bioavailability issue of NC 2067, a delivery agent was designed in 
our group. This novel carrier, called βCDgemini surfactant, was synthesized by chemical 
attachment of a βCD to a gemini surfactant. βCD, an oligosaccharide macrocycle, is a well-
known pharmaceutical carrier which can encapsulate lipophilic molecules and increase their 
solubility. Gemini surfactants are amphiphilic molecules with the ability to self-assemble and 
form nano-structures which enhance the delivery of small molecules and biotechnology drugs 
such as DNA into the mammalian cells. Gemini surfactants used to build βCDgemini surfactants 
are classified as imino substituted quaternary ammonium gemini surfactants (m-7NH-m) with 
various tail length and degree of unsaturation. Physicochemical characteristics and in vitro 
activity of the complexes of NC 2067 with βCDgemini surfactants were examined to expand our 
knowledge about this delivery agent. The previous work in our research group showed that NC 
2067 in complexed with βCD and βCDgemini surfactant (with twelve carbon tail, 12C) at 1:2 
drug-to-carrier mole ratio, was able to selectively kill A375 melanoma cells without affecting the 
human epidermal keratinocytes. Moreover, NC 2067/ βCDgemini surfactant increased caspase 3 
/7, apoptotic executioners in A375 melanoma cells and formed nanoparticles with positive 
charge. This study showed that encapsulation of NC compounds by βCD cavity can act as a 
delivery agent to replace cytotoxic organic solvents such as DMSO.
3
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The first step in my research was to further discover and explain the structural mode of the 
interaction of NC 2067 with βCD and βCDgemini surfactant. βCDgemini surfactant having 
gemini surfactant with twelve hydrocarbon tail, (12-7N[CD]-12) was selected for proof-of-
principle studies. It was previously found that having three interposing methylene moieties 
between nitrogen atoms of the spacer of the gemini surfactants, enhanced the formation of 
various lipid structures and transfection efficacy in lipoplex formulations.
166
  The presence of the 
non-carbon atoms (nitrogen) in the structure of the gemini surfactant spacer is crucial for 
addition of various functional groups. Moreover, hydrocarbon tails with more than 12 carbon 
atoms have limited solubility which made 12-7NH-12 gemini surfactant a suitable candidate to 
be attached to the βCD. Even though βCDgemini surfactant is the delivery agent that was 
reported to form nanoparticles and enhance the penetration through biomembranes in the 
previous study
3
, the physicochemical characteristics of the NC 2067/βCD complexes were not 
fully evaluated and the nanoparticle model was built on limited experimental data. Thus the need 
to comprehend the interaction of NC 2067 and βCDgemini surfactant to a greater extent and 
build evidence-based models was obvious.  
We proposed to examine the complexation of the βCD and its hydrophobic guest molecules by 
variety of techniques based on the alterations in spectroscopic properties, thermal behavior, 
ability to diffract X-ray and solubility in aqueous media. The original plan was to crystallize the 
complexes of NC 2067 with βCD or βCDgemini surfactant and employ single crystal X-ray 
crystallography to solve the structure. Unfortunately, the crystallization process was not 
successful and crystals obtained were single crystals of unbound NC 2067 or βCD (Appendix 
13.1).  In this research the formation of the inclusion complexes of NC 2067 with βCD or 
βCDgemini surfactant (12 carbon atoms in alkyl chain) was confirmed qualitatively with 
synchrotron-based powder X-ray diffraction, FTIR and TGA. The comparison of the inclusion 
complex pattern with the individual components and physical mixture was used to corroborate 
inclusion formation. In general, the behavior of the physical mixture was a representative of the 
properties of the two components whereas the inclusion complex was a new compound with new 
structural properties. Our studies confirmed (section 7.6) that the Bragg’s peaks of the individual 
components were identifiable in diffraction pattern of the physical mixture of NC 2067 with βCD 
or βCDgemini surfactant. On the other hand, new Bragg’s peaks were detected in diffractogram 
of the inclusion of NC 2067 with βCD. Powder X-ray diffraction of the complexes composed of 
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βCD and other small molecules, confirmed inclusion formation by revealing new peaks, which 
were not related to any of the components.
313,314
 The NC 2067/βCDgemini surfactant 
diffractogram showed an amorphous structure similar to native βCDgemini surfactant without 
any crystalline peaks corresponding to NC 2067. This data supported the inability to crystalize 
the βCDgemini surfactant-based systems. Moreover, in the FTIR spectra of the inclusion of NC 
2067 with βCD or βCDgemini surfactant, the signature peaks of NC 2067 corresponding to 
styryl moiety was absent or weakened, while they were observable in the physical mixtures’ 
spectra. TGA was another technique used to confirm the inclusion formation in these host/guest 
systems. In the thermogram of NC 2067/βCD complex, the water loss region corresponding to 
CD, disappeared. The similar results were reported in the other studies on the βCD complexes 
confirmed that the water located in the cavity of βCD was replaced by the guest molecule.260,360 
In contrast to βCD, βCDgemini surfactant did not lose any water at 30 ºC -70 ºC. This finding 
showed for the first time that the βCD cavity of βCDgemini surfactant was most likely occupied 
by another hydrophobic part of the molecule. It was hypothesized that the hydrocarbon tails of 
the gemini moiety might be encapsulated by βCD cavity, consistent with other studies showing 
the interaction of the tail of surfactants with CD cavity.
173,176-178,361,362
 Because we did not detect 
similar water loss trend for βCDgemini surfactant compared to βCD, the water loss mechanism 
could not be used to confirm the inclusion formation for NC 2067/βCDgemini surfactant 
complex. Nevertheless, the degradation temperature of NC 2067 complexed with βCD and 
βCDgemini surfactant was elevated and proved that a complex was formed with a higher 
stability compared to the free NC 2067. A similar thermal degradation was found for the 
inclusion complex of sulfamethoxazole with CD that started at higher thermal degradation in 
comparison to free drug.
254
 This behavior was assumed to occur because the drug molecule was 
protected by CD and formed a complex with greater stability. Further evidence of self-inclusion 
was provided by attempts to determine the critical micelle concentration (CMC) of the 
βCDgemini surfactants. In contrast to the expected behavior of gemini surfactants in aqueous 
media, increasing the concentration of free βCDgemini surfactant did not result in the formation 
of the self-assembling structures. This finding was supported by the conductivity versus 
concentration plot in which no CMC break point was detected (Appendix 13.2). Based on these 
findings, it seemed that βCDgemini surfactant had unexpected and complicated properties.  
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NMR techniques were used to further understand the self-inclusion behavior of the βCDgemini 
surfactant.  These techniques are the most accurate spectroscopy methods employed to assess the 
geometry of the host/guest inclusion complexes composed of CDs. 
The 
1
H NMR spectrum of the βCDgemini surfactant showed that the internal protons of the βCD 
cavity were shifted significantly upfield and the protons of the hydrocarbon tail of the gemini 
surfactant moiety were considerably broad. Further examination of this system, by 1D- and 2D 
ROESY techniques confirmed the spatial proximity of the βCD internal cavity (H3 and H5) to the 
gemini surfactant tail (Hγ, Hλ, and Hω) of the βCDgemini surfactant. This finding was in 
agreement with other studies showing the interaction of the βCD cavity with alkyl components of 
the regular surfactants
381
 and gemini surfactants
173,177
. A similar self-inclusion behavior was 
reported with a βCD derivative which was mono-substituted by an enyl containing amphiphilic 
moiety.
181
 To understand the mode of the inclusion of gemini tail into βCD cavity (intra- vs inter-
molecular interactions), the correlation between chemical shift as a function of surfactant 
concentration was monitored. It was concluded that the likelihood of the intramolecular 
interaction is significantly greater because no constant correspondence between the concentration 
of the βCDgemini surfactant and the chemical shifts of the cavity protons was detected. Overall, 
the physicochemical characterization of βCDgemini surfactant confirmed that the gemini 
surfactant moiety interacting with βCD and such interaction complicated the behavior of 
βCDgemini surfactant either as a self-assembling agent or a βCD derivative. 
The 
1
H NMR spectra of the NC 2067/βCD complexes displayed upfield shifts of the internal 
protons of the βCD cavity in a concentration dependent manner. It was hypothesized that this 
was due to the anisotropic shielding effect of the aromatic moieties of NC 2067. Similar findings 
were observed with guest molecules with π-electron containing moieties that interacted with CDs 
and replaced the water molecules inside the cavity.
270,271,273,274
 Moreover, the stoichiometry of 
NC 2067/βCD complexes estimated to be 1:2 mole ratio based on the continuous variation 
method. According to the molecular structure of NC 2067 having two styryl moieties, the 
encapsulation of NC 2067 by two βCD molecules was logical. Furthermore, 1D- and 2D ROESY 
spectra of NC 2067/βCD complex showed the interaction of the protons of not only styryl but 
also benzoyl moiety of the NC 2067 with βCD internal protons.  Even though we formerly 
hypothesized that NC 2067 can interact with βCD exclusively through the pharmacophore 
moiety (1,5-diaryl-3-oxo-1,4-pentadienyl)
374
, NMR results showed that the benzoyl aromatic 
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ring substituted on the 4-piperidineone nitrogen atom was involved in the interaction with cavity 
as well. Because the benzoyl moiety in NC 2067 structure located in the vicinity of the 
quaternary ammonium group, molecular docking was used to further examine the feasibility of 
the NMR findings and illustrate the topological mode of the NC 2067/βCD complex. Molecular 
docking results confirmed the 1D- and 2D ROESY observations and proposed a final model in 
which two βCD molecules encapsulated one drug molecule. First βCD cavity accommodated by 
one styryl ring and the other styryl moiety and benzoyl ring were co-included within the second 
βCD. Moreover, the polar carbonyl moieties were located between two βCD molecules. This 
model seems reasonable because of the hydrophobic effect and van der Waals interaction 
between aromatic rings of NC 2067 and βCD cavity. Moreover, the co-encapsulation of the 
second styryl moiety and benzoyl group, which are located at proximate spatial distance, reduced 
the steric hindrance. The quaternary ammonium was positioned outside of the cavity to form 
hydrated state and the carbonyl groups interacted with βCD protons by hydrogen bindings.  
The 
1
H NMR spectrum of NC 2067/βCDgemini surfactant did not show any alterations in 
chemical shifts of the internal protons of βCD compared to free βCDgemini surfactant. As well, 
in 2D ROESY spectrum of NC 2067/βCDgemini surfactant no correlation was found between 
βCD and NC 2067 while the interaction of the gemini surfactant moiety with βCD was evident. 
It was suggested that NC 2067 was not able to modify the self-inclusion behavior of βCDgemini 
surfactant. This can be explained by the fact that based on the previous studies of surfactant/βCD 
complexes
381
 the binding constant of the gemini surfactant alkyl chain moiety is most likely in 
order of 10
3
 L/mol or greater. However, the molecules bearing aromatic rings
372,386
 similar to NC 
2067 have lower binding affinity. Hence, in the NC 2067/βCDgemini surfactant system, the drug 
presumably was not able to displace the alkyl tail from βCD cavity. Based on the biological 
activity of NC 2067 complexed with βCDgemini surfactant3,374, the other possibility could be the 
formation of a ternary complex in which NC 2067 interacted weakly with the carrier. It was 
previously shown that a ternary complex of pyrene/n-octanol/βCD could be formed in which the 
alcohol was encapsulated by βCD and the aromatic ring of pyrene interacted with the hydroxyl 
groups on the rim of the βCD in a non-inclusion mode.388 A similar behavior can be anticipated 
with NC 2067/βCDgemini surfactant. Moreover, 1D ROESY spectrum showed a weak 
interaction of the benzoyl moiety of the NC 2067 with βCD of βCDgemini surfactant. 
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The other aspect of the physicochemical characterization of the NC 2067 complexes with 
βCDgemini surfactant was to evaluate their nanoparticulate behavior in the solution. The size of 
the free βCDgemini surfactants having various alkyl chain length and degree of unsaturation was 
measured. Among them, βCDgemini surfactant (18 carbon alkenyl chain) formed nano-sized 
particles. Even though it was previously reported that βCDgemini surfactant (12 carbon alkyl 
chain) produced nanoparticles with low PDI value
3
, the size measurement of the βCDgemini 
surfactants having 12 and 16 carbon alkyl tail resulted in inconsistent values corresponding to the 
heterogeneous aggregations. However, addition of NC 2067 to βCDgemini surfactants formed 
formulations with sizes ranging from 87 to 199 nm. It was demonstrated that changing a variety 
of parameters such as the structure of βCDgemini surfactant (various alkyl chain length, degree 
of unsaturation and linker nature), drug to delivery agent mole ratio and addition of helper lipid 
(DOPE) did not alter the nanoparticle size drastically. Formation of nanoparticles is 
advantageous for drug delivery as they can improve cellular uptake by endocytosis
23
 and elude 
the reticulo-endothelial system
13
. The other favorable mechanism of the nanoparticles is to 
overcome the multidrug resistance.
24,363
 Nanoparticles interact with the biomembrane of 
lysosomes and release the loaded drug into cytoplasm where the efflux pumps are not able to 
expel it outside the cell.
421
  
Thus, to assess our system, the nano-structural arrangements of the βCDgemini surfactant-based 
formulations were evaluated by the synchrotron-based SAXS/WAXS. Lipid-based self-
assembling molecules such as gemini surfactants are able to build different lyotropic liquid 
crystalline nanostructures in solution.
157
 Structural parameters of gemini surfactants such as 
nature and length of the hydrocarbon tail dictated the nano-arrangement of the amphiphiles.
162
 
The X-ray scattering pattern of various βCDgemini surfactants (different alkyl chain length and 
degree of unsaturation) showed a diffused peak independent from the surfactant concentration.
374
 
In a study about a system composed of a gemini surfactant and CDs, similar aggregations were 
detected using small-angle neutron scattering.
364
 This observation is consistent with the self-
inclusion behavior of βCDgemini surfactants resulting in the occupancy of the hydrocarbon tails 
of the gemini moiety due to the interaction with βCD.  
Addition of DOPE as a helper lipid to free βCDgemini surfactants (12 and 16 carbon alkyl chain) 
did not change the scattering pattern whereas the βCDgemini surfactant having 18 carbon 
alkenyl chain, dispersed in DOPE showed inverted hexagonal phase, characteristic to DOPE.
420
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Once again, the self-inclusion of βCDgemini surfactants hindered the interaction of gemini 
surfactant with the helper lipid. However, the presence of the inverted hexagonal phase of DOPE 
in βCDgemini surfactant (18 carbon alkenyl chain) /DOPE system could be attributed to the 
weaker propensity of the unsaturated tail for self-inclusion. It was shown that the mono-
unsaturation of the hydrocarbon tail of the lipids changed their geometry by producing a bend in 
the structure.
397
 Similar geometrical property of the gemini surfactant moiety of βCDgemini 
surfactant (18 carbon) resulted in less interaction with βCD.  
Addition of NC 2067 to βCDgemini surfactants at various drug-to-carrier mole ratios resulted in 
the appearance of a new Bragg’s peak (d-spacing of 23 Å). Prior to NMR results, we speculated 
that NC 2067 was able to compete with gemini surfactant and partially release the gemini tail 
from βCD cavity.374 Based on NMR spectra and the binding affinity estimations, NC 2067 
showed minimal effect on βCDgemini surfactant system. We hypothesized that this new peak is 
related to the weak interaction of NC 2067 with βCDgemini surfactant in a ternary complex 
system. This finding was confirmed with the fact that this new peak was observable in all NC 
2067/βCDgemini surfactant systems. Moreover, at lower concentrations of the delivery agent 
(βCDgemini surfactants having 12 and 16 carbon alkyl chain), other peaks corresponding to 
precipitated NC 2067 were detected. In contrast, the scattering pattern of NC 2067/βCDgemini 
surfactant (18 carbon alkenyl chain) did not show the NC 2067 peaks indicating the higher 
capacity of this βCDgemini surfactant to solubilize the drug. This finding further supports our 
hypothesis regarding the weaker self-inclusion of βCDgemini surfactant (18 carbon alkenyl 
chain) compared to saturated derivatives, which might result in the greater interaction of NC 
2067 with βCD.  
The anticancer activity of NC 2067 complexes with various βCDgemini surfactants was 
evaluated towards A375 melanoma cells. Based on the previous study in our group, NC 2067 
dissolved in DMSO showed high cytotoxicity towards A375 melanoma cell line with a low IC50 
value (half-maximal inhibitory concentration) without affecting healthy human epidermal 
keratinocytes. Moreover, the IC50 value for NC 2067/βCDgemini surfactant (12 carbon alkyl 
chain) reported to remain as low as 2 μM. To conduct a systematic evaluation and build data 
towards assessment of structure-activity relationships, the anticancer efficacy of NC 2067 was 
evaluated in various βCDgemini surfactant-based formulations by varying parameters such as the 
type of the βCDgemini surfactant, linker structure, drug-to-delivery agent mole ratio and addition 
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of helper lipid. It was found that NC 2067 complexed with a variety of βCDgemini surfactants 
retained its high toxicity towards A375 melanoma cells. The IC50 values were in the range of 1.8 
to 2.6 μM which were significantly more efficient compared to melphalan, an approved 
therapeutic agent for melanoma. Alterations of the structure of the βCDgemini surfactants 
(different acyl chain length and the degree of unsaturation of the hydrocarbon tail), the nature of 
the linker
374
 and the drug-to-carrier mole ratio
374
, in addition to the presence of DOPE in the 
formulations, did not influence the potency of NC 2067 to kill A375 melanoma cells. Moreover, 
intrinsic toxicity of various free βCDgemini surfactants was assessed towards A375 melanoma 
cells to corroborate the potential involvement of the delivery agent in the total toxicity of the 
formulations and estimate the safety of the βCDgemini surfactants. The intrinsic toxicity of the 
βCDgemini surfactants having 12 and 18 carbon chain was low whereas the compound with 16 
carbon alkyl chain showed higher cytotoxicity. The latter observation is possibly due the lower 
water solubility of the βCDgemini surfactant with 16 carbon tail that led to precipitation in cell 
culture. Even though βCD assumed to be an inert carrier, there are some studies showed that it 
could interact with biomembrane components such as cholesterol and distress cells. Conversely, 
the encapsulation of small molecules by the βCD cavity hindered the interaction with cellular 
membranes.
130
 In addition, the gemini surfactant component of the delivery system could have 
the potential to show cytotoxicity towards various cell lines according to their structural 
properties and concentration.
367
 Overall, the βCDgemini surfactants showed lower cytotoxicity in 
comparison to the amino acid-grafted gemini surfactants having similar gemini moiety.
165
 It was 
speculated that the low cytotoxicity of the βCDgemini surfactants might be related to the self-
inclusion behavior that impeded the negative interaction of either the βCD or gemini surfactant 
moiety with biological compounds. Altering the nature of the linker from ester to amide and 
addition of DOPE significantly increased the intrinsic toxicity of the βCDgemini surfactant. This 
observation can be explained with the fact that amide moieties are able to interact through 
hydrogen bindings with proteins consequently lead to cell death mechanisms.
365
 
In my research, the cell death mechanism of NC 2067 in presence of the βCDgemini surfactants 
was examined using flow-cytometry assays. The NC 2067 complexes with various βCDgemini 
surfactant induced apoptosis in A375 melanoma cells without triggering necrosis in the cell 
populations. This result confirmed the results of an earlier study showing that NC 2067 
complexed with βCDgemini surfactant (12 carbon alkyl chain) increased caspases 3 and 7 
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(apoptotic probes) in A375 melanoma cells.
3
 Among the formulations, NC 2067/βCDgemini 
surfactant (12 carbon alkyl chain) showed proapoptotic effect comparable to melphalan and 
caused chromatin condensation. Free βCDgemini surfactants did not induce apoptosis in A375 
melanoma cells excluding the 16 carbon alkyl chain which increased the population of 
necrotic/apoptotic cells, consistent with other cell viability assays. Based on the literature, 
curcumin and its analogs are able to induce cell death through both intrinsic and extrinsic 
apoptotic pathways. Mitochondrial membrane potential loss is a well-defined consequence of the 
stimulation of the intrinsic apoptotic cascade. Unfortunately, the NC 2067/βCDgemini surfactant 
formulations did not change the mitochondrial membrane potential in A375 melanoma cells. 
Similar results were obtained with various melanoma cells treated with curcumin revealing no 
mitochondrial membrane potential loss was detected.
231,232
 Moreover, NC 2067 based 
formulations were not able to induce ROS production. Lastly, the influence of the formulations 
on the cell cycle arrest was evaluated. Even though curcumin and its analogs arrested cancer 
cells at different phases of the cell cycle, NC 2067/βCDgemini surfactant formulations did not 
show any alterations in the cell cycle, confirming that the curcumin analogs bearing conjugated 
unsaturated styryl ketones, are possibly thiol alkylators and do not act through interference with 
genetic materials. 
In conclusion the inclusion formation of NC 2067 with βCD and βCDgemini surfactant was 
confirmed qualitatively by various analytical techniques such as powder X-ray diffraction, FTIR 
spectroscopy and TGA. Moreover, 1D- and 2D ROESY results showed the details of the 
geometrical interactions of the host/guest complexes of the βCDgemini surfactant, NC 
2067/βCD and NC 2067/βCDgemini surfactant. It was noted that βCDgemini surfactant showed 
intramolecular self-inclusion in which the hydrocarbon tails of the gemini moiety encapsulated 
by the βCD cavity. NC 2067 interacted with βCD cavity through its styryl and benzoyl moieties 
in a 1:2 drug-to-βCD mole ratio. It was confirmed that the addition of NC 2067 had minimal 
influence on the self-inclusion behavior of βCDgemini surfactant. As such the SAXS/WAXS 
study of NC 2067/βCDgemini surfactant complexes in solution did not show regular lyotropic 
liquid crystalline patterns corresponding to the self-assembling potential of the surfactants. 
However, various NC 2067/βCDgemini surfactant formulations formed nano-sized structures 
with high in vitro cytotoxicity towards A375 melanoma cells. The cell death mechanism of NC 
2067 in the presence of βCDgemini surfactant was reported to be a non-mitochondrial mediated 
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apoptosis without affecting cell cycle phases. Identification of the physicochemical properties 
and anticancer activity of NC 2067/βCDgemini surfactant drug delivery system, extend our 
knowledge to further develop more proficient anticancer therapies.  
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12. FUTURE DIRECTIONS 
βCDgemini surfactant as a novel delivery agent was able to solubilize a model anticancer agent, 
NC 2067. In vitro evaluation of NC 2067 in presence of the βCDgemini surfactant showed high 
cytotoxicity and proapoptotic activity. Moreover, it was reported that the βCDgemini surfactant 
was a safe delivery agent not affecting cancer cells on its own. These favorable properties made 
βCDgemini surfactant a promising carrier for lipophilic anticancer agents. However, the self-
inclusion behavior of βCDgemini surfactant complicated the interaction of the guest molecule 
and altered the self-assembling of the gemini surfactant moiety. Future work will focus on the 
modification of the βCDgemini surfactant to minimize the self-inclusion behavior. It seems that 
any structural alteration that can inhibit the gemini surfactant tail to be incorporated into βCD 
cavity is favorable to this system. For example, addition of bulky chemical moieties to the 
hydrocarbon tails of the gemini surfactant could produce steric hindrance.  βCDgemini surfactant 
is synthesized by mono-substitution of gemini surfactant on βCD. Amphiphilic poly-substituted 
βCD derivatives could be designed to potentially lower the self-inclusion. Any changes in the 
structure of the βCDgemini surfactant can be probed by NMR techniques. 
In addition, other strategies can be employed to design modified substitutes for βCDgemini 
surfactant. One approach could be the use of the polymer-based βCDs in which the βCD cavities 
are available for hydrophobic small molecules and the polymer moiety form nanostructures. The 
use of the βCD in liposomes and dendrimers are other examples that can modify the delivery 
agent. 
This work was the first step in elucidating cell death mechanisms. However, further studies are 
needed to understand which apoptotic pathway was triggered in A375 melanoma cells treated 
with NC 2067/βCDgemini surfactant systems. The activity and concentration of the protein 
molecules involved in the intrinsic and extrinsic apoptotic pathways such as cytochrome c, 
caspases and Bcl-2 family proteins can be evaluated. Moreover, the role of autophagy in the cell 
death can be examined. 
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13. Appendices 
Appendix 13.1- Single crystal X-ray Crystallography of βCD and NC 2067  
 
Crystallization procedure 
Different techniques and organic solvents were used as solvent and anti-solvent to obtain crystals 
from the inclusion complex of NC 2067/βCD and NC 2067/βCDgemini surfactant-12. The 
liquid-liquid diffusion (layering) technique was employed to crystalize NC 2067/βCD in which a 
mixture of water/DMSO (%60/40 v/v) and acetone were used as solvent and anti-solvent, 
respectively. The crystallization of the NC 2067/βCDgemini surfactant-12 was performed using 
EchoTherm
TM
 IN35 chilling incubator (Torrey Pines Scientific, USA). The temperature was 
cooled down from 40ᵒC to 10ᵒC with cooling rate of 0.1ᵒC per an hour. Unfortunately after data 
collection and analysis we found that the crystals obtained from NC 2067/βCD and NC 
2067/βCDgemini surfactant-12 samples were free βCD and free NC 2067, respectively. 
 
Data collection 
Synchrotron X-ray diffraction measurements were performed at Canadian light source (CLS, 
Saskatoon) on the beamline 08B1-1 (CMCF-BM, CLS) which is equipped with a versatile MD2 
micro-diffractometer and a Rayonix MX300HE CCD detector. A goniometer base with 18 mm 
copper pin length with GB-B3S-R-10 design (MiTeGen, USA) was employed as sample holder 
to mount sample on the beamline. A suitable single crystal, of 0.05-0.2 mm size in each 
dimension, was removed from the solution, quickly coated with oil (Paratone 8277, Exxon), 
collected inside a mounted CryoLoop
TM (Hampton Research, USA) with 10 μm nylon fiber 
diameter and 0.1-0.2 mm loop diameter attached to the goniometer base and immediately 
transferred into liquid nitrogen. Then, the sample holder was mounted on the beamline where a 
cold stream of cryojet (Oxford, UK) maintained the 100 K temperature to avoid crystal 
degradation.  
Data was collected at 18 KeV (corresponding to =0.68878 Å) at a 150 mm crystal to detector 
distance with exposure time of 1-2 seconds. A series of data frames at 1ᵒ increments of ω were 
collected. Data collection was completed by changing the detector angle to 2θ=10o and curving 
the cooper wire resulting in at least 4 data series for each crystal.  
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Data collection was performed using Macromolecular Crystallography Data Collector (MXDC) 
graphical interface.
422
 
Data processing 
The in-house script called Autoprocess
358
 was applied to index, integrate, merge and scale the 
diffraction data. Cell dimension refinement and data reduction were also performed using 
SAINT (Bruker,USA) or XPREP (Sheldrick)
423
. The programs used to solve structure were 
Shelxd or Shelxs (Sheldrick)
424,425
. For structure refinement Shelxl-97 was occupied 
(Sheldrick)
424
. The refined structure was visualized by XP (ShelxTL, Bruker, USA)
426
 or 
RasMol
427
. 
The flow chart of data processing has been shown in (Figure 13.1). 
 
Figure 13.1- Crystallography data processing chart 
 
Structure determination of βCD 
Crystal data, data collection and refinement statistics were shown in Table 13.1. The most 
probable crystal system and symmetric space group for βCD was suggested as triclinic and P1, 
respectively. Molecular structure of apo-βCD was solved, refined and visualized (Figure 13.2). 
 
 
 
 
 
 
 
 
 
 157 
 
 
Table 13.1- βCD crystal data and data collection and refinement  
Crystal data Data collection and refinement 
C42H70O35 
MW: 1135 g/mol 
Space group: triclinic, P1 
Z=2 
Unit cell dimensions:   
 a= 15.33 Å       
 b= 15.35 Å 
c= 15.61 Å 
Unit cell angles:        
α= 81.4ᵒ 
β= 86.9ᵒ   
γ=77.6ᵒ 
V: 3548 Å3 
Energy: 18 KeV 
λ: 0.6888 Å 
T: 100 K 
d: 150 mm (crystal to detector 
distance) 
4.45° < 2θ < 53.96° 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.2- Molecular structure of the apo-beta-cyclodextrin is illustrated by XP (SHELXTL). Hydrogen atoms 
have been omitted for clarity. The non-hydrogen atoms are represented by displacement ellipsoids at the 20% 
probability level. 
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Structure determination of NC 2067 
NC2067 needle shape crystals obtained from NC 2067/βCDgemini surfactant-12 sample by slow 
cooling down.  
Crystal data, data collection and refinement statistics were shown in Table 13.2. Molecular 
structure of NC 2067 was solved, refined and visualized (Figure 13.3). 
Table 13. 2- NC 2067 crystal data and data collection and refinement  
Crystal data Data collection and refinement  
C30H30N2O3 
MW: 503.05 g/mol 
Space group: monoclinic, P21 
Z=4 
Unit cell dimensions: 
a= 11.41Å 
b= 11.67Å 
c= 22.89Å 
Unit cell angles: 
α= 90ᵒ 
β= 91.53ᵒ 
γ=90ᵒ 
 
Energy: 18KeV 
λ: 0.6888Å 
T: 100K 
d: 150 mm (crystal to detector distance) 
4.45° < 2θ < 53.96°  
 
 
 
 
Figure 13.3- Molecular structure of NC2067 by RasMol. Hydrogen atoms have been omitted for clarity. The non-
hydrogen atoms are represented by displacement balls. 
 
 
 
O:red 
C:grey 
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Appendix 13.2- Critical micelle concentration (CMC) measurement of 
βCDgemini surfactant-12 using conductivity method 
 
Conductivity method was used to determine the CMC of βCDgemini surfactant-12 in water. In 
general, increasing the concentration of a regular surfactant will result in the formation of 
micellar self-assemblies. Increasing the concentration above CMC will lower the rate of the 
water conductivity increase. The gemini  surfactant compartment of βCDgemini surfactant-12, 
showed as 12-7NH-12, showed CMC of 2.4 mM measured by conductivity method.
167
 However, 
increasing the concentration of βCDgemini surfactant-12 to 6 mM did not result in any change in 
the conductivity rate suggesting that βCDgemini surfactant-12 most likely did not form self-
assemblies (Figure 13.4). 
 
 
Figure 13.4- CMC measurement of βCDgemini surfactant-12 using conductivity method 
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Appendix 13.3- Circular dichroism spectra of NC 2067/βCD and NC 
2067/βCDgemini surfactant-12  
Circular dichroism spectra of NC 2067, βCD, βCDgemini surfactant-12 and NC 2067/βCD and 
NC 2067/βCDgemini surfactant-12 were obtained (Figure 13.5A and B).  The results did not 
show any meaningful alteration in circular dichroism spectra of the complexes, NC 2067/βCD 
and NC 2067/βCDgemini surfactant-12 compared to free βCD or βCDgemini surfactant-12. 
 
 
Figure 13.5- Circular dichroism spectra of A) NC 2067, βCD and NC 2067/βCD and B) NC 2067, βCDgemini 
surfactant-12 and NC 2067/βCDgemini surfactant-12. 
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Appendix 13.4- Phase solubility diagram of NC 2067/βCDgemini surfactant-
12 using UV spectroscopy 
To evaluate the ability of βCDgemini surfactant-12 to solubilize NC 2067, extra amount of NC 
2067 was added to different concentrations of βCDgemini surfactant-12 and UV absorbance of 
NC 2067 at 330 nm measured (Figure 13.6). Although, increasing the βCDgemini surfactant-12 
concentration to 0.8 mM, enhanced the solubilization of NC 2067, the solubility of NC 2067 
(UV absorbance) decreased at higher concentrations of βCDgemini surfactant-12. These results 
suggested a more complicated system in comparison to a binary system of CDs and guest 
molecules. 
 
 
Figure 13.6- Phase solubility diagram of NC 2067 in presence of βCDgemini surfactant-12 using UV absorbance. 
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Appendix 13.5- 
1
H NMR study of βCDgemini surfactant-16 and βCDgemini- 
surfactant-18:1 
We obtained the 
1
H NMR spectra of βCDgemini surfactant-16 and βCDgemini surfactant-18:1 in 
D2O to evaluate their potential self-inclusion behavior. NMR spectra showed that the internal 
protons of βCD (H3 and H5) shifted upfield, with Δδ values of 0.052 ppm (H3) and 0.096 ppm 
(H5) for βCDgemini surfactant-16 and 0.077 ppm (H3) and 0.095 ppm (H5) for βCDgemini 
surfactant-18:1. The Δδ value of H3 for βCDgemini surfactant-18:1 is higher whereas the Δδ 
value of H5 is similar in both βCDgemini surfactants. Moreover, in both spectra the chemical 
shift change of H5 is greater than H3 (Table 13.3).  
Table 13.3- Chemical shifts (ppm) of the βCD protons in βCDgemini surfactant-16 and βCDgemini surfactants-18:1 
compared to free βCD. 
βCD 
βCDgemini 
surfactant-16 
βCDgemini 
surfactant-
18:1 
δ δ Δδ δ Δδ 
H1 5.001 4.988 0.013 4.992 0.009 
H2 3.580 3.568 0.011 3.597 -0.018 
H3 3.898 3.846 0.052 3.821 0.077 
H4 3.516 3.520 -0.004 3.551 -0.036 
H5 3.803 3.707 0.096 3.708 0.095 
H6 3.809 3.806 0.003 3.788 0.021 
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Appendix 13.6- In vitro cell toxicity of NC 2081 compared to NC 2067  
NC 2081 (Figure 13.7) is another curcumin analog with comparable structure to NC 2067 
(Figure 2.4). We evaluated the in vitro cytotoxicity of NC 2081 towards A375 melanoma cell 
line and compared with NC 2067 (Table 13.4). NC 2081 dissolved in DMSO showed high 
toxicity toward A375 cells comparable to NC 2067 with IC50 value of 0.8±0.2 μM. NC 2081 in 
presence of βCDgemini surfactant-12 (ester linker) at 1:2 drug to delivery agent mole ratio (IC50 
= 4 ± 1.9 μM) was not significantly different compared to NC 2067 formulation with an IC50 
value of 2 ± 0.25 μM (P>0.05). However, the IC50 value of NC 2081/βCDgemini surfactant-12 
having amide linker was significantly greater than the similar formulation with NC 2067. 
 
Figure 13.7- Chemical structure of NC 2081. 
 
Table 13.4- IC50 values of NC 2081 compared to NC 2067 dissolved in DMSO or in complexes with CDgemini 
surfactant-12 having ester or amide linker 
Curcumin 
analog 
Solvent /Delivery 
agent 
linker IC50 [μM] ± SD 
NC 2081 
DMSO NA 0.8 ± 0.2 
CDgemini-12 
Ester 4 ± 1.9 
Amide 32 ± 7 
NC 2067 
DMSO NA 0.5 ± 0.1 
CDgemini-12 
Ester 2.0 ± 0.25 
Amide 2.1 ± 0.3 
N
O
O
O
O
N
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Appendix 13.7- Evaluation of the mitochondrial membrane potential (ΔΨm) in 
A375 cells treated with NC 2067/βCDgemini surfactant complex by flow 
cytometry 
Mitochondrial membrane potential disruption is one of the key events in mitochondrial-
dependent apoptosis. The fluorescent dyes to probe ΔΨm are lipophilic cationic compounds that 
can accumulate in mitochondrial intermembrane matrix inversely proportional to ΔΨm (more 
negative ΔΨm, more accumulation of dye). We used two different mitochondrial fluorescent dyes 
named JC-1 ((5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzimidazolylcarbocyanine iodide) and 
TMRM (tetramethylrhodamine methyl ester). 
 
1. Evaluation of ΔΨm using JC-1 
We employed JC-1 dye to calculate the percentage of the cells having mitochondrial membrane 
potential loss. In healthy cells, JC-1 (cationic dye) accumulates in mitochondria with high 
membrane potential. Higher rate of the accumulation of JC-1 results in the formation of the J-
aggregates. Monomers of JC-1 emit fluorescence at green region (527 nm) whereas the 
aggregates are able to exhibit green and red fluorescence at 527 and 590 nm, respectively. The 
shift from red to green indicates the presence of higher amounts of monomers in comparison to 
aggregates subsequently showing the mitochondrial membrane potential loss (depolarization) 
and apoptosis.
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Material and Methods- Cells seeded in 6-well plates (25 x 10
4
 cells/well) and after 24 h of 
incubation at 37̊C in a humidified incubator with 5% CO2, they were treated with Melphalan (10 
μM), NC 2067 dissolved in DMSO (0.5 and 1 μM) and in ethanol (1 μM), NC 2067/βCDgemini 
surfactant-12 (2.5 μM) and βCDgemini surfactant-12 (5 μM). After 24 hours of incubation, JC-1 
(2.5 μg/ml) added to each well and incubated at 37̊C for 20 min. CCCP (80 μM) was added at the 
same time as JC-1. Immediately, media removed from wells and cells were washed twice by 
DPBS to remove JC-1 remaining outside of the cells. Then cells were trypsinized and harvested. 
Cells pellets resuspended in 500 μl DPBS, filtered and analyzed with a FACScalibur flow 
cytometer with excitation from the 488 nm argon laser and emission in the 585/42 and 530/30 
nm filters. The percentage of the green fluorescence of JC-1 monomers was employed to identify 
the cells with mitochondrial membrane potential drop. 
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Results- The percentage of the cells showing red and green fluorescence after treatment with 
different compounds is illustrated in Table 13.5. Cells treated with CCCP (80 μM) and apigenin 
(50 μg/ml) as positive controls, showed a shift from red to green in comparison to healthy cells 
confirming the decrease in mitochondrial membrane potential. This shift is significantly higher 
for cells treated with CCCP (%94.1 of cell population at Q3) (Figure 13.8-B) compared to 
untreated cells (Figure 13.8-A). NC 2067 dissolved in DMSO at 0.5 and 1 μM did not show any 
significant change in the cell population with green fluorescence compared to untreated cells 
(Table 13.5) (Figure 13.8-C). Surprisingly, 1% DMSO showed significantly higher green 
fluorescent population comparable to apigenin suggesting the effect of DMSO on mitochondrial 
membrane potential (data is not shown). To remove the possible effect of 1% DMSO we 
dissolved NC 2067 in lower amount of DMSO (0.1%) or ethanol. However, the results did not 
alter (data is not shown). Cells treated with NC 2067/βCDgemini surfactant-12 formulation and 
free βCDgemini surfactant-12 presented red and green fluorescent populations similar to 
untreated cells (Table 13.5) (Figure 13.8-D). These results showed that NC 2067 did not 
decrease mitochondrial membrane potential in A375 melanoma cells. 
 
Table 13.5- A375 melanoma cell populations stained with JC-1 showing red and green fluorescence after 24 hours 
of treatment with NC 2067- based formulations. 
% cells Untreated 
CCCP 
[80 μM] 
Apigenin 
[50 μg/ml] 
Melphalan 
[10 μM] 
NC 2067/ 
DMSO  
[0.5 μM] 
NC 2067/ 
DMSO  
[1 μM] 
NC 2067/ 
βCDgemini 
surfactant  
[2.5 μM] 
βCDgemini 
surfactant [5 
μM] 
NC 2067/ 
Ethanol  
[1 μM] 
Green+, Red+ 87.8 5.89 61.2 97.1 82.5 81.3 94.2 87.5 96.8 
Green+, Red- 12.2 94.1 38.8 2.9 17.5 18.7 5.83 12.5 3.19 
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Figure 13.8- Biexponential mitochondrial membrane potential loss of A375 melanoma cells stained with JC-1 in A) 
untreated and treated with B) CCCP, C) NC 2067 dissolved in DMSO and D) NC 2067/βCDgemini surfactant-12  
formulation for 24 hours by flow cytometry.  
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2. Evaluation of ΔΨm using TMRM 
TMRM is a fluorescent rhodamine derivative which its fluorescence intensity will be quenched 
upon accumulation in mitochondria.
395
 Therefore, the decrease in red fluorescence is the 
indicator of the mitochondrial membrane potential disruption. 
Material and Methods- Cells seeded in 6-well plates (25 x 10
4
 cells/well) and after 24 h of 
incubation at 37̊C in a humidified incubator with 5% CO2, they were treated with Melphalan (10 
μM), NC 2067 dissolved in DMSO (0.5 and 1 μM), NC 2067/βCDgemini surfactant-12 (2.5 μM) 
and βCDgemini surfactant-12 (5 μM). After 12 and 24 hours of incubation, cells were 
trypsinized and harvested. Then TMRM (0.5 μM) added to each sample and incubated at 37̊C for 
30 min. CCCP (80 μM) was added at the same time as TMRM. Immediately, media removed by 
centrifugation and cells were washed twice by DPBS to remove TMRM remaining outside of the 
cells. Cells pellets resuspended in 500 μl DPBS, filtered and analyzed with a FACScalibur flow 
cytometer with excitation from the 488 nm argon laser and emission in the 585/42 nm filter. The 
intensity of the red fluorescence of TMRM was employed to identify the cells with 
mitochondrial membrane potential drop. 
Results- The red fluorescence intensity of the cells treated with different compounds is 
illustrated in Table 13.6. Cells treated with CCCP (80 μM) as a positive control, showed a 
significant decrease in red fluorescence intensity (27.6) compared to untreated cells (243.3) 
(Table 13.6) confirming the mitochondrial membrane potential loss. Cells treated with NC 2067 
dissolved in DMSO (0.5 and 1 μM) or in complexed with βCDgemini surfactant-12 (2.5 μM) for 
12 or 24 hours exhibited red fluorescence intensity similar to the untreated A375 melanoma cells 
(Table 13.6). Moreover, cells treated with free βCDgemini surfactant-12 (5 μM) surfactant and 
0.1% DMSO did not alter the red intensity compared to untreated (data is not shown). The 
decrease in red fluorescence intensity was observed at the concentration of 10 μM of NC 2067 
dissolved in DMSO which is approximately 20 times more than IC50 value after 4-6 hours of 
incubation (data is not shown). This result is probably due to the high toxicity at this 
concentration which is not necessarily related to the mitochondrial-dependent apoptosis. Once 
again our findings suggested that NC 2067 did not decrease mitochondrial membrane potential in 
A375 melanoma cells at IC50. 
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Table 13.6- Red fluorescence intensity of A375 melanoma cells stained with TMRM after treatment with NC 2067 
based formulations. 
 
untreated 
CCCP  
[80 μM] 
NC 2067/ DMSO  
[0.5 μM] 
NC 2067/ DMSO  
[1 μM] 
NC 2067/ 
βCDgemini 
surfactant-12 
[ 2.5 μM] 
12 h 24 h 12 h 24 h 12 h 24 h 
Relative 
fluorescence 
intensity 
243.3 27.6 271.3 242.3 276.2 263.4 269.7 242.8 
 
  
 169 
 
Appendix 13.8- Evaluation of ROS generation in A375 cells treated with NC 
2067  
ROS generation is the stimulus for mitochondrial membrane potential disruption. To evaluate the 
ROS generation in A375 cells following the treatment with NC 2067 formulations, we used a 
cell permeable probe called 2ʹ-7ʹ-Dichlorodihydrofluorescein diacetate (DCFH-DA). This non-
fluorescent compound will be cleaved by intracellular esterases to form H2DCF, a cell 
impermeable molecule. Subsequently, the oxidation of H2DCF by intracellular ROS will result 
in the formation of the final product (DCF) which is highly fluorescent. An increase in the 
fluorescence intensity of cells stained with DCF at 530 nm when excited at 485 nm is the 
indicator of ROS generation. We probed ROS generation in A375 cells using DCF by both flow 
cytometry and plate reader.
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 Material and Methods- The cell culture media used for the following experiments did not 
contain phenol red. 
Flow cytometry  
Cells seeded in 6-well plates (25 x 10
4
 cells/well) and after 24 h of incubation at 37̊C in a 
humidified incubator with 5% CO2, they were treated with 5FU (10 μM) and NC 2067 dissolved 
in DMSO (0.5 and 1 μM). After 24 hours of incubation, cells were trypsinized and harvested. 
Then DCFH-DA (5 μM) added to each sample and incubated at 37̊C for 15 min. Immediately, 
media removed by centrifugation and cells were washed twice by DPBS to remove DCF leaked 
outside of the cells. Cell pellets resuspended in 500 μl DPBS (without magnesium and calcium 
ions), filtered and analyzed with a FACScalibur flow cytometer with excitation from the 488 nm 
argon laser and emission in the 530/30 nm filter. The intensity of the green fluorescence of DCF 
was employed to identify the cells produced ROS. 
Plate reader 
Cells seeded in 96-well plates (1 x 10
4
 cells per well) and after 24 h of incubation at 37̊C in a 
humidified incubator with 5% CO2, they were treated with NC 2067 dissolved in DMSO (0.5, 1 
and 5 μM). After 24 hours of incubation, cells were stained with DCFH-DA (5 μM) and 
incubated at 37̊C for 15 min. As a control H2O2 (100 μM) was added and incubated for 30 min 
before staining with DCFH-DA. Immediately, media removed and 100 μl of DPBS (without 
magnesium and calcium ions) added. The excitation and emission filters of 485/20 and 528/20 
nm, respectively used and fluorescence intensity recorded on a Synergy BioTek plate reader. 
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Results- A375 cells treated with 5FU (10μM) and NC 2067 (0.5 and 1 μM) and evaluated by 
flow cytometry showed no alteration in fluorescence intensity compared to the untreated cells 
(Table 13.7). The intensity slightly increased with higher concentration of NC 2067 (5 μM) 
which is ten times greater than IC50 value. 
Moreover, we observed that treatment with H2O2 (100 μM) significantly increased the intensity 
recorded by plate reader in comparison to the untreated cells (approximately four times greater 
intensity). Once more, NC 2067 at various concentrations (0.5, 1 and 5 μM) did not change the 
green fluorescence intensity. 
Based on our observations, we concluded that NC 2067 was not able to induce ROS generation 
at A375 melanoma cell line. Because the results for NC 2067 dissolved in DMSO was not 
desirable we did not evaluate NC 2067/βCDgemini surfactants. 
Table 13.7- Green fluorescence intensity detected in A375 melanoma cells stained with DCFH-DA after treatment 
with NC 2067 based formulations. 
Relative 
fluorescence 
intensity 
untreated 
5FU  
[10 μM] 
H2O2 [100 μM] 
NC 2067/ DMSO  
[0.5 μM] 
NC 2067/ DMSO  
[1 μM] 
NC 2067/ DMSO 
[5 μM] 
Flow cytometry 97.1 92.8 NA 137 86.7 132.1 
Plate reader 354.9 NA 1525.4 375.8 317.8 305.2 
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Appendix 13.9- Evaluation of the caspase-dependent apoptosis in A375 cells 
treated with NC 2067 /βCDgemini surfactant-12 complex  
We previously showed that NC 2067 dissolved in DMSO and in complexed with βCDgemini 
surfactant-12 were able to increase caspases -3 and -7 in A375 melanoma cells.
3
 Here, our aim 
was to evaluate the effect of a general caspase inhibitor such as z-VAD-fmk on cell toxicity of 
NC 2067/βCDgemini surfactant complexes.  
Material and Methods- Cells seeded in 96-well plates (1 x 10
4
 cells/well) and after 24 h of 
incubation at 37̊C in a humidified incubator with 5% CO2, they were treated with NC 2067 
dissolved in DMSO (1 μM) and melphalan (36 μM). After 24 hours of incubation, cells were 
treated with z-VAD-fmk (50 μM) and incubated at 37̊C for 1 hour. This stage was performed by 
either spiking the media with higher concentration of z-VAD-fmk or removing the media and 
providing fresh media containing z-VAD-fmk (50 μM). Afterwards, fresh supplemented media 
containing a final concentration of 450 μg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Invitrogen, Burlington, Canada) solution was added to each 
well and the plates were incubated for 2 h at 37 ᵒC.  Excess MTT solution was removed and the 
plates were dried.  DMSO was added to each well and the plates were incubated for 10 min at 37 
ᵒC to dissolve the trapped formazan. Absorbance at 550 nm was recorded using a Synergy 
BioTek plate reader. 
Results- The intrinsic toxicity of z-VAD-fmk at concentrations of 20-50 μM was evaluated. It 
was found that the %toxicity induced in A375 cells was less than 6% (data is not shown). 
Unfortunately, NC 2067 (1 μM) showed low toxicity at A375 cells in contrast to our previous 
findings and addition of z-VAD-fmk increased the toxicity. Moreover, the toxicity associated 
with melphalan did not change upon addition of z-VAD-fmk (Figure 13.9). 
 
 
 
 
 
 172 
 
 
Figure 13.9- % toxicity of A375 melanoma cells treated with NC 2067 (1 μM) and Melphalan (36 μM) in presence 
and absence of z-VAD-fmk (50 μM). 
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